[ { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 152.0000 g/L;\nThe ALB is 52.2000 g/L;\n The CRP is 0.5100 mg/L;\n The LDH is 169.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 5:More severe complications that require the patient to be hospitalized or undergo more frequent medical interventions.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 37.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.0333 ### months." } ], "images": [ "DMFS_train_1281/0000293387_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1360.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 39.8000 g/L;\n The CRP is 6.1800 mg/L;\n The LDH is 254.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.3333 ### months." } ], "images": [ "DMFS_train_1281/0000293099_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1740.0000 copies/mL;\nThe EBV of after treatment is 19.8000 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 43.2000 g/L;\n The CRP is 4.7200 mg/L;\n The LDH is 304.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 65.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.4333 ### months." } ], "images": [ "DMFS_train_1281/0000232635_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 184.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 37.5000 g/L;\n The CRP is 6.3900 mg/L;\n The LDH is 135.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 68.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 85.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 52.0333 ### months." } ], "images": [ "DMFS_train_1281/0000279167.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 45.8000 copies/mL;\nThe EBV of after treatment is 3.3000 copies/m; \nThe HGB is 142.7000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 3.0600 mg/L;\n The LDH is 254.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Sunitinib/ Nivolumab;\n The time interval between induction chemotherapy and post-treatment imaging is 40.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 60.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 7.3667 ### months." } ], "images": [ "DMFS_train_1281/0000292626_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 37.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 42.5000 g/L;\n The CRP is 0.7500 mg/L;\n The LDH is 140.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.6667 ### months." } ], "images": [ "DMFS_train_1281/0000268843.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 55 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 868.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 33.9000 g/L;\n The CRP is 1.7700 mg/L;\n The LDH is 255.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 175 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 74.0667 ### months." } ], "images": [ "DMFS_train_1281/0000257618.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 55 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 10.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 120.8000 g/L;\nThe ALB is 35.0000 g/L;\n The CRP is 3.2300 mg/L;\n The LDH is 173.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 309.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.7667 ### months." } ], "images": [ "DMFS_train_1281/0000298175_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 22.1000 copies/mL;\nThe EBV of after treatment is 0.1390 copies/m; \nThe HGB is 142.9000 g/L;\nThe ALB is 39.3000 g/L;\n The CRP is 18.0500 mg/L;\n The LDH is 231.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 175 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 37.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 58.0333 ### months." } ], "images": [ "DMFS_train_1281/0000286479.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 142.9000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 1.0500 mg/L;\n The LDH is 215.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.4333 ### months." } ], "images": [ "DMFS_train_1281/0000278905.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 13 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 1.7400 copies/mL;\nThe EBV of after treatment is 1.8800 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 44.7000 g/L;\n The CRP is 0.2800 mg/L;\n The LDH is 167.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 62.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 81.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 30.3667 ### months." } ], "images": [ "DMFS_train_1281/0000280323.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.7500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 43.1000 g/L;\n The CRP is 0.5600 mg/L;\n The LDH is 369.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 7.5667 ### months." } ], "images": [ "DMFS_train_1281/0000263289_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 70.2000 copies/mL;\nThe EBV of after treatment is 161.0000 copies/m; \nThe HGB is 155.0000 g/L;\nThe ALB is 46.7000 g/L;\n The CRP is 3.4800 mg/L;\n The LDH is 229.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 60 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Lobaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 19.5667 ### months." } ], "images": [ "DMFS_train_1281/0000257528_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 53.2000 copies/mL;\nThe EBV of after treatment is 1.1100 copies/m; \nThe HGB is 93.0000 g/L;\nThe ALB is 35.8000 g/L;\n The CRP is 12.0400 mg/L;\n The LDH is 223.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 61.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.5000 ### months." } ], "images": [ "DMFS_train_1281/0000287271_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 69.3000 copies/mL;\nThe EBV of after treatment is 7.8200 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 43.6000 g/L;\n The CRP is 2.3900 mg/L;\n The LDH is 196.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 83.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 40.6667 ### months." } ], "images": [ "DMFS_train_1281/0000283452.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 1.5900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 106.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 0.9300 mg/L;\n The LDH is 124.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 18.9667 ### months." } ], "images": [ "DMFS_train_1281/0000307952_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 161.0000 copies/mL;\nThe EBV of after treatment is 241.0000 copies/m; \nThe HGB is 123.0000 g/L;\nThe ALB is 39.5000 g/L;\n The CRP is 0.6600 mg/L;\n The LDH is 117.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 81.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.5333 ### months." } ], "images": [ "DMFS_train_1281/0000268504.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 14.5000 copies/mL;\nThe EBV of after treatment is 7.4800 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 41.6000 g/L;\n The CRP is 0.5600 mg/L;\n The LDH is 196.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Docetaxel;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 76.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 10.5333 ### months." } ], "images": [ "DMFS_train_1281/0000289330_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 216.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 147.0000 g/L;\nThe ALB is 43.5000 g/L;\n The CRP is 6.4900 mg/L;\n The LDH is 359.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.4333 ### months." } ], "images": [ "DMFS_train_1281/0000238505_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 81.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 128.3000 g/L;\nThe ALB is 45.6000 g/L;\n The CRP is 1.9600 mg/L;\n The LDH is 166.0000 U/L; \nThe Number of course is 6;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 214.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 229.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.1000 ### months." } ], "images": [ "DMFS_train_1281/0000271157_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 30 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 5160.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 156.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 3.2300 mg/L;\n The LDH is 507.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.7000 ### months." } ], "images": [ "DMFS_train_1281/0000241900_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 50 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 20.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 137.0000 g/L;\nThe ALB is 44.9000 g/L;\n The CRP is 2.0600 mg/L;\n The LDH is 160.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 14.0333 ### months." } ], "images": [ "DMFS_train_1281/0000269151_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.5120 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 165.0000 g/L;\nThe ALB is 45.2000 g/L;\n The CRP is 2.3300 mg/L;\n The LDH is 169.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 33.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 51.4000 ### months." } ], "images": [ "DMFS_train_1281/0000308992.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 189.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.0000 g/L;\nThe ALB is 38.3000 g/L;\n The CRP is 2.0400 mg/L;\n The LDH is 233.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 36.0333 ### months." } ], "images": [ "DMFS_train_1281/0000278621.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 37 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.1380 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 163.0000 g/L;\nThe ALB is 44.6000 g/L;\n The CRP is 1.4100 mg/L;\n The LDH is 219.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is 5-fu;\n The time interval between induction chemotherapy and post-treatment imaging is 350.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 350.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 18.0333 ### months." } ], "images": [ "DMFS_train_1281/0000275292_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 131.0000 g/L;\nThe ALB is 34.0000 g/L;\n The CRP is 45.0000 mg/L;\n The LDH is 135.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 45.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 23.5333 ### months." } ], "images": [ "DMFS_train_1281/0000248891_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 193.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.5000 g/L;\nThe ALB is 47.5000 g/L;\n The CRP is 2.4100 mg/L;\n The LDH is 188.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 260 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 22.2333 ### months." } ], "images": [ "DMFS_train_1281/0000284687_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 9.5300 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 163.0000 g/L;\nThe ALB is 47.2000 g/L;\n The CRP is 0.1800 mg/L;\n The LDH is 184.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 68.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 72.0333 ### months." } ], "images": [ "DMFS_train_1281/0000260213.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.9200 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 152.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 24.1000 mg/L;\n The LDH is 254.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 44.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 57.4000 ### months." } ], "images": [ "DMFS_train_1281/0000251634.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 415.0000 copies/mL;\nThe EBV of after treatment is 25.6000 copies/m; \nThe HGB is 172.0000 g/L;\nThe ALB is 39.5000 g/L;\n The CRP is 2.8900 mg/L;\n The LDH is 243.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 16.5333 ### months." } ], "images": [ "DMFS_train_1281/0000272021_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 34 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 175.0000 copies/mL;\nThe EBV of after treatment is 12.0000 copies/m; \nThe HGB is 158.0000 g/L;\nThe ALB is 43.1000 g/L;\n The CRP is 1.1900 mg/L;\n The LDH is 208.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 120 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 5.2000 ### months." } ], "images": [ "DMFS_train_1281/00C1113916_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 1.1900 copies/mL;\nThe EBV of after treatment is 0.0116 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 42.3000 g/L;\n The CRP is 8.7400 mg/L;\n The LDH is 152.7000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 139.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 148.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.9333 ### months." } ], "images": [ "DMFS_train_1281/0000298323.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 97.4000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 147.0000 g/L;\nThe ALB is 49.3000 g/L;\n The CRP is 4.0700 mg/L;\n The LDH is 184.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 2:Mild complications that require some medication or treatment to control, and may have a slight impact on daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 42.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 33.7667 ### months." } ], "images": [ "DMFS_train_1281/0000253162.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 20 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 3.1300 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 138.0000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 0.8400 mg/L;\n The LDH is 134.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 48.8667 ### months." } ], "images": [ "DMFS_train_1281/0000305471.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.4100 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 163.0000 g/L;\nThe ALB is 42.8000 g/L;\n The CRP is 0.5300 mg/L;\n The LDH is 162.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 140 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 2:Mild complications that require some medication or treatment to control, and may have a slight impact on daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.2667 ### months." } ], "images": [ "DMFS_train_1281/0000238087_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 21.9000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 46.5000 g/L;\n The CRP is 2.1300 mg/L;\n The LDH is 243.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 60.0667 ### months." } ], "images": [ "DMFS_train_1281/0000290273.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 22.3000 copies/mL;\nThe EBV of after treatment is 1.9600 copies/m; \nThe HGB is 141.3000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 0.2700 mg/L;\n The LDH is 193.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 4.5000 ### months." } ], "images": [ "DMFS_train_1281/0000234079_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 25 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 51.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 101.0000 g/L;\nThe ALB is 41.6000 g/L;\n The CRP is 10.6400 mg/L;\n The LDH is 699.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 45.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 89.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 21.1333 ### months." } ], "images": [ "DMFS_train_1281/0000279724_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 12.5000 copies/mL;\nThe EBV of after treatment is 0.2240 copies/m; \nThe HGB is 128.0000 g/L;\nThe ALB is 42.2000 g/L;\n The CRP is 23.7200 mg/L;\n The LDH is 197.2100 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 93.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.9667 ### months." } ], "images": [ "DMFS_train_1281/0000288070_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 60 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 6.5600 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.4000 g/L;\nThe ALB is 49.9000 g/L;\n The CRP is 1.0600 mg/L;\n The LDH is 148.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 67.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 24.6667 ### months." } ], "images": [ "DMFS_train_1281/0000302413.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 62.0000 copies/mL;\nThe EBV of after treatment is 1.9700 copies/m; \nThe HGB is 168.0000 g/L;\nThe ALB is 45.1000 g/L;\n The CRP is 0.5300 mg/L;\n The LDH is 171.6000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 70.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 90.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 18.5333 ### months." } ], "images": [ "DMFS_train_1281/0000343586_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 74 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 48.9000 copies/mL;\nThe EBV of after treatment is 9.1500 copies/m; \nThe HGB is 107.0000 g/L;\nThe ALB is 41.3000 g/L;\n The CRP is 0.6500 mg/L;\n The LDH is 213.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 46.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 33.5333 ### months." } ], "images": [ "DMFS_train_1281/0000257722.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 63.3000 copies/mL;\nThe EBV of after treatment is 4.7800 copies/m; \nThe HGB is 148.9000 g/L;\nThe ALB is 45.4000 g/L;\n The CRP is 7.6800 mg/L;\n The LDH is 227.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 10.9000 ### months." } ], "images": [ "DMFS_train_1281/0000267484_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 39 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 15.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 149.6000 g/L;\nThe ALB is 46.1000 g/L;\n The CRP is 1.2200 mg/L;\n The LDH is 167.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 12.3000 ### months." } ], "images": [ "DMFS_train_1281/0000283283_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 32 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 21.2000 copies/mL;\nThe EBV of after treatment is 53.4000 copies/m; \nThe HGB is 118.9000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 10.7600 mg/L;\n The LDH is 177.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Docetaxel;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 72.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 52.2333 ### months." } ], "images": [ "DMFS_train_1281/0000300298.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.8770 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 159.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 3.6300 mg/L;\n The LDH is 199.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 2:Mild complications that require some medication or treatment to control, and may have a slight impact on daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 31.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 27.5333 ### months." } ], "images": [ "DMFS_train_1281/0000312261_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 62 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 12.0000 copies/mL;\nThe EBV of after treatment is 0.0119 copies/m; \nThe HGB is 145.8000 g/L;\nThe ALB is 40.8000 g/L;\n The CRP is 12.7800 mg/L;\n The LDH is 201.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 7:Severe complications, where the health of patient is significantly affected, with a potential life-threatening condition, requiring emergency medical intervention.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.1333 ### months." } ], "images": [ "DMFS_train_1281/0000267209_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 5.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.2000 g/L;\nThe ALB is 48.0000 g/L;\n The CRP is 1.2000 mg/L;\n The LDH is 185.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is 5-fu;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 44.8667 ### months." } ], "images": [ "DMFS_train_1281/0000274588.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 11.5000 copies/mL;\nThe EBV of after treatment is 2.1900 copies/m; \nThe HGB is 96.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 0.2700 mg/L;\n The LDH is 213.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 16.3333 ### months." } ], "images": [ "DMFS_train_1281/0000264822_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 136.3000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 3.3100 mg/L;\n The LDH is 187.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Carboplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 41.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 71.0333 ### months." } ], "images": [ "DMFS_train_1281/0000261474.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 16.9000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 0.8200 mg/L;\n The LDH is 122.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 43.3333 ### months." } ], "images": [ "DMFS_train_1281/0000274789_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 65 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.7810 copies/mL;\nThe EBV of after treatment is 0.3540 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 44.7000 g/L;\n The CRP is 0.2100 mg/L;\n The LDH is 190.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 28.3000 ### months." } ], "images": [ "DMFS_train_1281/0000292156_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 46.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 44.6000 g/L;\n The CRP is 0.8000 mg/L;\n The LDH is 333.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 89.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 13.5667 ### months." } ], "images": [ "DMFS_train_1281/0000268787_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 31 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.2700 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 0.2000 mg/L;\n The LDH is 170.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 175 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 5:More severe complications that require the patient to be hospitalized or undergo more frequent medical interventions.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 29.8000 ### months." } ], "images": [ "DMFS_train_1281/0000249885_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.3650 copies/m; \nThe HGB is 127.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 0.9600 mg/L;\n The LDH is 175.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 40.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 27.8667 ### months." } ], "images": [ "DMFS_train_1281/0000304660.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 21 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 25.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 104.0000 g/L;\nThe ALB is 38.1000 g/L;\n The CRP is 54.3700 mg/L;\n The LDH is 197.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 519.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 28.0000 ### months." } ], "images": [ "DMFS_train_1281/0000322644_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.3100 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 115.0000 g/L;\nThe ALB is 39.4000 g/L;\n The CRP is 13.0000 mg/L;\n The LDH is 104.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is None; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 33.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 56.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 38.9000 ### months." } ], "images": [ "DMFS_train_1281/0000281737.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 29.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 179.0000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 35.0000 mg/L;\n The LDH is 154.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 45.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 81.1000 ### months." } ], "images": [ "DMFS_train_1281/0000246974.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 34 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.5300 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 45.5000 g/L;\n The CRP is 0.6700 mg/L;\n The LDH is 207.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 52.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 51.0667 ### months." } ], "images": [ "DMFS_train_1281/0000286008.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 12.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 171.0000 g/L;\nThe ALB is 42.9000 g/L;\n The CRP is 1.6200 mg/L;\n The LDH is 191.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 40.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 70.1667 ### months." } ], "images": [ "DMFS_train_1281/0000284366.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.2220 copies/mL;\nThe EBV of after treatment is 1.0200 copies/m; \nThe HGB is 141.1000 g/L;\nThe ALB is 41.3000 g/L;\n The CRP is 1.9900 mg/L;\n The LDH is 158.8000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 39.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 53.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 17.4333 ### months." } ], "images": [ "DMFS_train_1281/0000302389_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 53 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 97.4000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.6000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 5.1500 mg/L;\n The LDH is 253.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.9667 ### months." } ], "images": [ "DMFS_train_1281/0000234661_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 3.9000 copies/mL;\nThe EBV of after treatment is 0.6190 copies/m; \nThe HGB is 163.0000 g/L;\nThe ALB is 49.4000 g/L;\n The CRP is 0.7400 mg/L;\n The LDH is 220.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 61.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 87.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 60.8000 ### months." } ], "images": [ "DMFS_train_1281/0000281613.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 9.2600 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 124.0000 g/L;\nThe ALB is 46.9000 g/L;\n The CRP is 6.1900 mg/L;\n The LDH is 210.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 81.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 30.6333 ### months." } ], "images": [ "DMFS_train_1281/0000266998.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 50 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 4.4300 copies/m; \nThe HGB is 160.8000 g/L;\nThe ALB is 44.2000 g/L;\n The CRP is 1.1000 mg/L;\n The LDH is 160.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 63.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 71.6667 ### months." } ], "images": [ "DMFS_train_1281/0000263496.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 1:Benign or low grade malignant;\nThe Age is 52 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 33.2000 copies/mL;\nThe EBV of after treatment is 5.7800 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 0.5000 mg/L;\n The LDH is 206.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 106.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 116.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 58.9000 ### months." } ], "images": [ "DMFS_train_1281/0000245599_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 52.5000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 44.4000 g/L;\n The CRP is 27.0100 mg/L;\n The LDH is 190.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 57.8000 ### months." } ], "images": [ "DMFS_train_1281/0000309235.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 34 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 46.6000 copies/mL;\nThe EBV of after treatment is 4.1100 copies/m; \nThe HGB is 144.0000 g/L;\nThe ALB is 38.6000 g/L;\n The CRP is 4.5600 mg/L;\n The LDH is 208.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 24.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 36.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 58.3667 ### months." } ], "images": [ "DMFS_train_1281/0000237773.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.2640 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 158.0000 g/L;\nThe ALB is 43.3000 g/L;\n The CRP is 11.7700 mg/L;\n The LDH is 140.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 2:Mild complications that require some medication or treatment to control, and may have a slight impact on daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 51.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 40.0667 ### months." } ], "images": [ "DMFS_train_1281/0000308093.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 57 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 6.3100 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 161.0000 g/L;\nThe ALB is 42.2000 g/L;\n The CRP is 3.7100 mg/L;\n The LDH is 140.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 58.0000 ### months." } ], "images": [ "DMFS_train_1281/0000308896.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 76.1000 copies/mL;\nThe EBV of after treatment is 11.1000 copies/m; \nThe HGB is 163.4000 g/L;\nThe ALB is 48.1000 g/L;\n The CRP is 7.7700 mg/L;\n The LDH is 303.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 81.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 135.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 32.4000 ### months." } ], "images": [ "DMFS_train_1281/0000301982.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 3.0100 copies/mL;\nThe EBV of after treatment is 8.3700 copies/m; \nThe HGB is 128.0000 g/L;\nThe ALB is 42.0000 g/L;\n The CRP is 1.7900 mg/L;\n The LDH is 143.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 33.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 45.2000 ### months." } ], "images": [ "DMFS_train_1281/0000308606.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 55 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.5700 copies/mL;\nThe EBV of after treatment is 0.2970 copies/m; \nThe HGB is 146.0000 g/L;\nThe ALB is 40.4000 g/L;\n The CRP is 2.6200 mg/L;\n The LDH is 197.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 82.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 33.2667 ### months." } ], "images": [ "DMFS_train_1281/0000297982_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.3900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 121.0000 g/L;\nThe ALB is 48.8000 g/L;\n The CRP is 2.1900 mg/L;\n The LDH is 258.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 33.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 44.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.0667 ### months." } ], "images": [ "DMFS_train_1281/0000280378.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 49.5000 copies/mL;\nThe EBV of after treatment is 3.5900 copies/m; \nThe HGB is 115.3000 g/L;\nThe ALB is 36.9000 g/L;\n The CRP is 15.3400 mg/L;\n The LDH is 134.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 2:Mild complications that require some medication or treatment to control, and may have a slight impact on daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 65.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 90.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 33.7333 ### months." } ], "images": [ "DMFS_train_1281/0000304885.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 7.0300 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 109.0000 g/L;\nThe ALB is 41.2000 g/L;\n The CRP is 10.6700 mg/L;\n The LDH is 163.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 127.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 144.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.1667 ### months." } ], "images": [ "DMFS_train_1281/0000265451_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 3.9900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 42.0000 g/L;\n The CRP is 147.0000 mg/L;\n The LDH is 188.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 38.3667 ### months." } ], "images": [ "DMFS_train_1281/0000249701.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 28 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 46.9000 g/L;\n The CRP is 3.4500 mg/L;\n The LDH is 232.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 42.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 73.4333 ### months." } ], "images": [ "DMFS_train_1281/0000259448.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 44.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 42.3000 g/L;\n The CRP is 19.0600 mg/L;\n The LDH is 200.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 20.9333 ### months." } ], "images": [ "DMFS_train_1281/0000307320_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 3.3900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 41.9000 g/L;\n The CRP is 11.6100 mg/L;\n The LDH is 148.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 33.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 22.3333 ### months." } ], "images": [ "DMFS_train_1281/0000291959_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 5.7100 copies/mL;\nThe EBV of after treatment is 1.1900 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 43.5000 g/L;\n The CRP is 1.1200 mg/L;\n The LDH is 164.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 52.0333 ### months." } ], "images": [ "DMFS_train_1281/0000298902.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 26 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 5.2800 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 45.1000 g/L;\n The CRP is 0.2600 mg/L;\n The LDH is 150.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 56.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 36.8333 ### months." } ], "images": [ "DMFS_train_1281/0000281903.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 71.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 0.9700 mg/L;\n The LDH is 177.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 27.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 13.7333 ### months." } ], "images": [ "DMFS_train_1281/0000234802_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 50 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 92.9000 copies/mL;\nThe EBV of after treatment is 4.0000 copies/m; \nThe HGB is 155.0000 g/L;\nThe ALB is 46.1000 g/L;\n The CRP is 2.5300 mg/L;\n The LDH is 143.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 44.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.2667 ### months." } ], "images": [ "DMFS_train_1281/0000276921.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 16 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 87.4000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 110.5000 g/L;\nThe ALB is 46.2000 g/L;\n The CRP is 47.4400 mg/L;\n The LDH is 332.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 130 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 43.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 48.6333 ### months." } ], "images": [ "DMFS_train_1281/0000255984.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 20 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 39.7000 copies/mL;\nThe EBV of after treatment is 0.5950 copies/m; \nThe HGB is 149.0000 g/L;\nThe ALB is 46.2000 g/L;\n The CRP is 3.9600 mg/L;\n The LDH is 273.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 100 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 46.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 26.3333 ### months." } ], "images": [ "DMFS_train_1281/0000282281_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 62.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.0000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 12.2000 mg/L;\n The LDH is 195.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 33.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 21.4667 ### months." } ], "images": [ "DMFS_train_1281/0000249641_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 1:Benign or low grade malignant;\nThe Age is 48 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 113.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 137.0000 g/L;\nThe ALB is 45.5000 g/L;\n The CRP is 0.7800 mg/L;\n The LDH is 202.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 300 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 37.7000 ### months." } ], "images": [ "DMFS_train_1281/0000256497.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 25 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0506 copies/m; \nThe HGB is 152.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 0.8000 mg/L;\n The LDH is 146.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 57.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 58.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 56.9000 ### months." } ], "images": [ "DMFS_train_1281/0000310327.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.2520 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 147.0000 g/L;\nThe ALB is 41.4000 g/L;\n The CRP is 1.4800 mg/L;\n The LDH is 149.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 46.8000 ### months." } ], "images": [ "DMFS_train_1281/0000310972.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 32 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 44.4000 copies/mL;\nThe EBV of after treatment is 7.6500 copies/m; \nThe HGB is 160.0000 g/L;\nThe ALB is 45.2000 g/L;\n The CRP is 47.9200 mg/L;\n The LDH is 207.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 83.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.9000 ### months." } ], "images": [ "DMFS_train_1281/0000274360.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 14.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 126.0000 g/L;\nThe ALB is 44.2000 g/L;\n The CRP is 0.5000 mg/L;\n The LDH is 164.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 4:Moderate complications that affect daily life, require medical intervention, and may lead to a decline in some aspects of self-care ability.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 69.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 60.8000 ### months." } ], "images": [ "DMFS_train_1281/0000304489.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 37.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 31.3000 mg/L;\n The LDH is 218.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 145 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.2000 ### months." } ], "images": [ "DMFS_train_1281/0000251188_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 73 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.1300 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 150.0000 g/L;\nThe ALB is 38.5000 g/L;\n The CRP is 0.6100 mg/L;\n The LDH is 186.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 6; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Sunitinib/ Nivolumab;\n The time interval between induction chemotherapy and post-treatment imaging is 74.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 83.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 39.9000 ### months." } ], "images": [ "DMFS_train_1281/0000252915.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 29.2000 copies/mL;\nThe EBV of after treatment is 47.9000 copies/m; \nThe HGB is 113.0000 g/L;\nThe ALB is 40.0000 g/L;\n The CRP is 1.8000 mg/L;\n The LDH is 151.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 4:Moderate complications that affect daily life, require medical intervention, and may lead to a decline in some aspects of self-care ability.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 38.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 71.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.8667 ### months." } ], "images": [ "DMFS_train_1281/0000249999_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 144.0000 g/L;\nThe ALB is 43.5000 g/L;\n The CRP is 21.2300 mg/L;\n The LDH is 158.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 8:Extremely severe complications that may be life-threatening, with impaired function of multiple organ systems, requiring intensive care and emergency treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 28.1000 ### months." } ], "images": [ "DMFS_train_1281/0000258637_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 7.4500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 40.7000 g/L;\n The CRP is 17.2600 mg/L;\n The LDH is 240.4000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 80.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 91.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 53.5333 ### months." } ], "images": [ "DMFS_train_1281/0000238501.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 62 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 17.2000 copies/mL;\nThe EBV of after treatment is 6.5500 copies/m; \nThe HGB is 155.0000 g/L;\nThe ALB is 46.9000 g/L;\n The CRP is 0.6400 mg/L;\n The LDH is 174.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.3333 ### months." } ], "images": [ "DMFS_train_1281/0000293352.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.9000 copies/mL;\nThe EBV of after treatment is 0.3650 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 0.6600 mg/L;\n The LDH is 145.9000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 250 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 60.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 67.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.3000 ### months." } ], "images": [ "DMFS_train_1281/0000289813.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 74.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 113.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 0.4600 mg/L;\n The LDH is 212.4000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 112.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 132.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.3333 ### months." } ], "images": [ "DMFS_train_1281/0000238035_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 50 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 34.8000 copies/mL;\nThe EBV of after treatment is 0.1900 copies/m; \nThe HGB is 121.9000 g/L;\nThe ALB is 41.8000 g/L;\n The CRP is 1.3200 mg/L;\n The LDH is 243.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 300 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 59.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 75.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 59.3000 ### months." } ], "images": [ "DMFS_train_1281/0000285173.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 23.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 158.0000 g/L;\nThe ALB is 48.0000 g/L;\n The CRP is 2.5300 mg/L;\n The LDH is 194.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 6:More severe complications, where the health of patient is significantly affected and they may be unable to perform normal daily activities. Hospitalization or more frequent medical interventions are required.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.6333 ### months." } ], "images": [ "DMFS_train_1281/0000233512_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 17.5000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 44.2000 g/L;\n The CRP is 0.4900 mg/L;\n The LDH is 143.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 29.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 47.2333 ### months." } ], "images": [ "DMFS_train_1281/0000310015_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 54.7000 copies/mL;\nThe EBV of after treatment is 0.4380 copies/m; \nThe HGB is 161.0000 g/L;\nThe ALB is 45.9000 g/L;\n The CRP is 1.8500 mg/L;\n The LDH is 166.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 245 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.8000 ### months." } ], "images": [ "DMFS_train_1281/0000307229_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 10.1000 copies/mL;\nThe EBV of after treatment is 2.8400 copies/m; \nThe HGB is 141.6000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 5.1500 mg/L;\n The LDH is 193.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 130 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 70.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 79.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 48.9000 ### months." } ], "images": [ "DMFS_train_1281/0000265275.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 91.3000 copies/mL;\nThe EBV of after treatment is 15.3000 copies/m; \nThe HGB is 129.0000 g/L;\nThe ALB is 38.8000 g/L;\n The CRP is 2.9600 mg/L;\n The LDH is 135.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 41.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 47.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.0000 ### months." } ], "images": [ "DMFS_train_1281/0000274945.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 3.4100 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 47.8000 g/L;\n The CRP is 7.0300 mg/L;\n The LDH is 162.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 70.4333 ### months." } ], "images": [ "DMFS_train_1281/0000284399.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 72.7000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 138.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 0.7000 mg/L;\n The LDH is 190.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 62.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 62.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 88.8000 ### months." } ], "images": [ "DMFS_train_1281/0000236626.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 102.1000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 0.1800 mg/L;\n The LDH is 176.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 36.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 13.8333 ### months." } ], "images": [ "DMFS_train_1281/0000275246_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 634.0000 copies/mL;\nThe EBV of after treatment is 10.8000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 42.0000 g/L;\n The CRP is 0.9000 mg/L;\n The LDH is 250.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 235 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 52.7000 ### months." } ], "images": [ "DMFS_train_1281/0000246555_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.9370 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 45.4000 g/L;\n The CRP is 0.6100 mg/L;\n The LDH is 159.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 170 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 37.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 32.4000 ### months." } ], "images": [ "DMFS_train_1281/0000295397_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 64 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 156.4000 g/L;\nThe ALB is 38.7000 g/L;\n The CRP is 6.3800 mg/L;\n The LDH is 212.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 81.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 90.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 52.9000 ### months." } ], "images": [ "DMFS_train_1281/0000295663.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 44.2000 g/L;\n The CRP is 1.7400 mg/L;\n The LDH is 170.3000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 75.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 92.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.1333 ### months." } ], "images": [ "DMFS_train_1281/0000275271_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 14.7000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.4000 g/L;\nThe ALB is 47.1000 g/L;\n The CRP is 0.3800 mg/L;\n The LDH is 223.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 10.5333 ### months." } ], "images": [ "DMFS_train_1281/0000294160_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 12.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.1000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 2.4600 mg/L;\n The LDH is 182.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.3333 ### months." } ], "images": [ "DMFS_train_1281/0000283926_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 15.2000 copies/mL;\nThe EBV of after treatment is 0.6020 copies/m; \nThe HGB is 155.5000 g/L;\nThe ALB is 39.7000 g/L;\n The CRP is 3.1000 mg/L;\n The LDH is 207.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 51.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 3.5667 ### months." } ], "images": [ "DMFS_train_1281/0000292857_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.8910 copies/mL;\nThe EBV of after treatment is 1.3300 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 43.7000 g/L;\n The CRP is 0.3500 mg/L;\n The LDH is 269.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 25.4667 ### months." } ], "images": [ "DMFS_train_1281/0000293091_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 30 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 133.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 38.9000 g/L;\n The CRP is 23.0500 mg/L;\n The LDH is 264.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 64.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 79.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.8000 ### months." } ], "images": [ "DMFS_train_1281/0000274223.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 93.9000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 42.9000 g/L;\n The CRP is 1.7600 mg/L;\n The LDH is 244.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 42.3333 ### months." } ], "images": [ "DMFS_train_1281/0000279540_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 24 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 24.8000 copies/mL;\nThe EBV of after treatment is 0.0862 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 48.9000 g/L;\n The CRP is 0.6600 mg/L;\n The LDH is 191.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 63.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 16.4000 ### months." } ], "images": [ "DMFS_train_1281/0000287466_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.5400 copies/mL;\nThe EBV of after treatment is 0.1520 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 0.4200 mg/L;\n The LDH is 150.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 8:Extremely severe complications that may be life-threatening, with impaired function of multiple organ systems, requiring intensive care and emergency treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 31.2000 ### months." } ], "images": [ "DMFS_train_1281/0000288189_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 8.3600 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.6000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 2.8500 mg/L;\n The LDH is 181.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 52.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 46.3667 ### months." } ], "images": [ "DMFS_train_1281/0000283326_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1160.0000 copies/mL;\nThe EBV of after treatment is 0.1240 copies/m; \nThe HGB is 116.9000 g/L;\nThe ALB is 32.7000 g/L;\n The CRP is 6.0600 mg/L;\n The LDH is 627.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 60.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 90.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.3667 ### months." } ], "images": [ "DMFS_train_1281/0000284028_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 26.7000 copies/mL;\nThe EBV of after treatment is 26.7000 copies/m; \nThe HGB is 137.0000 g/L;\nThe ALB is 39.9000 g/L;\n The CRP is 7.9700 mg/L;\n The LDH is 349.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 38.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 60.5333 ### months." } ], "images": [ "DMFS_train_1281/0000283067.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 28 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 105.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 46.3000 g/L;\n The CRP is 0.2500 mg/L;\n The LDH is 145.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.1000 ### months." } ], "images": [ "DMFS_train_1281/0000278818_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2290.0000 copies/mL;\nThe EBV of after treatment is 3.0800 copies/m; \nThe HGB is 129.0000 g/L;\nThe ALB is 35.5000 g/L;\n The CRP is 6.0900 mg/L;\n The LDH is 189.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 76.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 26.9000 ### months." } ], "images": [ "DMFS_train_1281/0000277655_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 34 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 6.0400 copies/mL;\nThe EBV of after treatment is 0.0296 copies/m; \nThe HGB is 164.0000 g/L;\nThe ALB is 49.5000 g/L;\n The CRP is 3.0200 mg/L;\n The LDH is 182.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 67.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 76.4000 ### months." } ], "images": [ "DMFS_train_1281/0000254594.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 30 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 128.0000 g/L;\nThe ALB is 40.8000 g/L;\n The CRP is 1.8000 mg/L;\n The LDH is 156.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 41.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 75.4333 ### months." } ], "images": [ "DMFS_train_1281/00C1090356.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 22.9000 copies/mL;\nThe EBV of after treatment is 61.4000 copies/m; \nThe HGB is 140.0000 g/L;\nThe ALB is 43.2000 g/L;\n The CRP is 0.4400 mg/L;\n The LDH is 225.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 80.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 27.1667 ### months." } ], "images": [ "DMFS_train_1281/0000276422_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 170.0000 copies/mL;\nThe EBV of after treatment is 5.2500 copies/m; \nThe HGB is 160.0000 g/L;\nThe ALB is 46.8000 g/L;\n The CRP is 0.8900 mg/L;\n The LDH is 181.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 36.5000 ### months." } ], "images": [ "DMFS_train_1281/0000271216_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 16 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.1500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 110.3000 g/L;\nThe ALB is 39.7000 g/L;\n The CRP is 1.0000 mg/L;\n The LDH is 203.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 34.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 60.2667 ### months." } ], "images": [ "DMFS_train_1281/0000269109_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 5.0500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 94.7000 g/L;\nThe ALB is 36.7000 g/L;\n The CRP is 1.1900 mg/L;\n The LDH is 189.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 77.7333 ### months." } ], "images": [ "DMFS_train_1281/0000253461.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 87.7000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 155.0000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 1.1000 mg/L;\n The LDH is 143.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 44.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 79.5667 ### months." } ], "images": [ "DMFS_train_1281/00C1082591.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 62 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 11.5000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 44.4000 g/L;\n The CRP is 1.2400 mg/L;\n The LDH is 196.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 300 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 33.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 69.6000 ### months." } ], "images": [ "DMFS_train_1281/0000265731.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 55 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.3020 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 152.0000 g/L;\nThe ALB is 46.2000 g/L;\n The CRP is 3.3800 mg/L;\n The LDH is 172.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 47.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 73.4000 ### months." } ], "images": [ "DMFS_train_1281/0000258105.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 190.0000 copies/mL;\nThe EBV of after treatment is 59.4000 copies/m; \nThe HGB is 152.0000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 5.3000 mg/L;\n The LDH is 192.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 300 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 60.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 71.2333 ### months." } ], "images": [ "DMFS_train_1281/0000250277.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 22 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2220.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 39.4000 g/L;\n The CRP is 9.6900 mg/L;\n The LDH is 357.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.1667 ### months." } ], "images": [ "DMFS_train_1281/0000259582_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 53 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 39.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 122.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 3.0000 mg/L;\n The LDH is 151.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 49.9333 ### months." } ], "images": [ "DMFS_train_1281/0000246031_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 336.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 17.0000 mg/L;\n The LDH is 256.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.1667 ### months." } ], "images": [ "DMFS_train_1281/0000246867_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 65 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 9080.0000 copies/mL;\nThe EBV of after treatment is 2.8000 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 5.8600 mg/L;\n The LDH is 257.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 120 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 37.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 37.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 83.3333 ### months." } ], "images": [ "DMFS_train_1281/0000237233.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 695.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 169.0000 g/L;\nThe ALB is 47.0000 g/L;\n The CRP is 1.4500 mg/L;\n The LDH is 219.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 65.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 85.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 41.5000 ### months." } ], "images": [ "DMFS_train_1281/00C1075158_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 29 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 19.0000 copies/mL;\nThe EBV of after treatment is 62.1000 copies/m; \nThe HGB is 156.0000 g/L;\nThe ALB is 49.6000 g/L;\n The CRP is 1.4500 mg/L;\n The LDH is 224.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 41.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 57.3333 ### months." } ], "images": [ "DMFS_train_1281/0000240391_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 68 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 11.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.4000 g/L;\nThe ALB is 41.8000 g/L;\n The CRP is 4.7900 mg/L;\n The LDH is 183.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 185 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 36.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 74.7333 ### months." } ], "images": [ "DMFS_train_1281/0000230159_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 63 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 624.6900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 137.9000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 1.9800 mg/L;\n The LDH is 156.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 33.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 33.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 87.2333 ### months." } ], "images": [ "DMFS_train_1281/0000236071.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 2.3500 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 3.0900 mg/L;\n The LDH is 166.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 155 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 51.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 51.5000 ### months." } ], "images": [ "DMFS_train_1281/0000239925_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 62 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 3.6000 copies/mL;\nThe EBV of after treatment is 0.2490 copies/m; \nThe HGB is 120.3000 g/L;\nThe ALB is 38.7000 g/L;\n The CRP is 4.3400 mg/L;\n The LDH is 264.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 44.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 87.5000 ### months." } ], "images": [ "DMFS_train_1281/0000237435.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 56.9000 copies/mL;\nThe EBV of after treatment is 4.6000 copies/m; \nThe HGB is 124.8000 g/L;\nThe ALB is 45.7000 g/L;\n The CRP is 9.0800 mg/L;\n The LDH is 191.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 46.5500 months;\nThe time interval between diagnosis and post-treatment imaging is 96.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.2000 ### months." } ], "images": [ "DMFS_train_1281/0000279251_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 68.3000 copies/mL;\nThe EBV of after treatment is 4.6000 copies/m; \nThe HGB is 164.0000 g/L;\nThe ALB is 43.3000 g/L;\n The CRP is 77.4100 mg/L;\n The LDH is 373.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 46.5500 months;\nThe time interval between diagnosis and post-treatment imaging is 95.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 22.7667 ### months." } ], "images": [ "DMFS_train_1281/0000287095.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 55 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 18.8000 copies/mL;\nThe EBV of after treatment is 4.6000 copies/m; \nThe HGB is 122.0000 g/L;\nThe ALB is 42.7000 g/L;\n The CRP is 10.3900 mg/L;\n The LDH is 280.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 8:Extremely severe complications that may be life-threatening, with impaired function of multiple organ systems, requiring intensive care and emergency treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 46.5500 months;\nThe time interval between diagnosis and post-treatment imaging is 84.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 25.9667 ### months." } ], "images": [ "DMFS_train_1281/0000297492.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 11.4000 copies/mL;\nThe EBV of after treatment is 4.6000 copies/m; \nThe HGB is 109.0000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 5.1500 mg/L;\n The LDH is 193.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 46.5500 months;\nThe time interval between diagnosis and post-treatment imaging is 67.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 53.2000 ### months." } ], "images": [ "DMFS_train_1281/0000298637.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 54.5000 copies/mL;\nThe EBV of after treatment is 4.6000 copies/m; \nThe HGB is 137.0000 g/L;\nThe ALB is 38.1000 g/L;\n The CRP is 3.0100 mg/L;\n The LDH is 240.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 46.5500 months;\nThe time interval between diagnosis and post-treatment imaging is 132.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.7667 ### months." } ], "images": [ "DMFS_train_1281/0000258249_1.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 21.1000 copies/mL;\nThe EBV of after treatment is 4.6000 copies/m; \nThe HGB is 162.1000 g/L;\nThe ALB is 46.2000 g/L;\n The CRP is 0.7700 mg/L;\n The LDH is 170.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Docetaxel;\n The time interval between induction chemotherapy and post-treatment imaging is 46.5500 months;\nThe time interval between diagnosis and post-treatment imaging is 85.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 65.6667 ### months." } ], "images": [ "DMFS_train_1281/0000274721.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 62 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 36.1000 copies/mL;\nThe EBV of after treatment is 4.6000 copies/m; \nThe HGB is 144.0000 g/L;\nThe ALB is 51.0000 g/L;\n The CRP is 2.3000 mg/L;\n The LDH is 179.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 46.5500 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 57.5667 ### months." } ], "images": [ "DMFS_train_1281/0000249692.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 53 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 4.6000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 46.3000 g/L;\n The CRP is 11.0800 mg/L;\n The LDH is 222.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 4:Moderate complications that affect daily life, require medical intervention, and may lead to a decline in some aspects of self-care ability.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 46.5500 months;\nThe time interval between diagnosis and post-treatment imaging is 77.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 77.7000 ### months." } ], "images": [ "DMFS_train_1281/0000255885.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 62 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 27.7000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 125.0000 g/L;\nThe ALB is 39.4000 g/L;\n The CRP is 2.6800 mg/L;\n The LDH is 151.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 双眼视网膜病变:Bilateral retinopathy is a disease affecting the retinal vasculature and nerves, which in nasopharyngeal cancer patients may result from paraneoplastic immune response or radiation-induced damage. It may indicate distant metastasis or systemic vascular abnormalities, affecting prognosis and reducing treatment adherence and quality of life due to vision impairment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 68.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 36.1667 ### months." } ], "images": [ "DMFS_train_1281/0000283114.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 65 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 56.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 9.8000 mg/L;\n The LDH is 204.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 38.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 40.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 38.6333 ### months." } ], "images": [ "DMFS_train_1281/0000300607.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 34 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.3430 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 49.4000 g/L;\n The CRP is 2.3500 mg/L;\n The LDH is 182.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 39.8667 ### months." } ], "images": [ "DMFS_train_1281/0000300486.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 2.0900 copies/mL;\nThe EBV of after treatment is 0.1690 copies/m; \nThe HGB is 148.5000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 7.5600 mg/L;\n The LDH is 229.7000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 82.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 91.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 40.1333 ### months." } ], "images": [ "DMFS_train_1281/0000297048.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 22 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 97.4000 copies/mL;\nThe EBV of after treatment is 0.5950 copies/m; \nThe HGB is 171.0000 g/L;\nThe ALB is 44.3000 g/L;\n The CRP is 4.6600 mg/L;\n The LDH is 157.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 40.6000 ### months." } ], "images": [ "DMFS_train_1281/0000297986.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 18 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 10.5000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 133.0000 g/L;\nThe ALB is 42.8000 g/L;\n The CRP is 9.0900 mg/L;\n The LDH is 245.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 103.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 42.8333 ### months." } ], "images": [ "DMFS_train_1281/0000294754.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 50 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 34.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.1000 g/L;\nThe ALB is 39.0000 g/L;\n The CRP is 2.5900 mg/L;\n The LDH is 157.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 51.7333 ### months." } ], "images": [ "DMFS_train_1281/0000284472.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 126.0000 g/L;\nThe ALB is 40.3000 g/L;\n The CRP is 4.0500 mg/L;\n The LDH is 221.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 300 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 61.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 45.5667 ### months." } ], "images": [ "DMFS_train_1281/0000313917.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 5.2000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 154.0000 g/L;\nThe ALB is 44.9000 g/L;\n The CRP is 0.6000 mg/L;\n The LDH is 151.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 47.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 61.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 55.5667 ### months." } ], "images": [ "DMFS_train_1281/0000313542.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 112.0000 g/L;\nThe ALB is 43.3000 g/L;\n The CRP is 2.0800 mg/L;\n The LDH is 134.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 280 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 60.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 45.9667 ### months." } ], "images": [ "DMFS_train_1281/0000313698.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 16.4000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 152.0000 g/L;\nThe ALB is 46.6000 g/L;\n The CRP is 1.7900 mg/L;\n The LDH is 153.2000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 61.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 46.0667 ### months." } ], "images": [ "DMFS_train_1281/0000312655.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 9.5500 copies/mL;\nThe EBV of after treatment is 194.0000 copies/m; \nThe HGB is 140.0000 g/L;\nThe ALB is 43.6000 g/L;\n The CRP is 0.9200 mg/L;\n The LDH is 123.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 41.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 46.0667 ### months." } ], "images": [ "DMFS_train_1281/0000312645.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 27 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 27.7000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 159.0000 g/L;\nThe ALB is 45.9000 g/L;\n The CRP is 0.2300 mg/L;\n The LDH is 184.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 46.1000 ### months." } ], "images": [ "DMFS_train_1281/0000314285.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2.8700 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 1.2600 mg/L;\n The LDH is 167.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 58.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 46.1333 ### months." } ], "images": [ "DMFS_train_1281/0000311990.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.8180 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 126.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 0.6900 mg/L;\n The LDH is 141.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 60.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 46.1667 ### months." } ], "images": [ "DMFS_train_1281/0000312431.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 4.7400 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 162.0000 g/L;\nThe ALB is 48.2000 g/L;\n The CRP is 0.2500 mg/L;\n The LDH is 221.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Docetaxel;\n The time interval between induction chemotherapy and post-treatment imaging is 39.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 73.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 69.5667 ### months." } ], "images": [ "DMFS_train_1281/00C1125013.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 62 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.6230 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 126.0000 g/L;\nThe ALB is 45.6000 g/L;\n The CRP is 3.9300 mg/L;\n The LDH is 173.3000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 87.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 117.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 53.5000 ### months." } ], "images": [ "DMFS_train_1281/0000314474.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.9200 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 168.0000 g/L;\nThe ALB is 51.5000 g/L;\n The CRP is 2.2800 mg/L;\n The LDH is 186.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 71.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 56.7000 ### months." } ], "images": [ "DMFS_train_1281/0000313737.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.2200 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 121.0000 g/L;\nThe ALB is 38.7000 g/L;\n The CRP is 0.2800 mg/L;\n The LDH is 134.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 46.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 71.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 54.9000 ### months." } ], "images": [ "DMFS_train_1281/0000313756.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 29 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.4100 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 160.0000 g/L;\nThe ALB is 46.9000 g/L;\n The CRP is 1.5800 mg/L;\n The LDH is 122.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 69.7667 ### months." } ], "images": [ "DMFS_train_1281/0000286054.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 39 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 15.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 119.0000 g/L;\nThe ALB is 39.5000 g/L;\n The CRP is 1.1500 mg/L;\n The LDH is 155.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 45.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 46.7333 ### months." } ], "images": [ "DMFS_train_1281/0000283104.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 121.0000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 1.3400 mg/L;\n The LDH is 137.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 31.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 57.1667 ### months." } ], "images": [ "DMFS_train_1281/0000310902.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 156.0000 g/L;\nThe ALB is 46.8000 g/L;\n The CRP is 0.6200 mg/L;\n The LDH is 170.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 71.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 57.4000 ### months." } ], "images": [ "DMFS_train_1281/0000312028.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 2.0300 copies/mL;\nThe EBV of after treatment is 0.3470 copies/m; \nThe HGB is 141.0000 g/L;\nThe ALB is 47.8000 g/L;\n The CRP is 1.5900 mg/L;\n The LDH is 177.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 46.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 99.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 57.4667 ### months." } ], "images": [ "DMFS_train_1281/0000314103.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 11.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 158.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 7.1100 mg/L;\n The LDH is 124.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 57.5000 ### months." } ], "images": [ "DMFS_train_1281/0000310094.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 50 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.7660 copies/mL;\nThe EBV of after treatment is 12.5000 copies/m; \nThe HGB is 164.0000 g/L;\nThe ALB is 42.2000 g/L;\n The CRP is 3.9800 mg/L;\n The LDH is 166.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 6; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 38.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 47.2000 ### months." } ], "images": [ "DMFS_train_1281/0000310001.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 53 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 9.8300 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 2.1100 mg/L;\n The LDH is 172.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 57.6000 ### months." } ], "images": [ "DMFS_train_1281/0000311300.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 12.5000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 150.0000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 8.3400 mg/L;\n The LDH is 189.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 51.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 65.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 57.6000 ### months." } ], "images": [ "DMFS_train_1281/0000310713.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.8630 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 164.0000 g/L;\nThe ALB is 47.3000 g/L;\n The CRP is 4.0000 mg/L;\n The LDH is 197.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 51.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 52.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 47.4333 ### months." } ], "images": [ "DMFS_train_1281/0000309484.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 9 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.8110 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 114.0000 g/L;\nThe ALB is 37.0000 g/L;\n The CRP is 12.9400 mg/L;\n The LDH is 166.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 57.8333 ### months." } ], "images": [ "DMFS_train_1281/0000309476.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.9090 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 124.0000 g/L;\nThe ALB is 44.4000 g/L;\n The CRP is 1.2500 mg/L;\n The LDH is 183.7000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 110 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 40.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 85.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 57.8000 ### months." } ], "images": [ "DMFS_train_1281/0000312527.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 52.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 120.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 2.9600 mg/L;\n The LDH is 190.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 60.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 72.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 57.8667 ### months." } ], "images": [ "DMFS_train_1281/0000309401.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 11.6000 copies/mL;\nThe EBV of after treatment is 0.4130 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 43.3000 g/L;\n The CRP is 6.1900 mg/L;\n The LDH is 231.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 25.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 45.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 58.0000 ### months." } ], "images": [ "DMFS_train_1281/0000310325.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 11 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 4.2800 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 121.0000 g/L;\nThe ALB is 42.0000 g/L;\n The CRP is 5.6600 mg/L;\n The LDH is 230.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 41.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 58.0000 ### months." } ], "images": [ "DMFS_train_1281/0000310070.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 1.2600 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 125.0000 g/L;\nThe ALB is 42.7000 g/L;\n The CRP is 2.0900 mg/L;\n The LDH is 111.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is None; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 57.9333 ### months." } ], "images": [ "DMFS_train_1281/0000309047.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 32 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.9610 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.0000 g/L;\nThe ALB is 45.4000 g/L;\n The CRP is 0.2700 mg/L;\n The LDH is 163.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 58.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 58.0667 ### months." } ], "images": [ "DMFS_train_1281/0000309579.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.3970 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 126.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 0.5200 mg/L;\n The LDH is 254.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 31.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 58.0333 ### months." } ], "images": [ "DMFS_train_1281/0000308774.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 26 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 346.0000 copies/mL;\nThe EBV of after treatment is 0.2390 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 3.0800 mg/L;\n The LDH is 144.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 6; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Docetaxel;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 52.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 58.1333 ### months." } ], "images": [ "DMFS_train_1281/0000308240.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0555 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 136.0000 g/L;\nThe ALB is 47.2000 g/L;\n The CRP is 0.7200 mg/L;\n The LDH is 186.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 60.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 58.2333 ### months." } ], "images": [ "DMFS_train_1281/0000309315.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 61 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2.4900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 163.0000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 5.8900 mg/L;\n The LDH is 200.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 53.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 55.0333 ### months." } ], "images": [ "DMFS_train_1281/0000308556.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 7.9400 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 137.0000 g/L;\nThe ALB is 42.0000 g/L;\n The CRP is 12.9000 mg/L;\n The LDH is 175.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 33.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 58.6000 ### months." } ], "images": [ "DMFS_train_1281/0000307960.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 64 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.9640 copies/mL;\nThe EBV of after treatment is 0.5990 copies/m; \nThe HGB is 137.0000 g/L;\nThe ALB is 43.2000 g/L;\n The CRP is 9.4300 mg/L;\n The LDH is 170.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 58.7333 ### months." } ], "images": [ "DMFS_train_1281/0000307685.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 65 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.8430 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 131.0000 g/L;\nThe ALB is 37.0000 g/L;\n The CRP is 68.9000 mg/L;\n The LDH is 216.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Docetaxel;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 58.8333 ### months." } ], "images": [ "DMFS_train_1281/0000308419.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 29 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 3.6700 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 149.0000 g/L;\nThe ALB is 46.1000 g/L;\n The CRP is 1.6800 mg/L;\n The LDH is 152.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is 5-fu;\n The time interval between induction chemotherapy and post-treatment imaging is 47.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 60.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 58.9667 ### months." } ], "images": [ "DMFS_train_1281/0000307384.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.5660 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.0000 g/L;\nThe ALB is 37.7000 g/L;\n The CRP is 0.4300 mg/L;\n The LDH is 152.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 91.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 59.0667 ### months." } ], "images": [ "DMFS_train_1281/0000309386.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.2210 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 166.0000 g/L;\nThe ALB is 49.7000 g/L;\n The CRP is 0.1700 mg/L;\n The LDH is 177.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 59.1000 ### months." } ], "images": [ "DMFS_train_1281/0000308229.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 7.9300 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 138.0000 g/L;\nThe ALB is 44.2000 g/L;\n The CRP is 1.5800 mg/L;\n The LDH is 132.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is 5-fu;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 58.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 59.2667 ### months." } ], "images": [ "DMFS_train_1281/0000307316.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 5.0600 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 160.0000 g/L;\nThe ALB is 42.8000 g/L;\n The CRP is 11.6600 mg/L;\n The LDH is 170.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 220 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 71.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 59.3667 ### months." } ], "images": [ "DMFS_train_1281/0000306346.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 62 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 48.2000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 115.0000 g/L;\nThe ALB is 39.3000 g/L;\n The CRP is 36.7500 mg/L;\n The LDH is 158.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 2:Mild complications that require some medication or treatment to control, and may have a slight impact on daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 39.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 56.2667 ### months." } ], "images": [ "DMFS_train_1281/0000306322.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 50 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.4790 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 41.8000 g/L;\n The CRP is 0.2200 mg/L;\n The LDH is 184.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 63.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 51.9000 ### months." } ], "images": [ "DMFS_train_1281/0000306858.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 66 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.0600 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 114.0000 g/L;\nThe ALB is 42.5000 g/L;\n The CRP is 1.3900 mg/L;\n The LDH is 189.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 61.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 59.5000 ### months." } ], "images": [ "DMFS_train_1281/0000305897.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0117 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 146.0000 g/L;\nThe ALB is 43.9000 g/L;\n The CRP is 1.0100 mg/L;\n The LDH is 202.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 60.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 59.3000 ### months." } ], "images": [ "DMFS_train_1281/0000306588.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 44.3000 copies/mL;\nThe EBV of after treatment is 0.5450 copies/m; \nThe HGB is 165.0000 g/L;\nThe ALB is 49.8000 g/L;\n The CRP is 0.9200 mg/L;\n The LDH is 143.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 59.5667 ### months." } ], "images": [ "DMFS_train_1281/0000306233.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.3200 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 159.0000 g/L;\nThe ALB is 47.0000 g/L;\n The CRP is 0.4800 mg/L;\n The LDH is 155.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 59.5667 ### months." } ], "images": [ "DMFS_train_1281/0000305778.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 147.0000 g/L;\nThe ALB is 47.2000 g/L;\n The CRP is 4.9300 mg/L;\n The LDH is 145.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 38.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 59.8333 ### months." } ], "images": [ "DMFS_train_1281/0000306454.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 25.4000 copies/mL;\nThe EBV of after treatment is 25.4000 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 42.5000 g/L;\n The CRP is 23.8500 mg/L;\n The LDH is 137.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 47.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 53.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 59.8667 ### months." } ], "images": [ "DMFS_train_1281/0000305795.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 22 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 33.5000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 140.0000 g/L;\nThe ALB is 46.7000 g/L;\n The CRP is 8.6900 mg/L;\n The LDH is 251.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 34.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 59.8667 ### months." } ], "images": [ "DMFS_train_1281/0000305371.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 53 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 107.0000 g/L;\nThe ALB is 39.7000 g/L;\n The CRP is 0.8100 mg/L;\n The LDH is 178.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 69.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 59.8333 ### months." } ], "images": [ "DMFS_train_1281/0000305951.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 61 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2.0500 copies/mL;\nThe EBV of after treatment is 0.3660 copies/m; \nThe HGB is 136.0000 g/L;\nThe ALB is 38.6000 g/L;\n The CRP is 2.8300 mg/L;\n The LDH is 162.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 58.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 59.8333 ### months." } ], "images": [ "DMFS_train_1281/0000306664.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 17.9000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 168.0000 g/L;\nThe ALB is 40.9000 g/L;\n The CRP is 1.7200 mg/L;\n The LDH is 176.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 59.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 71.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 59.5667 ### months." } ], "images": [ "DMFS_train_1281/0000305731.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 152.0000 g/L;\nThe ALB is 45.7000 g/L;\n The CRP is 4.2100 mg/L;\n The LDH is 176.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 60.0333 ### months." } ], "images": [ "DMFS_train_1281/0000306117.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.9090 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 3.0600 mg/L;\n The LDH is 157.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 47.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 53.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 60.3000 ### months." } ], "images": [ "DMFS_train_1281/0000304789.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 57 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 18.4000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 127.0000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 0.7700 mg/L;\n The LDH is 195.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 47.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 56.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 58.9333 ### months." } ], "images": [ "DMFS_train_1281/0000307828.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 22.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 1.0600 mg/L;\n The LDH is 174.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 53.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 52.1667 ### months." } ], "images": [ "DMFS_train_1281/0000303945.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 35.7000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.0000 g/L;\nThe ALB is 39.8000 g/L;\n The CRP is 37.2100 mg/L;\n The LDH is 191.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 58.7667 ### months." } ], "images": [ "DMFS_train_1281/0000304275.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 12.2000 copies/mL;\nThe EBV of after treatment is 0.3110 copies/m; \nThe HGB is 150.6000 g/L;\nThe ALB is 47.7000 g/L;\n The CRP is 0.4500 mg/L;\n The LDH is 136.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 57.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 60.6333 ### months." } ], "images": [ "DMFS_train_1281/0000302829.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 24 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.5700 copies/mL;\nThe EBV of after treatment is 1.4300 copies/m; \nThe HGB is 121.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 4.4500 mg/L;\n The LDH is 150.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 66.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 50.7333 ### months." } ], "images": [ "DMFS_train_1281/0000302647.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 61 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.6650 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 144.0000 g/L;\nThe ALB is 48.6000 g/L;\n The CRP is 1.1500 mg/L;\n The LDH is 222.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 33.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.1000 ### months." } ], "images": [ "DMFS_train_1281/0000302880.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 50 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 18.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 5.8400 mg/L;\n The LDH is 180.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 44.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.1333 ### months." } ], "images": [ "DMFS_train_1281/0000304176.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 219.0000 copies/mL;\nThe EBV of after treatment is 22.8000 copies/m; \nThe HGB is 140.0000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 2.3000 mg/L;\n The LDH is 239.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 220 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 57.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 76.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.5000 ### months." } ], "images": [ "DMFS_train_1281/0000302914.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 3.2100 copies/mL;\nThe EBV of after treatment is 0.4870 copies/m; \nThe HGB is 129.0000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 5.1500 mg/L;\n The LDH is 193.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 170 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.3000 ### months." } ], "images": [ "DMFS_train_1281/0000302568.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 4.0800 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 2.4000 mg/L;\n The LDH is 194.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 44.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.3333 ### months." } ], "images": [ "DMFS_train_1281/0000302628.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 130.4000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 1.3100 mg/L;\n The LDH is 176.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 37.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 47.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.3333 ### months." } ], "images": [ "DMFS_train_1281/0000302361.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 10.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 128.0000 g/L;\nThe ALB is 43.6000 g/L;\n The CRP is 1.6500 mg/L;\n The LDH is 259.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 39.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.3667 ### months." } ], "images": [ "DMFS_train_1281/0000302170.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 22.0000 copies/mL;\nThe EBV of after treatment is 0.2080 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 43.6000 g/L;\n The CRP is 1.3100 mg/L;\n The LDH is 238.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 63.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 51.1667 ### months." } ], "images": [ "DMFS_train_1281/0000301964.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 24.5000 copies/mL;\nThe EBV of after treatment is 37.2000 copies/m; \nThe HGB is 112.0000 g/L;\nThe ALB is 37.3000 g/L;\n The CRP is 12.3200 mg/L;\n The LDH is 124.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.4000 ### months." } ], "images": [ "DMFS_train_1281/0000303419.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 57 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.1900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 129.0000 g/L;\nThe ALB is 43.5000 g/L;\n The CRP is 3.9100 mg/L;\n The LDH is 165.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 30.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.4000 ### months." } ], "images": [ "DMFS_train_1281/0000301615.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 50 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 6.4700 copies/m; \nThe HGB is 156.3000 g/L;\nThe ALB is 42.8000 g/L;\n The CRP is 2.4800 mg/L;\n The LDH is 195.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 2:Mild complications that require some medication or treatment to control, and may have a slight impact on daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 46.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.5333 ### months." } ], "images": [ "DMFS_train_1281/0000301400.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 26 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 2.2500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 3.3500 mg/L;\n The LDH is 173.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 59.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 75.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.7667 ### months." } ], "images": [ "DMFS_train_1281/0000302188.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 169.0000 copies/mL;\nThe EBV of after treatment is 110.0000 copies/m; \nThe HGB is 146.0000 g/L;\nThe ALB is 44.9000 g/L;\n The CRP is 0.3400 mg/L;\n The LDH is 318.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 51.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 51.4667 ### months." } ], "images": [ "DMFS_train_1281/0000275979.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 1.4000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 131.0000 g/L;\nThe ALB is 37.8000 g/L;\n The CRP is 7.0500 mg/L;\n The LDH is 144.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.7667 ### months." } ], "images": [ "DMFS_train_1281/0000301533.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 5.4400 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 43.1000 g/L;\n The CRP is 7.1800 mg/L;\n The LDH is 126.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 72.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 83.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.7333 ### months." } ], "images": [ "DMFS_train_1281/0000301050.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 1.4100 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 41.8000 g/L;\n The CRP is 1.3200 mg/L;\n The LDH is 157.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 2:Mild complications that require some medication or treatment to control, and may have a slight impact on daily activities.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.7667 ### months." } ], "images": [ "DMFS_train_1281/0000301413.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 39 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.6610 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 152.0000 g/L;\nThe ALB is 47.6000 g/L;\n The CRP is 0.6100 mg/L;\n The LDH is 225.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 37.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.9667 ### months." } ], "images": [ "DMFS_train_1281/0000301256.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.8840 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 1.0300 mg/L;\n The LDH is 222.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 60.1000 ### months." } ], "images": [ "DMFS_train_1281/0000302233.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.9300 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 162.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 0.7200 mg/L;\n The LDH is 151.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 2:Mild complications that require some medication or treatment to control, and may have a slight impact on daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.8000 ### months." } ], "images": [ "DMFS_train_1281/0000300902.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 16.2000 copies/mL;\nThe EBV of after treatment is 0.5600 copies/m; \nThe HGB is 135.6000 g/L;\nThe ALB is 41.2000 g/L;\n The CRP is 20.5300 mg/L;\n The LDH is 217.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 42.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 62.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.8333 ### months." } ], "images": [ "DMFS_train_1281/0000302078.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 31 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2.0700 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 128.0000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 6.1400 mg/L;\n The LDH is 264.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 60.3000 ### months." } ], "images": [ "DMFS_train_1281/0000301307.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2.0700 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 121.0000 g/L;\nThe ALB is 42.1000 g/L;\n The CRP is 2.2100 mg/L;\n The LDH is 140.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 47.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.1667 ### months." } ], "images": [ "DMFS_train_1281/0000300510.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 24 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 128.5000 g/L;\nThe ALB is 43.1000 g/L;\n The CRP is 13.7300 mg/L;\n The LDH is 165.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 45.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 60.5667 ### months." } ], "images": [ "DMFS_train_1281/0000299912.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 55 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.2710 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 138.0000 g/L;\nThe ALB is 44.3000 g/L;\n The CRP is 2.9500 mg/L;\n The LDH is 111.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 38.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.3000 ### months." } ], "images": [ "DMFS_train_1281/0000300503.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 57 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.8400 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 149.0000 g/L;\nThe ALB is 42.9000 g/L;\n The CRP is 4.0500 mg/L;\n The LDH is 173.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 84.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 102.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.4333 ### months." } ], "images": [ "DMFS_train_1281/0000300447.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 15.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 129.0000 g/L;\nThe ALB is 42.0000 g/L;\n The CRP is 4.2600 mg/L;\n The LDH is 148.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 280 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 5:More severe complications that require the patient to be hospitalized or undergo more frequent medical interventions.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 83.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.4667 ### months." } ], "images": [ "DMFS_train_1281/0000300351.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 39 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 5.2400 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 164.0000 g/L;\nThe ALB is 46.3000 g/L;\n The CRP is 4.0500 mg/L;\n The LDH is 202.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 220 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 63.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 52.5000 ### months." } ], "images": [ "DMFS_train_1281/0000298791.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.7500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 154.0000 g/L;\nThe ALB is 39.4000 g/L;\n The CRP is 2.1800 mg/L;\n The LDH is 144.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 10:Extremely severe complications, where the condition of patient may lead to death in a short period of time. The patient is in a terminal statu, with little effect from medical intervention.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 40.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 52.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.7667 ### months." } ], "images": [ "DMFS_train_1281/0000299445.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.1200 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 43.1000 g/L;\n The CRP is 2.3200 mg/L;\n The LDH is 213.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.1333 ### months." } ], "images": [ "DMFS_train_1281/0000299118.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.9600 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 146.0000 g/L;\nThe ALB is 42.7000 g/L;\n The CRP is 1.3300 mg/L;\n The LDH is 212.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 41.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 56.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.9333 ### months." } ], "images": [ "DMFS_train_1281/0000299416.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2.7700 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 127.0000 g/L;\nThe ALB is 39.7000 g/L;\n The CRP is 13.2000 mg/L;\n The LDH is 130.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 69.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.9333 ### months." } ], "images": [ "DMFS_train_1281/0000299724.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.9330 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 44.6000 g/L;\n The CRP is 3.0900 mg/L;\n The LDH is 199.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 59.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 77.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.0000 ### months." } ], "images": [ "DMFS_train_1281/0000298059.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 24 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 5.6100 copies/mL;\nThe EBV of after treatment is 1.5500 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 48.7000 g/L;\n The CRP is 0.3600 mg/L;\n The LDH is 118.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.1333 ### months." } ], "images": [ "DMFS_train_1281/0000299049.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 67 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 11.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 142.8000 g/L;\nThe ALB is 43.5000 g/L;\n The CRP is 1.0200 mg/L;\n The LDH is 186.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.0000 ### months." } ], "images": [ "DMFS_train_1281/0000298745.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 97.4000 copies/mL;\nThe EBV of after treatment is 0.1290 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 42.2000 g/L;\n The CRP is 2.1600 mg/L;\n The LDH is 124.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 44.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.0000 ### months." } ], "images": [ "DMFS_train_1281/0000299213.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 50 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.4560 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.3000 g/L;\nThe ALB is 44.6000 g/L;\n The CRP is 1.6800 mg/L;\n The LDH is 137.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.0000 ### months." } ], "images": [ "DMFS_train_1281/0000300409.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 121.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 45.6000 g/L;\n The CRP is 3.6500 mg/L;\n The LDH is 251.3000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 66.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 75.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 76.3333 ### months." } ], "images": [ "DMFS_train_1281/0000271547.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2.6700 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 130.0000 g/L;\nThe ALB is 41.1000 g/L;\n The CRP is 1.4400 mg/L;\n The LDH is 380.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 64.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 87.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 53.0000 ### months." } ], "images": [ "DMFS_train_1281/0000299103.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 28 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 93.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.7000 g/L;\nThe ALB is 44.4000 g/L;\n The CRP is 1.6600 mg/L;\n The LDH is 282.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 63.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.7333 ### months." } ], "images": [ "DMFS_train_1281/0000298216.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 19.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 147.0000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 1.3800 mg/L;\n The LDH is 191.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 79.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.4333 ### months." } ], "images": [ "DMFS_train_1281/0000299399.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 34 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 13.1000 copies/mL;\nThe EBV of after treatment is 0.2660 copies/m; \nThe HGB is 158.0000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 3.3600 mg/L;\n The LDH is 226.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.6000 ### months." } ], "images": [ "DMFS_train_1281/0000297647.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 3.5800 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.5000 g/L;\nThe ALB is 40.5000 g/L;\n The CRP is 5.3800 mg/L;\n The LDH is 153.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 44.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.4667 ### months." } ], "images": [ "DMFS_train_1281/0000297782.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 30 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.2060 copies/mL;\nThe EBV of after treatment is 0.5500 copies/m; \nThe HGB is 152.2000 g/L;\nThe ALB is 47.8000 g/L;\n The CRP is 0.4500 mg/L;\n The LDH is 172.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 39.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.6000 ### months." } ], "images": [ "DMFS_train_1281/0000298793.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 13 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 15.5000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 125.8000 g/L;\nThe ALB is 39.5000 g/L;\n The CRP is 7.6600 mg/L;\n The LDH is 145.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.7333 ### months." } ], "images": [ "DMFS_train_1281/0000296931.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.5040 copies/mL;\nThe EBV of after treatment is 0.0671 copies/m; \nThe HGB is 169.0000 g/L;\nThe ALB is 44.9000 g/L;\n The CRP is 7.2500 mg/L;\n The LDH is 168.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.5667 ### months." } ], "images": [ "DMFS_train_1281/0000296960.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 8.4600 copies/mL;\nThe EBV of after treatment is 0.3700 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 44.7000 g/L;\n The CRP is 2.7700 mg/L;\n The LDH is 169.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.7000 ### months." } ], "images": [ "DMFS_train_1281/0000297046.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2.8300 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 103.0000 g/L;\nThe ALB is 43.1000 g/L;\n The CRP is 1.1200 mg/L;\n The LDH is 135.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 7:Severe complications, where the health of patient is significantly affected, with a potential life-threatening condition, requiring emergency medical intervention.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.7000 ### months." } ], "images": [ "DMFS_train_1281/0000297587.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.3230 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 136.0000 g/L;\nThe ALB is 46.1000 g/L;\n The CRP is 1.1400 mg/L;\n The LDH is 215.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.8667 ### months." } ], "images": [ "DMFS_train_1281/0000297875.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 12.5000 copies/mL;\nThe EBV of after treatment is 0.4620 copies/m; \nThe HGB is 136.0000 g/L;\nThe ALB is 46.9000 g/L;\n The CRP is 2.7800 mg/L;\n The LDH is 173.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.9000 ### months." } ], "images": [ "DMFS_train_1281/0000296805.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2.9200 copies/mL;\nThe EBV of after treatment is 0.0091 copies/m; \nThe HGB is 136.0000 g/L;\nThe ALB is 48.6000 g/L;\n The CRP is 3.2400 mg/L;\n The LDH is 191.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 69.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.1000 ### months." } ], "images": [ "DMFS_train_1281/0000296950.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.5400 copies/mL;\nThe EBV of after treatment is 0.4170 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 43.2000 g/L;\n The CRP is 1.0600 mg/L;\n The LDH is 179.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 43.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.9333 ### months." } ], "images": [ "DMFS_train_1281/0000297007.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 114.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 156.0000 g/L;\nThe ALB is 48.8000 g/L;\n The CRP is 3.2500 mg/L;\n The LDH is 217.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 60.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 98.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.3333 ### months." } ], "images": [ "DMFS_train_1281/0000297956.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 2.6100 copies/mL;\nThe EBV of after treatment is 0.1450 copies/m; \nThe HGB is 159.0000 g/L;\nThe ALB is 43.5000 g/L;\n The CRP is 2.5000 mg/L;\n The LDH is 155.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 45.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.1333 ### months." } ], "images": [ "DMFS_train_1281/0000296628.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 28 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 6.7100 copies/mL;\nThe EBV of after treatment is 1.1200 copies/m; \nThe HGB is 154.7000 g/L;\nThe ALB is 49.3000 g/L;\n The CRP is 0.5200 mg/L;\n The LDH is 172.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.4333 ### months." } ], "images": [ "DMFS_train_1281/0000296240.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.4130 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 155.0000 g/L;\nThe ALB is 45.9000 g/L;\n The CRP is 1.3200 mg/L;\n The LDH is 160.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 37.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 288.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.6000 ### months." } ], "images": [ "DMFS_train_1281/0000295296.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 13 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.1200 copies/mL;\nThe EBV of after treatment is 0.0682 copies/m; \nThe HGB is 109.0000 g/L;\nThe ALB is 40.2000 g/L;\n The CRP is 6.8200 mg/L;\n The LDH is 157.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.4333 ### months." } ], "images": [ "DMFS_train_1281/0000295665.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 34 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 67.9000 copies/mL;\nThe EBV of after treatment is 0.1010 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 47.0000 g/L;\n The CRP is 3.3500 mg/L;\n The LDH is 214.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 62.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 81.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.2667 ### months." } ], "images": [ "DMFS_train_1281/0000295401.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 3.4900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 146.8000 g/L;\nThe ALB is 41.5000 g/L;\n The CRP is 2.5600 mg/L;\n The LDH is 151.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is 5-fu;\n The time interval between induction chemotherapy and post-treatment imaging is 75.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 84.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.3333 ### months." } ], "images": [ "DMFS_train_1281/0000295831.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.0600 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 43.1000 g/L;\n The CRP is 2.8400 mg/L;\n The LDH is 155.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 5:More severe complications that require the patient to be hospitalized or undergo more frequent medical interventions.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.3667 ### months." } ], "images": [ "DMFS_train_1281/0000295600.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2.2100 copies/mL;\nThe EBV of after treatment is 0.0527 copies/m; \nThe HGB is 147.8000 g/L;\nThe ALB is 41.5000 g/L;\n The CRP is 0.5900 mg/L;\n The LDH is 164.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 99.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.6667 ### months." } ], "images": [ "DMFS_train_1281/0000295708.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 285.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 48.7000 g/L;\n The CRP is 16.2400 mg/L;\n The LDH is 190.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 85.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.7667 ### months." } ], "images": [ "DMFS_train_1281/0000297181.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.4400 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 50.5000 g/L;\n The CRP is 1.6300 mg/L;\n The LDH is 205.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 51.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.6000 ### months." } ], "images": [ "DMFS_train_1281/0000295832.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 41 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.5940 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 43.6000 g/L;\n The CRP is 0.3300 mg/L;\n The LDH is 123.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 52.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.7000 ### months." } ], "images": [ "DMFS_train_1281/0000295784.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 40.5000 g/L;\n The CRP is 0.5900 mg/L;\n The LDH is 159.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 76.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.7333 ### months." } ], "images": [ "DMFS_train_1281/0000296004.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 9.7300 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 45.4000 g/L;\n The CRP is 4.6500 mg/L;\n The LDH is 189.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 6:More severe complications, where the health of patient is significantly affected and they may be unable to perform normal daily activities. Hospitalization or more frequent medical interventions are required.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 41.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.7667 ### months." } ], "images": [ "DMFS_train_1281/0000294985.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 24 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.6600 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 127.0000 g/L;\nThe ALB is 38.8000 g/L;\n The CRP is 0.5600 mg/L;\n The LDH is 92.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 26.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.1333 ### months." } ], "images": [ "DMFS_train_1281/0000294061.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.4340 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.1000 g/L;\nThe ALB is 46.2000 g/L;\n The CRP is 1.5700 mg/L;\n The LDH is 138.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 60.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 54.7000 ### months." } ], "images": [ "DMFS_train_1281/0000294534.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.1100 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.8000 g/L;\nThe ALB is 45.7000 g/L;\n The CRP is 2.3400 mg/L;\n The LDH is 202.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 170 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 40.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.9667 ### months." } ], "images": [ "DMFS_train_1281/0000294377.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 12.2000 copies/mL;\nThe EBV of after treatment is 0.3160 copies/m; \nThe HGB is 126.5000 g/L;\nThe ALB is 41.1000 g/L;\n The CRP is 0.1800 mg/L;\n The LDH is 100.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 54.8667 ### months." } ], "images": [ "DMFS_train_1281/0000294080.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.6000 copies/mL;\nThe EBV of after treatment is 0.1690 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 44.3000 g/L;\n The CRP is 2.1700 mg/L;\n The LDH is 136.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 47.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 73.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 65.2667 ### months." } ], "images": [ "DMFS_train_1281/0000295145.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 61 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.1770 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 158.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 1.6000 mg/L;\n The LDH is 168.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.1667 ### months." } ], "images": [ "DMFS_train_1281/0000293545.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 16 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 43.9000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 154.0000 g/L;\nThe ALB is 41.9000 g/L;\n The CRP is 3.4900 mg/L;\n The LDH is 161.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 37.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.6000 ### months." } ], "images": [ "DMFS_train_1281/0000293506.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 98.7000 copies/mL;\nThe EBV of after treatment is 1.8100 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 45.7000 g/L;\n The CRP is 4.2800 mg/L;\n The LDH is 201.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 65.4333 ### months." } ], "images": [ "DMFS_train_1281/0000293609.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 29 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 6.3500 copies/mL;\nThe EBV of after treatment is 0.0308 copies/m; \nThe HGB is 136.0000 g/L;\nThe ALB is 48.3000 g/L;\n The CRP is 2.2900 mg/L;\n The LDH is 177.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 51.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 135.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 65.4667 ### months." } ], "images": [ "DMFS_train_1281/00C1138525.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 5.4500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 133.0000 g/L;\nThe ALB is 42.0000 g/L;\n The CRP is 2.3000 mg/L;\n The LDH is 188.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 100 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 39.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.5667 ### months." } ], "images": [ "DMFS_train_1281/0000293434.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 62.5000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.0000 g/L;\nThe ALB is 38.9000 g/L;\n The CRP is 2.0400 mg/L;\n The LDH is 181.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.8000 ### months." } ], "images": [ "DMFS_train_1281/0000292781.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 39.0000 g/L;\n The CRP is 3.4600 mg/L;\n The LDH is 150.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.8000 ### months." } ], "images": [ "DMFS_train_1281/0000293048.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 29 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.2460 copies/mL;\nThe EBV of after treatment is 0.0565 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 40.7000 g/L;\n The CRP is 5.4400 mg/L;\n The LDH is 181.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 280 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 55.3000 ### months." } ], "images": [ "DMFS_train_1281/0000293374.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 29 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 31.9000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 154.0000 g/L;\nThe ALB is 44.5000 g/L;\n The CRP is 15.9400 mg/L;\n The LDH is 187.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 33.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 65.7000 ### months." } ], "images": [ "DMFS_train_1281/0000293253.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 9.2900 copies/mL;\nThe EBV of after treatment is 0.7020 copies/m; \nThe HGB is 133.0000 g/L;\nThe ALB is 42.0000 g/L;\n The CRP is 0.3100 mg/L;\n The LDH is 155.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 60 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Lobaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 47.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.0667 ### months." } ], "images": [ "DMFS_train_1281/0000293011.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 6.8400 copies/mL;\nThe EBV of after treatment is 0.2810 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 7.2900 mg/L;\n The LDH is 175.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 69.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.0667 ### months." } ], "images": [ "DMFS_train_1281/00C1131714.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 31 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 47.0000 g/L;\n The CRP is 0.4700 mg/L;\n The LDH is 199.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 32.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 55.8333 ### months." } ], "images": [ "DMFS_train_1281/0000292338.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 124.0000 g/L;\nThe ALB is 40.1000 g/L;\n The CRP is 2.1600 mg/L;\n The LDH is 179.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 32.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 55.8667 ### months." } ], "images": [ "DMFS_train_1281/0000292346.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.4740 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 159.0000 g/L;\nThe ALB is 46.6000 g/L;\n The CRP is 2.6800 mg/L;\n The LDH is 126.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 51.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.2333 ### months." } ], "images": [ "DMFS_train_1281/0000293076.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 3.6900 copies/mL;\nThe EBV of after treatment is 0.2060 copies/m; \nThe HGB is 144.2000 g/L;\nThe ALB is 42.9000 g/L;\n The CRP is 8.3200 mg/L;\n The LDH is 120.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 47.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 69.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.3333 ### months." } ], "images": [ "DMFS_train_1281/0000292554.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 169.4000 g/L;\nThe ALB is 47.6000 g/L;\n The CRP is 0.8000 mg/L;\n The LDH is 171.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.3667 ### months." } ], "images": [ "DMFS_train_1281/00C1130980.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 39 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 1.2100 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 156.0000 g/L;\nThe ALB is 50.3000 g/L;\n The CRP is 0.7300 mg/L;\n The LDH is 149.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 33.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 56.0333 ### months." } ], "images": [ "DMFS_train_1281/0000293412.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 43.5000 copies/mL;\nThe EBV of after treatment is 0.3070 copies/m; \nThe HGB is 125.0000 g/L;\nThe ALB is 39.7000 g/L;\n The CRP is 4.8600 mg/L;\n The LDH is 263.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 72.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 56.0667 ### months." } ], "images": [ "DMFS_train_1281/0000293746.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 64 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 5.3500 copies/mL;\nThe EBV of after treatment is 0.1200 copies/m; \nThe HGB is 159.1000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 1.3600 mg/L;\n The LDH is 166.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 5:More severe complications that require the patient to be hospitalized or undergo more frequent medical interventions.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 26.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 58.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.2667 ### months." } ], "images": [ "DMFS_train_1281/0000293176.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.1600 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 117.0000 g/L;\nThe ALB is 44.9000 g/L;\n The CRP is 1.7900 mg/L;\n The LDH is 207.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.5333 ### months." } ], "images": [ "DMFS_train_1281/0000292328.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 17 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2.9500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 135.7000 g/L;\nThe ALB is 46.2000 g/L;\n The CRP is 2.5300 mg/L;\n The LDH is 212.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 44.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 56.2667 ### months." } ], "images": [ "DMFS_train_1281/0000291905.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.4820 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.9000 g/L;\nThe ALB is 45.6000 g/L;\n The CRP is 0.5500 mg/L;\n The LDH is 152.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 86.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.6667 ### months." } ], "images": [ "DMFS_train_1281/0000292476.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.7030 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 43.3000 g/L;\n The CRP is 0.8000 mg/L;\n The LDH is 183.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 26.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 33.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.8000 ### months." } ], "images": [ "DMFS_train_1281/0000291265.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.3000 copies/mL;\nThe EBV of after treatment is 4.1400 copies/m; \nThe HGB is 131.0000 g/L;\nThe ALB is 44.3000 g/L;\n The CRP is 1.0200 mg/L;\n The LDH is 162.8000 U/L; \nThe Number of course is 6;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 135.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 146.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.8000 ### months." } ], "images": [ "DMFS_train_1281/0000291457.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 27 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.6290 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 163.0000 g/L;\nThe ALB is 48.7000 g/L;\n The CRP is 1.4800 mg/L;\n The LDH is 200.7000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is 5-fu;\n The time interval between induction chemotherapy and post-treatment imaging is 63.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 71.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.8000 ### months." } ], "images": [ "DMFS_train_1281/0000291591.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 2.4700 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 138.0000 g/L;\nThe ALB is 47.2000 g/L;\n The CRP is 0.9500 mg/L;\n The LDH is 207.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 63.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.8000 ### months." } ], "images": [ "DMFS_train_1281/0000291756.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 4.1900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 126.0000 g/L;\nThe ALB is 41.9000 g/L;\n The CRP is 2.6800 mg/L;\n The LDH is 199.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 51.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.7667 ### months." } ], "images": [ "DMFS_train_1281/00C1129879.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 32 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.1850 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 159.0000 g/L;\nThe ALB is 48.1000 g/L;\n The CRP is 0.7700 mg/L;\n The LDH is 163.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 57.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 65.0333 ### months." } ], "images": [ "DMFS_train_1281/0000291125.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 40.9000 g/L;\n The CRP is 0.7200 mg/L;\n The LDH is 144.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is 5-fu;\n The time interval between induction chemotherapy and post-treatment imaging is 67.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 71.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 56.5333 ### months." } ], "images": [ "DMFS_train_1281/0000290790.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 9.8800 copies/mL;\nThe EBV of after treatment is 1.8500 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 47.1000 g/L;\n The CRP is 1.0000 mg/L;\n The LDH is 266.8000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 68.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 76.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.0333 ### months." } ], "images": [ "DMFS_train_1281/0000290993.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 28 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 12.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.2000 g/L;\nThe ALB is 49.2000 g/L;\n The CRP is 5.2500 mg/L;\n The LDH is 173.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 37.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 51.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.1000 ### months." } ], "images": [ "DMFS_train_1281/0000291169.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.8610 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 128.0000 g/L;\nThe ALB is 44.1000 g/L;\n The CRP is 0.5200 mg/L;\n The LDH is 165.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 45.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 56.7333 ### months." } ], "images": [ "DMFS_train_1281/0000290839.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 46.7000 g/L;\n The CRP is 0.6400 mg/L;\n The LDH is 129.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 25.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.1333 ### months." } ], "images": [ "DMFS_train_1281/0000290920.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.2330 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 46.9000 g/L;\n The CRP is 7.9600 mg/L;\n The LDH is 158.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.2667 ### months." } ], "images": [ "DMFS_train_1281/00C1129012.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 3.5400 copies/mL;\nThe EBV of after treatment is 7.5800 copies/m; \nThe HGB is 103.0000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 1.5700 mg/L;\n The LDH is 227.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.2667 ### months." } ], "images": [ "DMFS_train_1281/0000290416.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 55 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 10.5000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.4000 g/L;\nThe ALB is 44.1000 g/L;\n The CRP is 1.2000 mg/L;\n The LDH is 246.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is 5-fu;\n The time interval between induction chemotherapy and post-treatment imaging is 40.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.2333 ### months." } ], "images": [ "DMFS_train_1281/0000290739.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 145.5000 g/L;\nThe ALB is 39.9000 g/L;\n The CRP is 8.2600 mg/L;\n The LDH is 144.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 36.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.3000 ### months." } ], "images": [ "DMFS_train_1281/0000289845.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.9830 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 131.1000 g/L;\nThe ALB is 44.9000 g/L;\n The CRP is 0.7900 mg/L;\n The LDH is 153.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 33.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.4000 ### months." } ], "images": [ "DMFS_train_1281/0000290114.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 41.0000 copies/mL;\nThe EBV of after treatment is 1.6300 copies/m; \nThe HGB is 135.9000 g/L;\nThe ALB is 46.9000 g/L;\n The CRP is 0.5600 mg/L;\n The LDH is 152.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 300 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 57.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 92.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 57.1667 ### months." } ], "images": [ "DMFS_train_1281/0000291634.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 146.0000 g/L;\nThe ALB is 47.7000 g/L;\n The CRP is 1.1200 mg/L;\n The LDH is 201.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 40.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 65.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.5000 ### months." } ], "images": [ "DMFS_train_1281/0000291092.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 3.5900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 146.0000 g/L;\nThe ALB is 48.4000 g/L;\n The CRP is 4.9000 mg/L;\n The LDH is 206.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 4:Moderate complications that affect daily life, require medical intervention, and may lead to a decline in some aspects of self-care ability.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 47.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.6333 ### months." } ], "images": [ "DMFS_train_1281/0000290488.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 45.1000 g/L;\n The CRP is 2.0000 mg/L;\n The LDH is 241.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 57.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 62.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.6333 ### months." } ], "images": [ "DMFS_train_1281/0000289453.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 26 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.4800 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 155.0000 g/L;\nThe ALB is 47.0000 g/L;\n The CRP is 0.2100 mg/L;\n The LDH is 141.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 33.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.7000 ### months." } ], "images": [ "DMFS_train_1281/0000289189.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 57 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 167.0000 g/L;\nThe ALB is 46.1000 g/L;\n The CRP is 0.7900 mg/L;\n The LDH is 219.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 47.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.8333 ### months." } ], "images": [ "DMFS_train_1281/0000290074.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.6900 copies/mL;\nThe EBV of after treatment is 0.4020 copies/m; \nThe HGB is 123.0000 g/L;\nThe ALB is 44.9000 g/L;\n The CRP is 7.8900 mg/L;\n The LDH is 157.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 47.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.8333 ### months." } ], "images": [ "DMFS_train_1281/0000289280.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 16.5000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 130.1000 g/L;\nThe ALB is 42.5000 g/L;\n The CRP is 5.1800 mg/L;\n The LDH is 174.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 300 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 61.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 57.6000 ### months." } ], "images": [ "DMFS_train_1281/0000288957.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.5660 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 133.0000 g/L;\nThe ALB is 44.9000 g/L;\n The CRP is 0.3700 mg/L;\n The LDH is 189.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 58.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.9667 ### months." } ], "images": [ "DMFS_train_1281/0000290471.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 53 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.9200 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 120.0000 g/L;\nThe ALB is 39.6000 g/L;\n The CRP is 1.5600 mg/L;\n The LDH is 174.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Docetaxel;\n The time interval between induction chemotherapy and post-treatment imaging is 45.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 65.3667 ### months." } ], "images": [ "DMFS_train_1281/00C1127846.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 136.0000 g/L;\nThe ALB is 42.7000 g/L;\n The CRP is 1.4200 mg/L;\n The LDH is 148.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 56.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.1667 ### months." } ], "images": [ "DMFS_train_1281/0000288434.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 66 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.3400 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 43.4000 g/L;\n The CRP is 4.8200 mg/L;\n The LDH is 312.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 46.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 56.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 65.0333 ### months." } ], "images": [ "DMFS_train_1281/0000288585.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 14 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 15.7000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 105.0000 g/L;\nThe ALB is 40.1000 g/L;\n The CRP is 7.4000 mg/L;\n The LDH is 196.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 57.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 87.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.2667 ### months." } ], "images": [ "DMFS_train_1281/0000289600.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 31 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.1430 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 156.0000 g/L;\nThe ALB is 50.1000 g/L;\n The CRP is 1.7700 mg/L;\n The LDH is 257.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 慢性荨麻疹:Chronic urticaria (CU) is a skin condition caused by immune system abnormalities. For nasopharyngeal carcinoma patients, CU can impact cancer treatment outcomes through immune dysregulation, drug interactions, and increased risk of complications. In particular, the use of immunosuppressive drugs may weaken treatment effectiveness and increase the risk of side effects and infections.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 59.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 90.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.4000 ### months." } ], "images": [ "DMFS_train_1281/00C1126907.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 3.2200 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 131.0000 g/L;\nThe ALB is 43.6000 g/L;\n The CRP is 13.2900 mg/L;\n The LDH is 147.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.4000 ### months." } ], "images": [ "DMFS_train_1281/0000287551.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 14.5000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 1.6500 mg/L;\n The LDH is 191.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 67.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.4333 ### months." } ], "images": [ "DMFS_train_1281/0000288113.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 30 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 7.5000 copies/mL;\nThe EBV of after treatment is 19.8000 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 47.5000 g/L;\n The CRP is 13.5200 mg/L;\n The LDH is 215.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 72.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.5000 ### months." } ], "images": [ "DMFS_train_1281/0000288721.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 31 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.4260 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 127.0000 g/L;\nThe ALB is 40.0000 g/L;\n The CRP is 1.7400 mg/L;\n The LDH is 132.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 140 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 58.2667 ### months." } ], "images": [ "DMFS_train_1281/0000287584.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 50 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 43.6000 g/L;\n The CRP is 0.9600 mg/L;\n The LDH is 243.4000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 47.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.5667 ### months." } ], "images": [ "DMFS_train_1281/0000287739.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.2210 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 149.0000 g/L;\nThe ALB is 41.8000 g/L;\n The CRP is 2.0000 mg/L;\n The LDH is 160.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 57.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 72.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.6667 ### months." } ], "images": [ "DMFS_train_1281/0000287808.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 30 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.6160 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 129.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 0.8800 mg/L;\n The LDH is 174.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.7333 ### months." } ], "images": [ "DMFS_train_1281/0000287916.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 39 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 1.4800 copies/mL;\nThe EBV of after treatment is 0.0388 copies/m; \nThe HGB is 149.0000 g/L;\nThe ALB is 43.3000 g/L;\n The CRP is 1.0700 mg/L;\n The LDH is 199.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 60.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 81.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.8667 ### months." } ], "images": [ "DMFS_train_1281/0000288072.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 3.9400 copies/mL;\nThe EBV of after treatment is 2.0900 copies/m; \nThe HGB is 162.9000 g/L;\nThe ALB is 40.4000 g/L;\n The CRP is 4.2300 mg/L;\n The LDH is 208.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 36.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.9000 ### months." } ], "images": [ "DMFS_train_1281/0000286515.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 27 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 3.6500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.1000 g/L;\nThe ALB is 49.0000 g/L;\n The CRP is 0.2500 mg/L;\n The LDH is 173.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Docetaxel;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.9667 ### months." } ], "images": [ "DMFS_train_1281/0000286580.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 1.5100 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 154.0000 g/L;\nThe ALB is 47.4000 g/L;\n The CRP is 0.5400 mg/L;\n The LDH is 181.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 300 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.9667 ### months." } ], "images": [ "DMFS_train_1281/0000286569.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 31 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 3.7000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 44.2000 g/L;\n The CRP is 2.5800 mg/L;\n The LDH is 150.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 44.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.9667 ### months." } ], "images": [ "DMFS_train_1281/0000287442.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 3.8200 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 140.0000 g/L;\nThe ALB is 42.2000 g/L;\n The CRP is 0.3200 mg/L;\n The LDH is 256.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.9000 ### months." } ], "images": [ "DMFS_train_1281/0000287541.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 39 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.8350 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 160.0000 g/L;\nThe ALB is 41.9000 g/L;\n The CRP is 1.9400 mg/L;\n The LDH is 152.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 62.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 90.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 69.1000 ### months." } ], "images": [ "DMFS_train_1281/0000287152.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 61 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.4140 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 149.0000 g/L;\nThe ALB is 42.0000 g/L;\n The CRP is 3.8600 mg/L;\n The LDH is 252.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 65.5333 ### months." } ], "images": [ "DMFS_train_1281/0000287655.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 61 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 19.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 138.7000 g/L;\nThe ALB is 43.6000 g/L;\n The CRP is 0.7300 mg/L;\n The LDH is 186.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 61.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 83.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 59.0000 ### months." } ], "images": [ "DMFS_train_1281/0000285534.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 62 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 47.5000 g/L;\n The CRP is 2.0100 mg/L;\n The LDH is 164.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 61.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 85.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.2333 ### months." } ], "images": [ "DMFS_train_1281/0000285442.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 28 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 15.4000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 144.0000 g/L;\nThe ALB is 45.2000 g/L;\n The CRP is 6.1500 mg/L;\n The LDH is 224.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 44.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 69.4333 ### months." } ], "images": [ "DMFS_train_1281/0000285921.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 3.8500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 138.2000 g/L;\nThe ALB is 47.1000 g/L;\n The CRP is 2.1000 mg/L;\n The LDH is 205.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 33.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 51.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 69.3333 ### months." } ], "images": [ "DMFS_train_1281/0000286826.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 152.2000 g/L;\nThe ALB is 42.0000 g/L;\n The CRP is 0.3800 mg/L;\n The LDH is 171.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 47.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 56.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 59.0667 ### months." } ], "images": [ "DMFS_train_1281/0000286048.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 34.9000 copies/mL;\nThe EBV of after treatment is 0.2690 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 47.8000 g/L;\n The CRP is 2.8000 mg/L;\n The LDH is 228.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 69.3333 ### months." } ], "images": [ "DMFS_train_1281/0000286160.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 3.5200 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 155.0000 g/L;\nThe ALB is 48.7000 g/L;\n The CRP is 0.7900 mg/L;\n The LDH is 168.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Docetaxel;\n The time interval between induction chemotherapy and post-treatment imaging is 63.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 89.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 69.4667 ### months." } ], "images": [ "DMFS_train_1281/0000286720.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 13.9000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 129.0000 g/L;\nThe ALB is 46.5000 g/L;\n The CRP is 1.8900 mg/L;\n The LDH is 173.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 37.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 69.5000 ### months." } ], "images": [ "DMFS_train_1281/0000285599.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 47.7000 g/L;\n The CRP is 1.4700 mg/L;\n The LDH is 242.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 170 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.2000 ### months." } ], "images": [ "DMFS_train_1281/0000289470.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 52.5000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 140.0000 g/L;\nThe ALB is 45.4000 g/L;\n The CRP is 8.2100 mg/L;\n The LDH is 175.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 46.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 56.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 59.4000 ### months." } ], "images": [ "DMFS_train_1281/00C1093728.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 16.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 171.0000 g/L;\nThe ALB is 44.9000 g/L;\n The CRP is 17.5300 mg/L;\n The LDH is 149.5000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 120 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 75.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 96.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 69.6333 ### months." } ], "images": [ "DMFS_train_1281/00C1124207.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 113.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 155.0000 g/L;\nThe ALB is 47.3000 g/L;\n The CRP is 1.7600 mg/L;\n The LDH is 218.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 47.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 69.7333 ### months." } ], "images": [ "DMFS_train_1281/0000285184.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.4970 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 44.2000 g/L;\n The CRP is 1.0500 mg/L;\n The LDH is 234.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 溃疡性结肠炎:Ulcerative colitis (UC) is a chronic intestinal inflammation treated with immunosuppressive drugs. For nasopharyngeal carcinoma patients, UC can impact cancer treatment outcomes and prognosis by suppressing the immune system, drug interactions, malnutrition, and chronic inflammation, increasing risks and complications during treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.4333 ### months." } ], "images": [ "DMFS_train_1281/0000287587.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 155.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 0.3000 mg/L;\n The LDH is 237.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 45.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 59.7000 ### months." } ], "images": [ "DMFS_train_1281/0000285108.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 61 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.9700 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 133.0000 g/L;\nThe ALB is 43.3000 g/L;\n The CRP is 0.2300 mg/L;\n The LDH is 151.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 47.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 60.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.0000 ### months." } ], "images": [ "DMFS_train_1281/0000284582.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.7200 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 40.3000 g/L;\n The CRP is 0.2300 mg/L;\n The LDH is 209.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 73.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 83.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 70.1667 ### months." } ], "images": [ "DMFS_train_1281/0000283804.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 8.8600 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 147.0000 g/L;\nThe ALB is 47.0000 g/L;\n The CRP is 2.7600 mg/L;\n The LDH is 209.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 70.1667 ### months." } ], "images": [ "DMFS_train_1281/0000284060.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 31 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 35.9000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 158.0000 g/L;\nThe ALB is 47.6000 g/L;\n The CRP is 0.7300 mg/L;\n The LDH is 223.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 6; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 38.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 45.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 70.2667 ### months." } ], "images": [ "DMFS_train_1281/0000284089.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 53 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 9.4900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 40.7000 g/L;\n The CRP is 0.8600 mg/L;\n The LDH is 190.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Docetaxel;\n The time interval between induction chemotherapy and post-treatment imaging is 40.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 60.1667 ### months." } ], "images": [ "DMFS_train_1281/0000284649.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2.3900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 146.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 1.2100 mg/L;\n The LDH is 168.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 60.2667 ### months." } ], "images": [ "DMFS_train_1281/0000283724.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 27 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 3.1700 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 149.8000 g/L;\nThe ALB is 48.0000 g/L;\n The CRP is 2.4100 mg/L;\n The LDH is 162.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 53.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 60.3000 ### months." } ], "images": [ "DMFS_train_1281/0000284194.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 28 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 32.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 149.8000 g/L;\nThe ALB is 48.2000 g/L;\n The CRP is 13.3600 mg/L;\n The LDH is 211.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 43.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 63.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 60.3333 ### months." } ], "images": [ "DMFS_train_1281/0000283797.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 22.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 140.0000 g/L;\nThe ALB is 48.2000 g/L;\n The CRP is 0.7600 mg/L;\n The LDH is 164.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 37.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 60.4000 ### months." } ], "images": [ "DMFS_train_1281/0000283054.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 63 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 121.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 152.9000 g/L;\nThe ALB is 45.5000 g/L;\n The CRP is 0.7500 mg/L;\n The LDH is 212.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 2:Mild complications that require some medication or treatment to control, and may have a slight impact on daily activities.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 40.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 60.5000 ### months." } ], "images": [ "DMFS_train_1281/0000257612.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 127.0000 g/L;\nThe ALB is 46.2000 g/L;\n The CRP is 1.3300 mg/L;\n The LDH is 166.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 60.6333 ### months." } ], "images": [ "DMFS_train_1281/0000282817.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.4000 g/L;\nThe ALB is 44.4000 g/L;\n The CRP is 3.7300 mg/L;\n The LDH is 185.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 53.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 60.6333 ### months." } ], "images": [ "DMFS_train_1281/0000283599.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 98.2000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 46.2000 g/L;\n The CRP is 3.9000 mg/L;\n The LDH is 189.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Docetaxel;\n The time interval between induction chemotherapy and post-treatment imaging is 41.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 60.8000 ### months." } ], "images": [ "DMFS_train_1281/0000283139.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 64 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 113.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 131.1000 g/L;\nThe ALB is 40.5000 g/L;\n The CRP is 3.5800 mg/L;\n The LDH is 180.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 84.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 60.8000 ### months." } ], "images": [ "DMFS_train_1281/0000283456.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 9.5200 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 159.6000 g/L;\nThe ALB is 41.7000 g/L;\n The CRP is 1.4600 mg/L;\n The LDH is 217.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 60.8333 ### months." } ], "images": [ "DMFS_train_1281/0000283256.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 30 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 125.6000 g/L;\nThe ALB is 47.8000 g/L;\n The CRP is 0.5700 mg/L;\n The LDH is 180.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 33.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 47.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.0000 ### months." } ], "images": [ "DMFS_train_1281/0000281969.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 19 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 5.2700 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 150.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 0.1000 mg/L;\n The LDH is 183.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 51.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.0667 ### months." } ], "images": [ "DMFS_train_1281/0000282385.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 149.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.6000 g/L;\nThe ALB is 44.3000 g/L;\n The CRP is 1.4100 mg/L;\n The LDH is 130.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 47.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 51.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.1000 ### months." } ], "images": [ "DMFS_train_1281/0000281733.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 443.0000 copies/mL;\nThe EBV of after treatment is 14.1000 copies/m; \nThe HGB is 137.0000 g/L;\nThe ALB is 38.3000 g/L;\n The CRP is 2.4900 mg/L;\n The LDH is 141.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 44.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.1000 ### months." } ], "images": [ "DMFS_train_1281/0000281783.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 29 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 47.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 156.0000 g/L;\nThe ALB is 45.2000 g/L;\n The CRP is 7.0600 mg/L;\n The LDH is 197.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 65.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.1000 ### months." } ], "images": [ "DMFS_train_1281/0000282101.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 97.4000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 45.2000 g/L;\n The CRP is 6.9900 mg/L;\n The LDH is 247.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 67.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.1667 ### months." } ], "images": [ "DMFS_train_1281/0000282488.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 61 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 57.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 147.0000 g/L;\nThe ALB is 46.9000 g/L;\n The CRP is 5.2000 mg/L;\n The LDH is 202.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2+7; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.2667 ### months." } ], "images": [ "DMFS_train_1281/0000282344.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 177.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 158.9000 g/L;\nThe ALB is 46.5000 g/L;\n The CRP is 0.5000 mg/L;\n The LDH is 277.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 100 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 33.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 51.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.2667 ### months." } ], "images": [ "DMFS_train_1281/0000282583.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 16 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 18.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 150.0000 g/L;\nThe ALB is 41.8000 g/L;\n The CRP is 12.4300 mg/L;\n The LDH is 146.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 37.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.3000 ### months." } ], "images": [ "DMFS_train_1281/0000281499.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 146.0000 g/L;\nThe ALB is 47.2000 g/L;\n The CRP is 11.5900 mg/L;\n The LDH is 157.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 6; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 65.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.3000 ### months." } ], "images": [ "DMFS_train_1281/00C1119281.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 30.9000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 125.8000 g/L;\nThe ALB is 37.5000 g/L;\n The CRP is 34.5900 mg/L;\n The LDH is 129.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 69.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.4667 ### months." } ], "images": [ "DMFS_train_1281/0000283230.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 14.8000 copies/mL;\nThe EBV of after treatment is 41.5000 copies/m; \nThe HGB is 150.0000 g/L;\nThe ALB is 38.9000 g/L;\n The CRP is 1.5000 mg/L;\n The LDH is 150.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2+6; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 32.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.5000 ### months." } ], "images": [ "DMFS_train_1281/0000280635.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 18.7000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 140.7000 g/L;\nThe ALB is 46.1000 g/L;\n The CRP is 4.9200 mg/L;\n The LDH is 196.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 38.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.5000 ### months." } ], "images": [ "DMFS_train_1281/0000281162.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 6.3400 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 156.0000 g/L;\nThe ALB is 42.2000 g/L;\n The CRP is 3.9900 mg/L;\n The LDH is 188.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 62.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.5000 ### months." } ], "images": [ "DMFS_train_1281/0000281455.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 13.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 154.0000 g/L;\nThe ALB is 43.9000 g/L;\n The CRP is 1.4000 mg/L;\n The LDH is 185.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 7:Severe complications, where the health of patient is significantly affected, with a potential life-threatening condition, requiring emergency medical intervention.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.5333 ### months." } ], "images": [ "DMFS_train_1281/0000282323.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.2800 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 161.3000 g/L;\nThe ALB is 50.1000 g/L;\n The CRP is 0.3100 mg/L;\n The LDH is 123.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.6667 ### months." } ], "images": [ "DMFS_train_1281/0000281030.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 104.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.9000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 3.5900 mg/L;\n The LDH is 133.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 220 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 62.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 83.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.7333 ### months." } ], "images": [ "DMFS_train_1281/0000280898.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 46.1000 copies/mL;\nThe EBV of after treatment is 0.2740 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 41.8000 g/L;\n The CRP is 0.6600 mg/L;\n The LDH is 310.8000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 45.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.7667 ### months." } ], "images": [ "DMFS_train_1281/0000280364.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 23 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 34.5000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 43.7000 g/L;\n The CRP is 1.4900 mg/L;\n The LDH is 177.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.7667 ### months." } ], "images": [ "DMFS_train_1281/0000280577.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 43.4000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 152.0000 g/L;\nThe ALB is 47.2000 g/L;\n The CRP is 0.6300 mg/L;\n The LDH is 187.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 51.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 60.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.7667 ### months." } ], "images": [ "DMFS_train_1281/0000280582.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 152.0000 g/L;\nThe ALB is 44.1000 g/L;\n The CRP is 1.1800 mg/L;\n The LDH is 198.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.7667 ### months." } ], "images": [ "DMFS_train_1281/0000280694.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 39 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 46.3000 g/L;\n The CRP is 8.6000 mg/L;\n The LDH is 180.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 300 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.8333 ### months." } ], "images": [ "DMFS_train_1281/0000280777.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 27 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1080.0000 copies/mL;\nThe EBV of after treatment is 796.0000 copies/m; \nThe HGB is 139.4000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 5.4500 mg/L;\n The LDH is 137.9000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 100 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 61.9333 ### months." } ], "images": [ "DMFS_train_1281/0000280187.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 27 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 170.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 147.0000 g/L;\nThe ALB is 42.1000 g/L;\n The CRP is 18.6100 mg/L;\n The LDH is 292.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 145 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.0000 ### months." } ], "images": [ "DMFS_train_1281/0000279894.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 120.9000 g/L;\nThe ALB is 42.7000 g/L;\n The CRP is 3.7800 mg/L;\n The LDH is 219.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 36.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.1333 ### months." } ], "images": [ "DMFS_train_1281/0000279653.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 5.2600 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 158.5000 g/L;\nThe ALB is 49.5000 g/L;\n The CRP is 0.9200 mg/L;\n The LDH is 191.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.1667 ### months." } ], "images": [ "DMFS_train_1281/0000279652.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 39 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 989.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 146.0000 g/L;\nThe ALB is 36.8000 g/L;\n The CRP is 7.1500 mg/L;\n The LDH is 411.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 81.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.2000 ### months." } ], "images": [ "DMFS_train_1281/0000280624.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 14.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 47.0000 g/L;\n The CRP is 1.0400 mg/L;\n The LDH is 173.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 60.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.3000 ### months." } ], "images": [ "DMFS_train_1281/0000279495.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 64.8000 copies/mL;\nThe EBV of after treatment is 0.7590 copies/m; \nThe HGB is 154.0000 g/L;\nThe ALB is 41.3000 g/L;\n The CRP is 0.9000 mg/L;\n The LDH is 168.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.3000 ### months." } ], "images": [ "DMFS_train_1281/0000280503.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 61 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 60.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 123.0000 g/L;\nThe ALB is 42.1000 g/L;\n The CRP is 0.8000 mg/L;\n The LDH is 210.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 8:Extremely severe complications that may be life-threatening, with impaired function of multiple organ systems, requiring intensive care and emergency treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 60.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.3667 ### months." } ], "images": [ "DMFS_train_1281/0000257702.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 32 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 5.9400 copies/mL;\nThe EBV of after treatment is 14.3000 copies/m; \nThe HGB is 129.3000 g/L;\nThe ALB is 44.9000 g/L;\n The CRP is 0.8100 mg/L;\n The LDH is 145.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.3667 ### months." } ], "images": [ "DMFS_train_1281/0000280222.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 106.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 45.5000 g/L;\n The CRP is 11.5200 mg/L;\n The LDH is 195.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 47.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.4000 ### months." } ], "images": [ "DMFS_train_1281/0000281731.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 2.6200 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.3000 g/L;\nThe ALB is 47.7000 g/L;\n The CRP is 0.7000 mg/L;\n The LDH is 156.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 51.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.4000 ### months." } ], "images": [ "DMFS_train_1281/0000279415.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 10.7000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 133.0000 g/L;\nThe ALB is 40.4000 g/L;\n The CRP is 0.2100 mg/L;\n The LDH is 151.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.5667 ### months." } ], "images": [ "DMFS_train_1281/0000279054.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 85.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 0.9700 mg/L;\n The LDH is 163.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 44.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.6000 ### months." } ], "images": [ "DMFS_train_1281/0000278864.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 25 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 5.1800 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 129.0000 g/L;\nThe ALB is 46.7000 g/L;\n The CRP is 8.1700 mg/L;\n The LDH is 149.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 280 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 76.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.6333 ### months." } ], "images": [ "DMFS_train_1281/0000278318.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 50 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 207.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 146.0000 g/L;\nThe ALB is 46.2000 g/L;\n The CRP is 5.4100 mg/L;\n The LDH is 263.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 51.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 75.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.7333 ### months." } ], "images": [ "DMFS_train_1281/00C1117114.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 24 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 2.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 123.0000 g/L;\nThe ALB is 44.3000 g/L;\n The CRP is 0.7800 mg/L;\n The LDH is 152.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 185 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 62.9000 ### months." } ], "images": [ "DMFS_train_1281/0000278637.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 125.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 44.4000 g/L;\n The CRP is 3.1800 mg/L;\n The LDH is 156.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 69.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 80.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.0000 ### months." } ], "images": [ "DMFS_train_1281/0000280151.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 147.0000 g/L;\nThe ALB is 38.7000 g/L;\n The CRP is 1.4900 mg/L;\n The LDH is 148.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 75.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.0000 ### months." } ], "images": [ "DMFS_train_1281/0000279068.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 27 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.8500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.0000 g/L;\nThe ALB is 47.8000 g/L;\n The CRP is 3.9500 mg/L;\n The LDH is 149.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 100 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 63.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.0000 ### months." } ], "images": [ "DMFS_train_1281/0000280943.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 62 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1030.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 41.4000 g/L;\n The CRP is 2.9300 mg/L;\n The LDH is 285.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 58.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 89.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.1000 ### months." } ], "images": [ "DMFS_train_1281/0000279328.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 55 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 27.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 115.7000 g/L;\nThe ALB is 42.1000 g/L;\n The CRP is 19.1300 mg/L;\n The LDH is 140.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2+7; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 60.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.1000 ### months." } ], "images": [ "DMFS_train_1281/0000280493.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 53 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 1.3900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 146.0000 g/L;\nThe ALB is 40.7000 g/L;\n The CRP is 2.6100 mg/L;\n The LDH is 175.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 2:Mild complications that require some medication or treatment to control, and may have a slight impact on daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.2333 ### months." } ], "images": [ "DMFS_train_1281/0000279985.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 152.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 1.3700 mg/L;\n The LDH is 144.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 300 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 81.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.2667 ### months." } ], "images": [ "DMFS_train_1281/0000278708.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 128.0000 copies/mL;\nThe EBV of after treatment is 2.2300 copies/m; \nThe HGB is 138.0000 g/L;\nThe ALB is 42.9000 g/L;\n The CRP is 1.6200 mg/L;\n The LDH is 172.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.3000 ### months." } ], "images": [ "DMFS_train_1281/0000277846.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 29 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 10.9000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 163.0000 g/L;\nThe ALB is 47.3000 g/L;\n The CRP is 1.0800 mg/L;\n The LDH is 142.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 61.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 117.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.4333 ### months." } ], "images": [ "DMFS_train_1281/0000283008.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 111.0000 g/L;\nThe ALB is 38.3000 g/L;\n The CRP is 1.0400 mg/L;\n The LDH is 217.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.6000 ### months." } ], "images": [ "DMFS_train_1281/0000276384.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 75.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 38.4000 g/L;\n The CRP is 2.1000 mg/L;\n The LDH is 211.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 120 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 58.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 69.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.6000 ### months." } ], "images": [ "DMFS_train_1281/0000277174.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 2.5500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 128.0000 g/L;\nThe ALB is 40.5000 g/L;\n The CRP is 0.5500 mg/L;\n The LDH is 226.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 68.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 93.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.6000 ### months." } ], "images": [ "DMFS_train_1281/0000277448.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 15.4000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.1000 g/L;\nThe ALB is 38.3000 g/L;\n The CRP is 2.6700 mg/L;\n The LDH is 225.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 72.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.6000 ### months." } ], "images": [ "DMFS_train_1281/0000278548.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 57 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 265.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 149.0000 g/L;\nThe ALB is 45.7000 g/L;\n The CRP is 0.7500 mg/L;\n The LDH is 216.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 79.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.6333 ### months." } ], "images": [ "DMFS_train_1281/00C1115646.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 131.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 149.0000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 17.3600 mg/L;\n The LDH is 206.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 8:Extremely severe complications that may be life-threatening, with impaired function of multiple organ systems, requiring intensive care and emergency treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.6667 ### months." } ], "images": [ "DMFS_train_1281/0000276967.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 53.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 44.5000 g/L;\n The CRP is 3.3100 mg/L;\n The LDH is 139.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 7:Severe complications, where the health of patient is significantly affected, with a potential life-threatening condition, requiring emergency medical intervention.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 59.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 77.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.8333 ### months." } ], "images": [ "DMFS_train_1281/0000275986.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 29 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 5.2600 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 109.0000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 8.2000 mg/L;\n The LDH is 173.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.8333 ### months." } ], "images": [ "DMFS_train_1281/0000276653.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 24.2000 copies/mL;\nThe EBV of after treatment is 5.4500 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 45.8000 g/L;\n The CRP is 1.5800 mg/L;\n The LDH is 203.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 62.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 63.8333 ### months." } ], "images": [ "DMFS_train_1281/0000279360.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 5.9900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.6000 g/L;\nThe ALB is 42.2000 g/L;\n The CRP is 4.4700 mg/L;\n The LDH is 158.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 120 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 79.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.0333 ### months." } ], "images": [ "DMFS_train_1281/0000277230.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 804.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 45.2000 g/L;\n The CRP is 3.8300 mg/L;\n The LDH is 235.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.1333 ### months." } ], "images": [ "DMFS_train_1281/0000276401.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 22.7000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 126.4000 g/L;\nThe ALB is 41.8000 g/L;\n The CRP is 0.5700 mg/L;\n The LDH is 213.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 69.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.4000 ### months." } ], "images": [ "DMFS_train_1281/00C1112580.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 39 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 108.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.3000 g/L;\nThe ALB is 47.0000 g/L;\n The CRP is 2.6000 mg/L;\n The LDH is 184.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 36.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.4667 ### months." } ], "images": [ "DMFS_train_1281/0000275048.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 14.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 155.0000 g/L;\nThe ALB is 40.1000 g/L;\n The CRP is 2.0800 mg/L;\n The LDH is 239.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 8:Extremely severe complications that may be life-threatening, with impaired function of multiple organ systems, requiring intensive care and emergency treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.4667 ### months." } ], "images": [ "DMFS_train_1281/00C1112136.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 50 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 2.8400 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 146.0000 g/L;\nThe ALB is 37.1000 g/L;\n The CRP is 1.9400 mg/L;\n The LDH is 163.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.5000 ### months." } ], "images": [ "DMFS_train_1281/0000275617.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 67 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 130.0000 copies/mL;\nThe EBV of after treatment is 36.8000 copies/m; \nThe HGB is 131.8000 g/L;\nThe ALB is 37.0000 g/L;\n The CRP is 3.3100 mg/L;\n The LDH is 147.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is TP;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 71.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.5000 ### months." } ], "images": [ "DMFS_train_1281/0000275954.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 481.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 138.0000 g/L;\nThe ALB is 42.1000 g/L;\n The CRP is 0.6400 mg/L;\n The LDH is 226.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.5000 ### months." } ], "images": [ "DMFS_train_1281/0000276349.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 12.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 155.0000 g/L;\nThe ALB is 45.1000 g/L;\n The CRP is 0.6900 mg/L;\n The LDH is 243.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 300 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 57.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 69.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.6000 ### months." } ], "images": [ "DMFS_train_1281/0000274463.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 17 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 3.3800 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.1000 g/L;\nThe ALB is 48.7000 g/L;\n The CRP is 1.6100 mg/L;\n The LDH is 159.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 130 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 40.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.6667 ### months." } ], "images": [ "DMFS_train_1281/0000274780.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 32 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 1.7400 mg/L;\n The LDH is 182.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 60 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Lobaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.7000 ### months." } ], "images": [ "DMFS_train_1281/0000276895.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 23 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 62.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 1.7000 mg/L;\n The LDH is 169.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 67.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.7667 ### months." } ], "images": [ "DMFS_train_1281/0000252857.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 53 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.6200 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 131.3000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 0.5500 mg/L;\n The LDH is 194.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.7333 ### months." } ], "images": [ "DMFS_train_1281/0000274122.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 39 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 53.8000 copies/mL;\nThe EBV of after treatment is 11.1000 copies/m; \nThe HGB is 126.0000 g/L;\nThe ALB is 41.1000 g/L;\n The CRP is 1.4600 mg/L;\n The LDH is 139.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 102.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.7333 ### months." } ], "images": [ "DMFS_train_1281/0000278843.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 11 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 20.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 116.0000 g/L;\nThe ALB is 38.3000 g/L;\n The CRP is 28.9800 mg/L;\n The LDH is 224.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 61.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.8667 ### months." } ], "images": [ "DMFS_train_1281/0000273913.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 31 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 6.6500 copies/mL;\nThe EBV of after treatment is 0.9560 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 46.9000 g/L;\n The CRP is 0.7500 mg/L;\n The LDH is 147.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 60.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 76.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.9000 ### months." } ], "images": [ "DMFS_train_1281/0000273914.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 40.7000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 137.0000 g/L;\nThe ALB is 42.8000 g/L;\n The CRP is 2.3700 mg/L;\n The LDH is 215.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 83.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.9000 ### months." } ], "images": [ "DMFS_train_1281/0000275897.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 116.0000 g/L;\nThe ALB is 41.1000 g/L;\n The CRP is 0.7100 mg/L;\n The LDH is 232.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 7:Severe complications, where the health of patient is significantly affected, with a potential life-threatening condition, requiring emergency medical intervention.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 73.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 64.9667 ### months." } ], "images": [ "DMFS_train_1281/0000276043.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 45.6000 g/L;\n The CRP is 6.5900 mg/L;\n The LDH is 171.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 38.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 60.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 65.0000 ### months." } ], "images": [ "DMFS_train_1281/0000274657.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 112.0000 g/L;\nThe ALB is 45.5000 g/L;\n The CRP is 0.4100 mg/L;\n The LDH is 143.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 63.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 65.2000 ### months." } ], "images": [ "DMFS_train_1281/0000273188.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 246.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 126.0000 g/L;\nThe ALB is 42.9000 g/L;\n The CRP is 2.0700 mg/L;\n The LDH is 234.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 66.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 84.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 65.2000 ### months." } ], "images": [ "DMFS_train_1281/0000274243.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 35.9000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 115.0000 g/L;\nThe ALB is 46.6000 g/L;\n The CRP is 1.8700 mg/L;\n The LDH is 175.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 75.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 65.3333 ### months." } ], "images": [ "DMFS_train_1281/0000272983.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 126.0000 g/L;\nThe ALB is 38.4000 g/L;\n The CRP is 1.0000 mg/L;\n The LDH is 165.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 59.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 85.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 65.3333 ### months." } ], "images": [ "DMFS_train_1281/0000274268.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 154.0000 g/L;\nThe ALB is 47.7000 g/L;\n The CRP is 0.9200 mg/L;\n The LDH is 195.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 42.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 51.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 65.4333 ### months." } ], "images": [ "DMFS_train_1281/0000273157.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 184.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 138.0000 g/L;\nThe ALB is 42.1000 g/L;\n The CRP is 4.6400 mg/L;\n The LDH is 129.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 235 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 65.5333 ### months." } ], "images": [ "DMFS_train_1281/0000272558.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 31 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 11.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 46.2000 g/L;\n The CRP is 3.4600 mg/L;\n The LDH is 220.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 5:More severe complications that require the patient to be hospitalized or undergo more frequent medical interventions.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 37.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 62.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 65.5333 ### months." } ], "images": [ "DMFS_train_1281/00C1109541.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 27 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2780.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 130.0000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 84.6200 mg/L;\n The LDH is 178.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 68.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 65.5667 ### months." } ], "images": [ "DMFS_train_1281/0000273559.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 19.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.2000 g/L;\nThe ALB is 46.6000 g/L;\n The CRP is 2.4200 mg/L;\n The LDH is 184.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 38.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 65.6000 ### months." } ], "images": [ "DMFS_train_1281/0000272922.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 634.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 39.8000 g/L;\n The CRP is 7.9700 mg/L;\n The LDH is 190.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 65.6000 ### months." } ], "images": [ "DMFS_train_1281/0000273184.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 152.0000 g/L;\nThe ALB is 42.5000 g/L;\n The CRP is 0.7000 mg/L;\n The LDH is 119.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 101.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 65.7667 ### months." } ], "images": [ "DMFS_train_1281/0000274963.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 39 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 22.7000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.6000 g/L;\nThe ALB is 48.0000 g/L;\n The CRP is 0.3000 mg/L;\n The LDH is 172.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 60.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 69.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 65.8333 ### months." } ], "images": [ "DMFS_train_1281/0000272483.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 15.2000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 147.0000 g/L;\nThe ALB is 43.4000 g/L;\n The CRP is 22.6900 mg/L;\n The LDH is 160.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 62.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 65.8333 ### months." } ], "images": [ "DMFS_train_1281/0000272649.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 56.4000 copies/mL;\nThe EBV of after treatment is 5.6200 copies/m; \nThe HGB is 143.6000 g/L;\nThe ALB is 43.6000 g/L;\n The CRP is 2.0800 mg/L;\n The LDH is 160.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 26.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 65.8333 ### months." } ], "images": [ "DMFS_train_1281/0000272865.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 501.0000 copies/mL;\nThe EBV of after treatment is 5.5600 copies/m; \nThe HGB is 133.4000 g/L;\nThe ALB is 41.1000 g/L;\n The CRP is 4.7100 mg/L;\n The LDH is 226.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 8:Extremely severe complications that may be life-threatening, with impaired function of multiple organ systems, requiring intensive care and emergency treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 44.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 65.9667 ### months." } ], "images": [ "DMFS_train_1281/0000271203.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 130.0000 g/L;\nThe ALB is 38.1000 g/L;\n The CRP is 1.6200 mg/L;\n The LDH is 179.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 300 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 89.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.0333 ### months." } ], "images": [ "DMFS_train_1281/0000272802.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 2.9200 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 124.4000 g/L;\nThe ALB is 47.1000 g/L;\n The CRP is 1.5500 mg/L;\n The LDH is 191.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 44.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 53.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.2667 ### months." } ], "images": [ "DMFS_train_1281/00C1108216.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 62 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 383.0000 copies/mL;\nThe EBV of after treatment is 5.7400 copies/m; \nThe HGB is 124.0000 g/L;\nThe ALB is 39.1000 g/L;\n The CRP is 20.9500 mg/L;\n The LDH is 201.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Carboplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.4333 ### months." } ], "images": [ "DMFS_train_1281/0000270793.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 1:Benign or low grade malignant;\nThe Age is 50 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 1.7400 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 1.9900 mg/L;\n The LDH is 136.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.4667 ### months." } ], "images": [ "DMFS_train_1281/0000270726.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 64 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 97.4000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 152.0000 g/L;\nThe ALB is 43.2000 g/L;\n The CRP is 1.5700 mg/L;\n The LDH is 177.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 41.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.4667 ### months." } ], "images": [ "DMFS_train_1281/0000271193.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 9.2000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 135.5000 g/L;\nThe ALB is 42.8000 g/L;\n The CRP is 2.5400 mg/L;\n The LDH is 186.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 40.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.4667 ### months." } ], "images": [ "DMFS_train_1281/0000271298.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 39 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 189.0000 copies/mL;\nThe EBV of after treatment is 10.7000 copies/m; \nThe HGB is 156.0000 g/L;\nThe ALB is 47.3000 g/L;\n The CRP is 3.6300 mg/L;\n The LDH is 273.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 68.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.4667 ### months." } ], "images": [ "DMFS_train_1281/00C1108274.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 29 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 8.3900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 125.0000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 0.5300 mg/L;\n The LDH is 146.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is None; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 41.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 69.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.5000 ### months." } ], "images": [ "DMFS_train_1281/0000272313.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 25 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 46.3000 g/L;\n The CRP is 12.5800 mg/L;\n The LDH is 146.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 25.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.5667 ### months." } ], "images": [ "DMFS_train_1281/0000271583.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 31 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 92.7000 copies/mL;\nThe EBV of after treatment is 1.3100 copies/m; \nThe HGB is 118.0000 g/L;\nThe ALB is 42.8000 g/L;\n The CRP is 0.6700 mg/L;\n The LDH is 773.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 60.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.6333 ### months." } ], "images": [ "DMFS_train_1281/0000272232.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 244.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 150.0000 g/L;\nThe ALB is 46.1000 g/L;\n The CRP is 0.9100 mg/L;\n The LDH is 162.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 38.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.7667 ### months." } ], "images": [ "DMFS_train_1281/0000270116.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 15.0000 copies/mL;\nThe EBV of after treatment is 4.7600 copies/m; \nThe HGB is 130.9000 g/L;\nThe ALB is 41.3000 g/L;\n The CRP is 1.4700 mg/L;\n The LDH is 140.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 300 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.7667 ### months." } ], "images": [ "DMFS_train_1281/0000270245.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 39 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 398.0000 copies/mL;\nThe EBV of after treatment is 9.5700 copies/m; \nThe HGB is 109.0000 g/L;\nThe ALB is 40.9000 g/L;\n The CRP is 0.1800 mg/L;\n The LDH is 156.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 59.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.8000 ### months." } ], "images": [ "DMFS_train_1281/0000270006.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 23 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.2130 copies/mL;\nThe EBV of after treatment is 1.4100 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 48.9000 g/L;\n The CRP is 0.6900 mg/L;\n The LDH is 195.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 41.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.8000 ### months." } ], "images": [ "DMFS_train_1281/0000270426.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 71.4000 copies/mL;\nThe EBV of after treatment is 3.1100 copies/m; \nThe HGB is 122.3000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 1.7600 mg/L;\n The LDH is 146.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 37.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.8000 ### months." } ], "images": [ "DMFS_train_1281/0000271246.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 154.0000 g/L;\nThe ALB is 44.9000 g/L;\n The CRP is 0.4200 mg/L;\n The LDH is 163.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 70.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 83.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.9000 ### months." } ], "images": [ "DMFS_train_1281/0000270579.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 2.7500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 162.2000 g/L;\nThe ALB is 46.7000 g/L;\n The CRP is 2.5300 mg/L;\n The LDH is 195.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 33.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 41.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 66.9333 ### months." } ], "images": [ "DMFS_train_1281/0000270335.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 1.5100 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 170.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 2.2900 mg/L;\n The LDH is 210.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 300 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 62.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.0000 ### months." } ], "images": [ "DMFS_train_1281/0000269660.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 60 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 17.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 133.3000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 1.0400 mg/L;\n The LDH is 233.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.0000 ### months." } ], "images": [ "DMFS_train_1281/0000270707.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 25.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 119.2000 g/L;\nThe ALB is 40.7000 g/L;\n The CRP is 2.0900 mg/L;\n The LDH is 158.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 44.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.3333 ### months." } ], "images": [ "DMFS_train_1281/0000269152.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 245.0000 copies/mL;\nThe EBV of after treatment is 148.0000 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 46.5000 g/L;\n The CRP is 1.9100 mg/L;\n The LDH is 159.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 42.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 51.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.3333 ### months." } ], "images": [ "DMFS_train_1281/0000269669.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 313.0000 copies/mL;\nThe EBV of after treatment is 18.0000 copies/m; \nThe HGB is 149.4000 g/L;\nThe ALB is 48.0000 g/L;\n The CRP is 1.5400 mg/L;\n The LDH is 195.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 69.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.3333 ### months." } ], "images": [ "DMFS_train_1281/0000269944.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 57 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 1.8100 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 158.0000 g/L;\nThe ALB is 48.6000 g/L;\n The CRP is 4.3600 mg/L;\n The LDH is 210.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 260 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 57.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 80.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.3333 ### months." } ], "images": [ "DMFS_train_1281/0000270621.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 27 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 333.0000 copies/mL;\nThe EBV of after treatment is 6.9900 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 45.6000 g/L;\n The CRP is 5.0700 mg/L;\n The LDH is 226.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 100 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 87.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.3333 ### months." } ], "images": [ "DMFS_train_1281/00C1110577.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 125.0000 copies/mL;\nThe EBV of after treatment is 48.0000 copies/m; \nThe HGB is 114.0000 g/L;\nThe ALB is 43.2000 g/L;\n The CRP is 2.2800 mg/L;\n The LDH is 156.8000 U/L; \nThe Number of course is 5;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 123.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 145.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.4667 ### months." } ], "images": [ "DMFS_train_1281/0000270155.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 6.8800 copies/mL;\nThe EBV of after treatment is 1.4700 copies/m; \nThe HGB is 156.0000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 9.2000 mg/L;\n The LDH is 169.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.5000 ### months." } ], "images": [ "DMFS_train_1281/0000269639.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 50 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 141.0000 copies/mL;\nThe EBV of after treatment is 7.8500 copies/m; \nThe HGB is 135.9000 g/L;\nThe ALB is 45.4000 g/L;\n The CRP is 1.5400 mg/L;\n The LDH is 154.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 36.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.5667 ### months." } ], "images": [ "DMFS_train_1281/0000268880.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 64 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 54.5000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 44.6000 g/L;\n The CRP is 3.7900 mg/L;\n The LDH is 188.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 45.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 71.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.5667 ### months." } ], "images": [ "DMFS_train_1281/0000268949.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 41 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 43.2000 copies/mL;\nThe EBV of after treatment is 2.2800 copies/m; \nThe HGB is 111.0000 g/L;\nThe ALB is 42.9000 g/L;\n The CRP is 13.5500 mg/L;\n The LDH is 214.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 42.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.7000 ### months." } ], "images": [ "DMFS_train_1281/0000269153.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 7.0500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 150.0000 g/L;\nThe ALB is 41.9000 g/L;\n The CRP is 16.4900 mg/L;\n The LDH is 215.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 60.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.7333 ### months." } ], "images": [ "DMFS_train_1281/0000268817.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 39 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 20.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 154.0000 g/L;\nThe ALB is 46.1000 g/L;\n The CRP is 0.2800 mg/L;\n The LDH is 174.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 60 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Lobaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 37.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.8000 ### months." } ], "images": [ "DMFS_train_1281/0000268618.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 16.2000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.0000 g/L;\nThe ALB is 44.3000 g/L;\n The CRP is 5.4400 mg/L;\n The LDH is 170.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 8:Extremely severe complications that may be life-threatening, with impaired function of multiple organ systems, requiring intensive care and emergency treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 61.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.9000 ### months." } ], "images": [ "DMFS_train_1281/0000268447.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 27 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 8.4000 copies/mL;\nThe EBV of after treatment is 5.6300 copies/m; \nThe HGB is 138.0000 g/L;\nThe ALB is 45.4000 g/L;\n The CRP is 0.2600 mg/L;\n The LDH is 154.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 40.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 67.9000 ### months." } ], "images": [ "DMFS_train_1281/0000268517.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 23 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 35.2000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 138.0000 g/L;\nThe ALB is 37.0000 g/L;\n The CRP is 1.7000 mg/L;\n The LDH is 149.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 250 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 33.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 53.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.1667 ### months." } ], "images": [ "DMFS_train_1281/0000247970.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.8800 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.0000 g/L;\nThe ALB is 43.6000 g/L;\n The CRP is 0.2100 mg/L;\n The LDH is 171.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is TP;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 63.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.2000 ### months." } ], "images": [ "DMFS_train_1281/0000268361.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2.1600 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 161.0000 g/L;\nThe ALB is 44.9000 g/L;\n The CRP is 1.3100 mg/L;\n The LDH is 206.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 47.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 63.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.2667 ### months." } ], "images": [ "DMFS_train_1281/0000267881.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 21.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 115.5000 g/L;\nThe ALB is 43.3000 g/L;\n The CRP is 4.7300 mg/L;\n The LDH is 154.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.3333 ### months." } ], "images": [ "DMFS_train_1281/0000270151.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 31 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 4.5700 copies/m; \nThe HGB is 92.0000 g/L;\nThe ALB is 36.2000 g/L;\n The CRP is 7.6600 mg/L;\n The LDH is 154.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 53.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.5000 ### months." } ], "images": [ "DMFS_train_1281/0000267650.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 57 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 5.0800 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 165.0000 g/L;\nThe ALB is 42.6000 g/L;\n The CRP is 10.2700 mg/L;\n The LDH is 317.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 62.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.5000 ### months." } ], "images": [ "DMFS_train_1281/0000267890.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 39 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 66.5000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 131.0000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 1.5800 mg/L;\n The LDH is 181.2000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 8:Extremely severe complications that may be life-threatening, with impaired function of multiple organ systems, requiring intensive care and emergency treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 83.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 113.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.5000 ### months." } ], "images": [ "DMFS_train_1281/0000268659.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 5.9500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 156.0000 g/L;\nThe ALB is 44.9000 g/L;\n The CRP is 3.5300 mg/L;\n The LDH is 175.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.6667 ### months." } ], "images": [ "DMFS_train_1281/0000268545.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 39 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 196.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 138.9000 g/L;\nThe ALB is 33.2000 g/L;\n The CRP is 2.2200 mg/L;\n The LDH is 234.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 63.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 63.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.7333 ### months." } ], "images": [ "DMFS_train_1281/0000267125.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 23 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 8.3300 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 150.3000 g/L;\nThe ALB is 46.4000 g/L;\n The CRP is 1.6500 mg/L;\n The LDH is 198.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 39.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.8333 ### months." } ], "images": [ "DMFS_train_1281/0000267364.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 26 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 32.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 160.0000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 5.1500 mg/L;\n The LDH is 189.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 43.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 60.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.8667 ### months." } ], "images": [ "DMFS_train_1281/0000267824.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.7800 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 138.2000 g/L;\nThe ALB is 41.6000 g/L;\n The CRP is 3.0900 mg/L;\n The LDH is 112.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 245 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 42.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 53.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.9333 ### months." } ], "images": [ "DMFS_train_1281/0000266728.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 163.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 146.1000 g/L;\nThe ALB is 39.5000 g/L;\n The CRP is 1.4800 mg/L;\n The LDH is 156.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 47.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 51.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.9667 ### months." } ], "images": [ "DMFS_train_1281/0000266722.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 32.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 152.0000 g/L;\nThe ALB is 51.0000 g/L;\n The CRP is 0.6000 mg/L;\n The LDH is 167.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 69.1667 ### months." } ], "images": [ "DMFS_train_1281/0000267563.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 50 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 247.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 144.0000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 10.8000 mg/L;\n The LDH is 126.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 2:Mild complications that require some medication or treatment to control, and may have a slight impact on daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 60.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 84.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 69.3000 ### months." } ], "images": [ "DMFS_train_1281/0000244301.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 28 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 29.7000 copies/mL;\nThe EBV of after treatment is 6.7800 copies/m; \nThe HGB is 155.0000 g/L;\nThe ALB is 46.9000 g/L;\n The CRP is 0.8900 mg/L;\n The LDH is 300.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 300 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 76.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 69.3333 ### months." } ], "images": [ "DMFS_train_1281/0000266452.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 34 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 47.5000 g/L;\n The CRP is 4.7200 mg/L;\n The LDH is 247.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 47.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 69.3333 ### months." } ], "images": [ "DMFS_train_1281/0000266646.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 21.4000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 163.0000 g/L;\nThe ALB is 50.8000 g/L;\n The CRP is 1.8600 mg/L;\n The LDH is 182.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 190 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 47.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 69.3667 ### months." } ], "images": [ "DMFS_train_1281/0000266850.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 28.7000 copies/mL;\nThe EBV of after treatment is 1.5100 copies/m; \nThe HGB is 137.5000 g/L;\nThe ALB is 47.6000 g/L;\n The CRP is 0.1700 mg/L;\n The LDH is 187.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 80.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 69.3667 ### months." } ], "images": [ "DMFS_train_1281/0000267723.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.5760 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 172.0000 g/L;\nThe ALB is 42.9000 g/L;\n The CRP is 1.9800 mg/L;\n The LDH is 218.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 33.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 39.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 69.5333 ### months." } ], "images": [ "DMFS_train_1281/0000266113.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 20.7000 copies/mL;\nThe EBV of after treatment is 29.8000 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 46.5000 g/L;\n The CRP is 1.6100 mg/L;\n The LDH is 145.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 40.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 69.5667 ### months." } ], "images": [ "DMFS_train_1281/0000266533.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 68.2000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 138.0000 g/L;\nThe ALB is 45.9000 g/L;\n The CRP is 7.9400 mg/L;\n The LDH is 200.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 40.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 58.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 69.6333 ### months." } ], "images": [ "DMFS_train_1281/0000266437.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.9060 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 44.1000 g/L;\n The CRP is 1.3200 mg/L;\n The LDH is 266.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 280 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 68.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 69.6667 ### months." } ], "images": [ "DMFS_train_1281/0000266028.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.7600 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 171.0000 g/L;\nThe ALB is 50.3000 g/L;\n The CRP is 0.4700 mg/L;\n The LDH is 187.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 76.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 69.8000 ### months." } ], "images": [ "DMFS_train_1281/0000266399.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 24.2000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 131.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 0.6400 mg/L;\n The LDH is 235.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 280 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 57.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 71.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 69.8333 ### months." } ], "images": [ "DMFS_train_1281/0000265812.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 34 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 97.4000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.6000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 5.1500 mg/L;\n The LDH is 193.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 70.2667 ### months." } ], "images": [ "DMFS_train_1281/0000265075.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 33.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.4000 g/L;\nThe ALB is 42.1000 g/L;\n The CRP is 2.7600 mg/L;\n The LDH is 202.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 44.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 70.3000 ### months." } ], "images": [ "DMFS_train_1281/0000266152.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 1.6500 mg/L;\n The LDH is 170.6000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 97.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 115.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 70.4333 ### months." } ], "images": [ "DMFS_train_1281/0000264786.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 6.9900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 155.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 13.0500 mg/L;\n The LDH is 187.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 87.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 102.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 70.4667 ### months." } ], "images": [ "DMFS_train_1281/0000266347.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 23.4000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 39.2000 g/L;\n The CRP is 1.3200 mg/L;\n The LDH is 115.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 51.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 60.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 70.7667 ### months." } ], "images": [ "DMFS_train_1281/0000263274.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 32 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 3.2500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 140.0000 g/L;\nThe ALB is 49.0000 g/L;\n The CRP is 1.8200 mg/L;\n The LDH is 224.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 70.7667 ### months." } ], "images": [ "DMFS_train_1281/0000264117.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 61 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 16.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.0000 g/L;\nThe ALB is 43.6000 g/L;\n The CRP is 30.3000 mg/L;\n The LDH is 136.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 38.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 70.8000 ### months." } ], "images": [ "DMFS_train_1281/0000263765.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 61 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 6.9500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 43.4000 g/L;\n The CRP is 1.8900 mg/L;\n The LDH is 295.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 71.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 70.9000 ### months." } ], "images": [ "DMFS_train_1281/0000264485.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 457.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 129.7000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 0.9300 mg/L;\n The LDH is 158.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 68.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 70.9333 ### months." } ], "images": [ "DMFS_train_1281/0000263801.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 1.0100 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 121.0000 g/L;\nThe ALB is 40.0000 g/L;\n The CRP is 0.6200 mg/L;\n The LDH is 169.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 94.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 108.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 71.0000 ### months." } ], "images": [ "DMFS_train_1281/0000242267.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 64 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 18.4000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 115.0000 g/L;\nThe ALB is 44.9000 g/L;\n The CRP is 2.1000 mg/L;\n The LDH is 158.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 71.0333 ### months." } ], "images": [ "DMFS_train_1281/0000263576.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.8700 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 155.0000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 5.1500 mg/L;\n The LDH is 193.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 71.0333 ### months." } ], "images": [ "DMFS_train_1281/0000264447.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 124.0000 g/L;\nThe ALB is 40.7000 g/L;\n The CRP is 9.2900 mg/L;\n The LDH is 164.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 71.1333 ### months." } ], "images": [ "DMFS_train_1281/0000264300.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 5.8600 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 149.4000 g/L;\nThe ALB is 44.2000 g/L;\n The CRP is 2.0700 mg/L;\n The LDH is 213.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 170 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 42.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 71.1667 ### months." } ], "images": [ "DMFS_train_1281/0000263272.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 6.8600 copies/mL;\nThe EBV of after treatment is 1.8000 copies/m; \nThe HGB is 166.4000 g/L;\nThe ALB is 45.1000 g/L;\n The CRP is 1.3700 mg/L;\n The LDH is 136.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 47.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 71.2000 ### months." } ], "images": [ "DMFS_train_1281/0000264923.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 119.4000 g/L;\nThe ALB is 43.2000 g/L;\n The CRP is 0.3800 mg/L;\n The LDH is 161.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 71.2333 ### months." } ], "images": [ "DMFS_train_1281/0000262365.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 32 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 36.7000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 1.0500 mg/L;\n The LDH is 213.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 47.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 61.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 71.3333 ### months." } ], "images": [ "DMFS_train_1281/0000263095.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 5.5200 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 136.0000 g/L;\nThe ALB is 41.6000 g/L;\n The CRP is 4.0500 mg/L;\n The LDH is 184.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 81.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 71.3333 ### months." } ], "images": [ "DMFS_train_1281/0000264095.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 150.0000 g/L;\nThe ALB is 42.6000 g/L;\n The CRP is 0.8800 mg/L;\n The LDH is 173.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 71.4000 ### months." } ], "images": [ "DMFS_train_1281/0000263355.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 24 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 152.0000 g/L;\nThe ALB is 49.8000 g/L;\n The CRP is 0.2200 mg/L;\n The LDH is 199.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 41.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 60.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 71.5333 ### months." } ], "images": [ "DMFS_train_1281/0000263062.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 26 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 468.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 45.9000 g/L;\n The CRP is 4.7300 mg/L;\n The LDH is 303.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 68.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 96.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 71.5667 ### months." } ], "images": [ "DMFS_train_1281/0000263475.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 31 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 12.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 137.3000 g/L;\nThe ALB is 45.7000 g/L;\n The CRP is 0.6700 mg/L;\n The LDH is 154.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 71.6333 ### months." } ], "images": [ "DMFS_train_1281/0000262089.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 28 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 65.6000 copies/mL;\nThe EBV of after treatment is 4.6900 copies/m; \nThe HGB is 132.0000 g/L;\nThe ALB is 44.6000 g/L;\n The CRP is 3.5800 mg/L;\n The LDH is 160.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 80.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 71.7000 ### months." } ], "images": [ "DMFS_train_1281/0000263015.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 470.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 167.0000 g/L;\nThe ALB is 42.5000 g/L;\n The CRP is 2.5900 mg/L;\n The LDH is 218.5000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 82.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 91.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 71.7667 ### months." } ], "images": [ "DMFS_train_1281/0000264276.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 154.0000 g/L;\nThe ALB is 46.3000 g/L;\n The CRP is 5.0100 mg/L;\n The LDH is 132.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 71.8333 ### months." } ], "images": [ "DMFS_train_1281/0000262212.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 8.0100 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 137.7000 g/L;\nThe ALB is 39.1000 g/L;\n The CRP is 9.8800 mg/L;\n The LDH is 151.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 72.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 71.8667 ### months." } ], "images": [ "DMFS_train_1281/0000262128.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 152.0000 g/L;\nThe ALB is 43.3000 g/L;\n The CRP is 1.7200 mg/L;\n The LDH is 206.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 71.9000 ### months." } ], "images": [ "DMFS_train_1281/0000261448.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 183.0000 g/L;\nThe ALB is 52.2000 g/L;\n The CRP is 7.4100 mg/L;\n The LDH is 241.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 45.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 71.9000 ### months." } ], "images": [ "DMFS_train_1281/0000261696.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 465.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 100.6000 g/L;\nThe ALB is 40.8000 g/L;\n The CRP is 0.3800 mg/L;\n The LDH is 218.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 72.0000 ### months." } ], "images": [ "DMFS_train_1281/0000240518.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 16.5000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 100.0000 g/L;\nThe ALB is 41.2000 g/L;\n The CRP is 12.0800 mg/L;\n The LDH is 153.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 280 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 133.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 72.1000 ### months." } ], "images": [ "DMFS_train_1281/0000267124.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 63 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 411.0000 copies/mL;\nThe EBV of after treatment is 5.1600 copies/m; \nThe HGB is 134.9000 g/L;\nThe ALB is 43.1000 g/L;\n The CRP is 2.9700 mg/L;\n The LDH is 185.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 75.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 141.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 72.1667 ### months." } ], "images": [ "DMFS_train_1281/0000264601.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 22 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 28.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 133.0000 g/L;\nThe ALB is 40.9000 g/L;\n The CRP is 4.3800 mg/L;\n The LDH is 222.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 147.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 72.3667 ### months." } ], "images": [ "DMFS_train_1281/0000267095.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 117.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 155.0000 g/L;\nThe ALB is 44.3000 g/L;\n The CRP is 11.3600 mg/L;\n The LDH is 247.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 84.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 72.4000 ### months." } ], "images": [ "DMFS_train_1281/0000261536.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 43.2000 g/L;\n The CRP is 0.4700 mg/L;\n The LDH is 209.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 72.4333 ### months." } ], "images": [ "DMFS_train_1281/0000260830.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 49 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 15.7000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 120.0000 g/L;\nThe ALB is 41.3000 g/L;\n The CRP is 2.1300 mg/L;\n The LDH is 211.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 72.5333 ### months." } ], "images": [ "DMFS_train_1281/0000262092.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 31 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 12.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 126.7000 g/L;\nThe ALB is 35.8000 g/L;\n The CRP is 13.9200 mg/L;\n The LDH is 149.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 46.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 63.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 72.5333 ### months." } ], "images": [ "DMFS_train_1281/0000262626.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 57 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 149.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 14.2000 mg/L;\n The LDH is 190.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 72.6333 ### months." } ], "images": [ "DMFS_train_1281/0000260358.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 42.0000 g/L;\n The CRP is 0.4400 mg/L;\n The LDH is 148.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 60.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 72.7667 ### months." } ], "images": [ "DMFS_train_1281/0000260311.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 4.1300 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 164.0000 g/L;\nThe ALB is 48.3000 g/L;\n The CRP is 2.3200 mg/L;\n The LDH is 228.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 61.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 77.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 72.8667 ### months." } ], "images": [ "DMFS_train_1281/0000260400.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 154.9000 g/L;\nThe ALB is 43.5000 g/L;\n The CRP is 0.7300 mg/L;\n The LDH is 133.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 43.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 67.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 72.9667 ### months." } ], "images": [ "DMFS_train_1281/0000260961.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 16.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 133.0000 g/L;\nThe ALB is 47.5000 g/L;\n The CRP is 0.4700 mg/L;\n The LDH is 207.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 60 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Lobaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 53.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 73.0000 ### months." } ], "images": [ "DMFS_train_1281/0000259997.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 17 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 32.7000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 125.0000 g/L;\nThe ALB is 44.3000 g/L;\n The CRP is 0.1600 mg/L;\n The LDH is 155.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 73.0000 ### months." } ], "images": [ "DMFS_train_1281/0000262486.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 3.5000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 131.0000 g/L;\nThe ALB is 41.7000 g/L;\n The CRP is 2.2600 mg/L;\n The LDH is 150.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 71.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 83.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 73.0333 ### months." } ], "images": [ "DMFS_train_1281/0000259762.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 12.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 138.1000 g/L;\nThe ALB is 48.2000 g/L;\n The CRP is 0.6500 mg/L;\n The LDH is 128.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 43.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 73.2667 ### months." } ], "images": [ "DMFS_train_1281/0000259562.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 55 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 59.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.2000 g/L;\nThe ALB is 40.2000 g/L;\n The CRP is 6.2200 mg/L;\n The LDH is 240.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 170 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 42.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 52.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 73.3000 ### months." } ], "images": [ "DMFS_train_1281/0000259092.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 152.0000 g/L;\nThe ALB is 51.0000 g/L;\n The CRP is 1.3100 mg/L;\n The LDH is 184.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 5:More severe complications that require the patient to be hospitalized or undergo more frequent medical interventions.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 58.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 73.4667 ### months." } ], "images": [ "DMFS_train_1281/0000259254.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 50 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 99.1000 copies/mL;\nThe EBV of after treatment is 133.0000 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 38.1000 g/L;\n The CRP is 11.2500 mg/L;\n The LDH is 128.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 4+强直性脊柱炎:Ankylosing spondylitis with moderate complications, affecting daily life, requiring medical intervention, and potentially leading to a decline in some aspects of self-care ability. At the same time, it may indirectly impact the treatment effectiveness and prognosis of nasopharyngeal carcinoma through factors such as immune system effects, drug interactions, comorbidity challenges, pain, and activity limitations.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 90.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 73.7000 ### months." } ], "images": [ "DMFS_train_1281/0000259046.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 28 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 97.4000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 5.1500 mg/L;\n The LDH is 193.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 52.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 73.7000 ### months." } ], "images": [ "DMFS_train_1281/0000261074.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 7.7400 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 140.0000 g/L;\nThe ALB is 40.4000 g/L;\n The CRP is 2.7400 mg/L;\n The LDH is 167.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 60 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Lobaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 33.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 40.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 73.8333 ### months." } ], "images": [ "DMFS_train_1281/0000258560.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 166.0000 g/L;\nThe ALB is 42.4000 g/L;\n The CRP is 3.5900 mg/L;\n The LDH is 195.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 44.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 73.9333 ### months." } ], "images": [ "DMFS_train_1281/0000260042.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 3.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 168.7000 g/L;\nThe ALB is 41.1000 g/L;\n The CRP is 12.5000 mg/L;\n The LDH is 264.4000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 245 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 86.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 104.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 73.9333 ### months." } ], "images": [ "DMFS_train_1281/0000258813.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 787.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.1000 g/L;\nThe ALB is 43.2000 g/L;\n The CRP is 2.3100 mg/L;\n The LDH is 159.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3+巨细胞瘤术后:Post-surgical giant cell tumor with moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment. This may lead to a decline in immune function, treatment delays or interference, limitations in local function, and increased complexity in the treatment process, thus negatively impacting the prognosis of nasopharyngeal carcinoma.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 73.9667 ### months." } ], "images": [ "DMFS_train_1281/0000258314.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 31 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 149.0000 g/L;\nThe ALB is 49.0000 g/L;\n The CRP is 8.1300 mg/L;\n The LDH is 199.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 74.2000 ### months." } ], "images": [ "DMFS_train_1281/0000258324.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 53.7000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 130.2000 g/L;\nThe ALB is 44.1000 g/L;\n The CRP is 1.2700 mg/L;\n The LDH is 162.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 74.3333 ### months." } ], "images": [ "DMFS_train_1281/0000258169.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 29 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 157.6000 g/L;\nThe ALB is 46.8000 g/L;\n The CRP is 0.2000 mg/L;\n The LDH is 208.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 26.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 37.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 74.4333 ### months." } ], "images": [ "DMFS_train_1281/0000259188.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 50 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 40.6000 copies/mL;\nThe EBV of after treatment is 5.0400 copies/m; \nThe HGB is 136.0000 g/L;\nThe ALB is 43.9000 g/L;\n The CRP is 9.2100 mg/L;\n The LDH is 330.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 58.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 74.6667 ### months." } ], "images": [ "DMFS_train_1281/0000257392.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 369.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.0000 g/L;\nThe ALB is 42.5000 g/L;\n The CRP is 1.1800 mg/L;\n The LDH is 171.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 155 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 42.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 58.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 74.7333 ### months." } ], "images": [ "DMFS_train_1281/0000259788.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 164.0000 g/L;\nThe ALB is 46.5000 g/L;\n The CRP is 0.2900 mg/L;\n The LDH is 213.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 74.7667 ### months." } ], "images": [ "DMFS_train_1281/0000257061.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 60 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 314.0000 copies/mL;\nThe EBV of after treatment is 1.9800 copies/m; \nThe HGB is 138.0000 g/L;\nThe ALB is 38.8000 g/L;\n The CRP is 9.7200 mg/L;\n The LDH is 218.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 74.8000 ### months." } ], "images": [ "DMFS_train_1281/0000257340.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 150.0000 g/L;\nThe ALB is 45.8000 g/L;\n The CRP is 0.5200 mg/L;\n The LDH is 167.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 190 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 74.8000 ### months." } ], "images": [ "DMFS_train_1281/0000257744.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 21.5000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.2000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 0.6900 mg/L;\n The LDH is 161.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 40.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 74.8000 ### months." } ], "images": [ "DMFS_train_1281/0000259249.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 149.0000 g/L;\nThe ALB is 47.7000 g/L;\n The CRP is 0.2600 mg/L;\n The LDH is 181.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 63.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 84.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 75.0333 ### months." } ], "images": [ "DMFS_train_1281/0000257440.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.1460 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 5.1500 mg/L;\n The LDH is 193.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 36.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 75.0333 ### months." } ], "images": [ "DMFS_train_1281/0000258701.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 10.2000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 145.1000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 3.6100 mg/L;\n The LDH is 207.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 37.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 72.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 75.1000 ### months." } ], "images": [ "DMFS_train_1281/00C1091740.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 69.5000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 138.0000 g/L;\nThe ALB is 45.1000 g/L;\n The CRP is 0.6600 mg/L;\n The LDH is 154.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 58.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 75.2667 ### months." } ], "images": [ "DMFS_train_1281/0000257119.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 264.0000 copies/mL;\nThe EBV of after treatment is 4.8000 copies/m; \nThe HGB is 147.0000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 2.6700 mg/L;\n The LDH is 300.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 75.3000 ### months." } ], "images": [ "DMFS_train_1281/0000256787.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 43 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 117.0000 g/L;\nThe ALB is 43.4000 g/L;\n The CRP is 0.3600 mg/L;\n The LDH is 132.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 60 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Lobaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 75.3333 ### months." } ], "images": [ "DMFS_train_1281/0000256057.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 26 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 97.4000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.0000 g/L;\nThe ALB is 44.3000 g/L;\n The CRP is 6.6300 mg/L;\n The LDH is 150.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 57.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 75.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 75.4333 ### months." } ], "images": [ "DMFS_train_1281/0000256403.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 30 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 128.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 133.7000 g/L;\nThe ALB is 39.4000 g/L;\n The CRP is 1.6200 mg/L;\n The LDH is 237.9000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is 5-fu;\n The time interval between induction chemotherapy and post-treatment imaging is 41.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 53.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 75.4667 ### months." } ], "images": [ "DMFS_train_1281/0000255794.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 52.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 150.4000 g/L;\nThe ALB is 49.7000 g/L;\n The CRP is 3.2400 mg/L;\n The LDH is 164.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 69.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 75.4667 ### months." } ], "images": [ "DMFS_train_1281/0000256126.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 3.7200 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 131.0000 g/L;\nThe ALB is 42.4000 g/L;\n The CRP is 9.1000 mg/L;\n The LDH is 205.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 36.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 75.5333 ### months." } ], "images": [ "DMFS_train_1281/0000255931.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 50 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 85.4000 copies/mL;\nThe EBV of after treatment is 10.4000 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 49.0000 g/L;\n The CRP is 1.3600 mg/L;\n The LDH is 192.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 47.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 75.5333 ### months." } ], "images": [ "DMFS_train_1281/0000256088.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 28 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 136.0000 g/L;\nThe ALB is 47.4000 g/L;\n The CRP is 0.4400 mg/L;\n The LDH is 159.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 75.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 75.5333 ### months." } ], "images": [ "DMFS_train_1281/0000256547.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 75 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 41.8000 g/L;\n The CRP is 0.3900 mg/L;\n The LDH is 158.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 33.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 75.6000 ### months." } ], "images": [ "DMFS_train_1281/0000255858.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 12 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 13.7000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 116.3000 g/L;\nThe ALB is 35.4000 g/L;\n The CRP is 33.0100 mg/L;\n The LDH is 208.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 75.6000 ### months." } ], "images": [ "DMFS_train_1281/0000255977.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 66.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 137.6000 g/L;\nThe ALB is 40.5000 g/L;\n The CRP is 9.5700 mg/L;\n The LDH is 584.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 100 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 42.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 61.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 75.6000 ### months." } ], "images": [ "DMFS_train_1281/0000256365.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 14.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 127.0000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 2.8000 mg/L;\n The LDH is 170.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 67.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 75.6333 ### months." } ], "images": [ "DMFS_train_1281/0000257142.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.8070 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 45.4000 g/L;\n The CRP is 0.5700 mg/L;\n The LDH is 174.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 51.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 75.7000 ### months." } ], "images": [ "DMFS_train_1281/0000256092.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 117.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.1000 g/L;\nThe ALB is 41.1000 g/L;\n The CRP is 10.3900 mg/L;\n The LDH is 250.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 76.0000 ### months." } ], "images": [ "DMFS_train_1281/0000255206.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 24 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 16.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 2.4200 mg/L;\n The LDH is 183.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 67.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 76.1000 ### months." } ], "images": [ "DMFS_train_1281/0000256951.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 62 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 5.1100 copies/mL;\nThe EBV of after treatment is 0.5800 copies/m; \nThe HGB is 138.6000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 57.5900 mg/L;\n The LDH is 234.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 76.1333 ### months." } ], "images": [ "DMFS_train_1281/0000235208.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 23 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2.5000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.0000 g/L;\nThe ALB is 37.0000 g/L;\n The CRP is 4.2800 mg/L;\n The LDH is 173.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 76.1667 ### months." } ], "images": [ "DMFS_train_1281/0000255603.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 74.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 2.9600 mg/L;\n The LDH is 205.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 71.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 76.1667 ### months." } ], "images": [ "DMFS_train_1281/0000256896.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 1.1200 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.8000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 0.8700 mg/L;\n The LDH is 148.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 190 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 39.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 76.2667 ### months." } ], "images": [ "DMFS_train_1281/0000254937.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 3.2800 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.6000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 5.1500 mg/L;\n The LDH is 193.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 190 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 37.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 45.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 76.4667 ### months." } ], "images": [ "DMFS_train_1281/0000254435.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 26 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2.3200 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 146.0000 g/L;\nThe ALB is 47.0000 g/L;\n The CRP is 3.5800 mg/L;\n The LDH is 180.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 76.4667 ### months." } ], "images": [ "DMFS_train_1281/0000255262.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.9900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 173.0000 g/L;\nThe ALB is 43.1000 g/L;\n The CRP is 8.4400 mg/L;\n The LDH is 146.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 76.5000 ### months." } ], "images": [ "DMFS_train_1281/0000254647.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 29 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 117.0000 g/L;\nThe ALB is 43.6000 g/L;\n The CRP is 0.7700 mg/L;\n The LDH is 141.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 175 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 76.5000 ### months." } ], "images": [ "DMFS_train_1281/0000254728.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 146.0000 g/L;\nThe ALB is 42.4000 g/L;\n The CRP is 30.7300 mg/L;\n The LDH is 200.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 80.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 76.5000 ### months." } ], "images": [ "DMFS_train_1281/0000255180.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 7.8900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 44.3000 g/L;\n The CRP is 1.9600 mg/L;\n The LDH is 163.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 44.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 76.6333 ### months." } ], "images": [ "DMFS_train_1281/0000254371.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 60 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 15.2000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 46.1000 g/L;\n The CRP is 1.7700 mg/L;\n The LDH is 213.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 140 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 42.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 82.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 76.6333 ### months." } ], "images": [ "DMFS_train_1281/0000255821.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 5.8900 copies/m; \nThe HGB is 161.0000 g/L;\nThe ALB is 39.3000 g/L;\n The CRP is 1.0700 mg/L;\n The LDH is 168.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 47.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 62.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 76.6667 ### months." } ], "images": [ "DMFS_train_1281/0000254379.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 14.7000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 125.0000 g/L;\nThe ALB is 41.3000 g/L;\n The CRP is 1.0500 mg/L;\n The LDH is 171.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 68.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 76.7333 ### months." } ], "images": [ "DMFS_train_1281/0000254522.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 957.0000 copies/mL;\nThe EBV of after treatment is 0.2530 copies/m; \nThe HGB is 137.0000 g/L;\nThe ALB is 34.2000 g/L;\n The CRP is 45.9600 mg/L;\n The LDH is 303.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 7:Severe complications, where the health of patient is significantly affected, with a potential life-threatening condition, requiring emergency medical intervention.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 36.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 77.0000 ### months." } ], "images": [ "DMFS_train_1281/0000255165.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 150.0000 g/L;\nThe ALB is 44.4000 g/L;\n The CRP is 1.0400 mg/L;\n The LDH is 190.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 60.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 69.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 77.0667 ### months." } ], "images": [ "DMFS_train_1281/0000253523.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 191.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 2.3600 mg/L;\n The LDH is 233.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 77.0667 ### months." } ], "images": [ "DMFS_train_1281/0000253700.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 97.4000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 140.0000 g/L;\nThe ALB is 47.6000 g/L;\n The CRP is 0.2500 mg/L;\n The LDH is 159.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 42.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 77.2667 ### months." } ], "images": [ "DMFS_train_1281/0000254723.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 73 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 17.3000 copies/mL;\nThe EBV of after treatment is 5.8500 copies/m; \nThe HGB is 132.0000 g/L;\nThe ALB is 43.4000 g/L;\n The CRP is 1.7500 mg/L;\n The LDH is 157.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 77.3667 ### months." } ], "images": [ "DMFS_train_1281/0000253353.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.3300 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 167.0000 g/L;\nThe ALB is 45.8000 g/L;\n The CRP is 1.9300 mg/L;\n The LDH is 176.6000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 75.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 105.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 77.4000 ### months." } ], "images": [ "DMFS_train_1281/0000254076.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 61 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 27.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 136.0000 g/L;\nThe ALB is 43.5000 g/L;\n The CRP is 0.4500 mg/L;\n The LDH is 172.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 41.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 77.8333 ### months." } ], "images": [ "DMFS_train_1281/0000254496.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 50 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 8.3300 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 131.4000 g/L;\nThe ALB is 39.6000 g/L;\n The CRP is 5.9200 mg/L;\n The LDH is 144.7000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 71.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 77.9667 ### months." } ], "images": [ "DMFS_train_1281/0000253649.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 73 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 10.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 137.0000 g/L;\nThe ALB is 39.9000 g/L;\n The CRP is 10.8400 mg/L;\n The LDH is 155.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 75.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 78.1000 ### months." } ], "images": [ "DMFS_train_1281/0000254531.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 53 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 10.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 0.9000 mg/L;\n The LDH is 200.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 78.2333 ### months." } ], "images": [ "DMFS_train_1281/0000251579.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 2.4600 copies/mL;\nThe EBV of after treatment is 0.3930 copies/m; \nThe HGB is 130.0000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 4.3000 mg/L;\n The LDH is 169.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 78.4667 ### months." } ], "images": [ "DMFS_train_1281/0000252298.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 30 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 47.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 152.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 10.9000 mg/L;\n The LDH is 256.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 61.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 78.6667 ### months." } ], "images": [ "DMFS_train_1281/0000251256.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 122.0000 g/L;\nThe ALB is 42.0000 g/L;\n The CRP is 2.1000 mg/L;\n The LDH is 146.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 65.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 78.7333 ### months." } ], "images": [ "DMFS_train_1281/0000252690.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.5960 copies/mL;\nThe EBV of after treatment is 0.4530 copies/m; \nThe HGB is 161.0000 g/L;\nThe ALB is 48.0000 g/L;\n The CRP is 1.0400 mg/L;\n The LDH is 208.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 78.8000 ### months." } ], "images": [ "DMFS_train_1281/0000252252.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 31 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 6.8500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 168.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 1.1000 mg/L;\n The LDH is 179.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 40.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 78.8667 ### months." } ], "images": [ "DMFS_train_1281/00C1083891.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 19 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.1070 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 164.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 1.4000 mg/L;\n The LDH is 285.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 78.9333 ### months." } ], "images": [ "DMFS_train_1281/0000250537.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 4.5400 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 2.1000 mg/L;\n The LDH is 140.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 225 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 79.0333 ### months." } ], "images": [ "DMFS_train_1281/0000250004.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 20 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 119.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 1.4000 mg/L;\n The LDH is 159.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 6; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 79.1333 ### months." } ], "images": [ "DMFS_train_1281/0000250257.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 60 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 140.0000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 1.6000 mg/L;\n The LDH is 258.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 40.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 74.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 79.4000 ### months." } ], "images": [ "DMFS_train_1281/0000251369.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 60 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.3920 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 1.4000 mg/L;\n The LDH is 195.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 6; \nThe Cumulative crisplatin dose is 125 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 52.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 79.4333 ### months." } ], "images": [ "DMFS_train_1281/0000250336.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 126.0000 g/L;\nThe ALB is 39.0000 g/L;\n The CRP is 2.1000 mg/L;\n The LDH is 302.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 100 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 46.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 61.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 79.4667 ### months." } ], "images": [ "DMFS_train_1281/0000250292.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 57 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.6200 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 7.2000 mg/L;\n The LDH is 166.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 30.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 79.5333 ### months." } ], "images": [ "DMFS_train_1281/0000249335.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 3440.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 147.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 7.2000 mg/L;\n The LDH is 362.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Carboplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 61.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 91.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 79.5333 ### months." } ], "images": [ "DMFS_train_1281/0000250327.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.0000 g/L;\nThe ALB is 42.0000 g/L;\n The CRP is 0.3000 mg/L;\n The LDH is 180.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 79.5667 ### months." } ], "images": [ "DMFS_train_1281/0000249348.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 22 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 145.0000 copies/mL;\nThe EBV of after treatment is 34.3000 copies/m; \nThe HGB is 158.0000 g/L;\nThe ALB is 51.0000 g/L;\n The CRP is 0.5000 mg/L;\n The LDH is 201.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 33.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 44.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 79.6000 ### months." } ], "images": [ "DMFS_train_1281/0000249746.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 302.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 136.0000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 23.2000 mg/L;\n The LDH is 188.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 79.6333 ### months." } ], "images": [ "DMFS_train_1281/0000249768.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 13.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 1.8000 mg/L;\n The LDH is 180.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 45.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 79.6333 ### months." } ], "images": [ "DMFS_train_1281/0000249913.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 39 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 144.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 0.9000 mg/L;\n The LDH is 159.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 40.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 80.1333 ### months." } ], "images": [ "DMFS_train_1281/0000249009.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 55 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 22.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.0000 g/L;\nThe ALB is 40.0000 g/L;\n The CRP is 2.6000 mg/L;\n The LDH is 290.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 145 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 39.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 80.4333 ### months." } ], "images": [ "DMFS_train_1281/0000248696.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 5.7700 copies/mL;\nThe EBV of after treatment is 22.0000 copies/m; \nThe HGB is 163.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 5.8000 mg/L;\n The LDH is 132.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Docetaxel;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 69.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 80.6000 ### months." } ], "images": [ "DMFS_train_1281/0000248143.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 184.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 159.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 0.9000 mg/L;\n The LDH is 128.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 39.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 80.6667 ### months." } ], "images": [ "DMFS_train_1281/0000247914.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 5.3500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 129.0000 g/L;\nThe ALB is 47.0000 g/L;\n The CRP is 12.0400 mg/L;\n The LDH is 190.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 8:Extremely severe complications that may be life-threatening, with impaired function of multiple organ systems, requiring intensive care and emergency treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 38.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 80.8000 ### months." } ], "images": [ "DMFS_train_1281/0000248264.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 323.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 49.0000 g/L;\n The CRP is 0.7000 mg/L;\n The LDH is 207.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 51.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 63.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 80.8000 ### months." } ], "images": [ "DMFS_train_1281/0000248372.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 53 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.2790 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 4.7000 mg/L;\n The LDH is 142.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 51.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 63.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 80.8667 ### months." } ], "images": [ "DMFS_train_1281/0000248317.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 39 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 1.8600 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 127.0000 g/L;\nThe ALB is 40.0000 g/L;\n The CRP is 0.7000 mg/L;\n The LDH is 164.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 6; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 38.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 81.2000 ### months." } ], "images": [ "DMFS_train_1281/0000247244.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 28 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 0.5000 mg/L;\n The LDH is 254.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 38.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 81.2000 ### months." } ], "images": [ "DMFS_train_1281/0000247641.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 7 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.3620 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 126.0000 g/L;\nThe ALB is 38.0000 g/L;\n The CRP is 6.5000 mg/L;\n The LDH is 277.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 71.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 83.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 81.2000 ### months." } ], "images": [ "DMFS_train_1281/0000247697.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.9210 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 3.8000 mg/L;\n The LDH is 201.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 46.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 63.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 81.3000 ### months." } ], "images": [ "DMFS_train_1281/0000247283.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 28 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.1890 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 47.0000 g/L;\n The CRP is 1.1000 mg/L;\n The LDH is 199.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 94.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 119.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 81.3667 ### months." } ], "images": [ "DMFS_train_1281/0000248167.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 280.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 1.1000 mg/L;\n The LDH is 143.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 81.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 81.8000 ### months." } ], "images": [ "DMFS_train_1281/0000248028.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 49.5000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 147.0000 g/L;\nThe ALB is 48.0000 g/L;\n The CRP is 0.6000 mg/L;\n The LDH is 152.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 51.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 62.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 81.9333 ### months." } ], "images": [ "DMFS_train_1281/0000246182.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 1380.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 47.0000 g/L;\n The CRP is 0.4000 mg/L;\n The LDH is 202.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 61.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 81.9667 ### months." } ], "images": [ "DMFS_train_1281/0000246374.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 66 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 39.0000 g/L;\n The CRP is 6.4000 mg/L;\n The LDH is 191.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 62.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 81.9667 ### months." } ], "images": [ "DMFS_train_1281/0000246685.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 3.9300 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 0.3600 mg/L;\n The LDH is 191.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 59.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 77.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 82.0333 ### months." } ], "images": [ "DMFS_train_1281/0000246912.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 4.2000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 158.0000 g/L;\nThe ALB is 49.0000 g/L;\n The CRP is 1.5000 mg/L;\n The LDH is 148.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 97.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 82.0333 ### months." } ], "images": [ "DMFS_train_1281/0000248056.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 57 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 181.0000 copies/m; \nThe HGB is 136.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 0.8000 mg/L;\n The LDH is 168.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 82.1667 ### months." } ], "images": [ "DMFS_train_1281/0000246392.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 120.0000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 0.6000 mg/L;\n The LDH is 152.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 102.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 122.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 82.2000 ### months." } ], "images": [ "DMFS_train_1281/0000245744.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 34 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 146.0000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 1.9000 mg/L;\n The LDH is 162.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 120 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 37.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 82.4000 ### months." } ], "images": [ "DMFS_train_1281/0000245462.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 63 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 144.0000 g/L;\nThe ALB is 48.0000 g/L;\n The CRP is 0.9000 mg/L;\n The LDH is 236.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 60.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 71.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 82.5333 ### months." } ], "images": [ "DMFS_train_1281/0000245767.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 60 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 80.7000 copies/mL;\nThe EBV of after treatment is 19.2000 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 1.0300 mg/L;\n The LDH is 203.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 104.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 114.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 82.5333 ### months." } ], "images": [ "DMFS_train_1281/0000245792.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 29 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 158.0000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 1.4000 mg/L;\n The LDH is 191.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 63.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 82.7333 ### months." } ], "images": [ "DMFS_train_1281/0000245710.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.3400 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 160.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 0.7300 mg/L;\n The LDH is 161.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 275 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 82.9000 ### months." } ], "images": [ "DMFS_train_1281/0000245738.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 22 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 120.0000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 9.0000 mg/L;\n The LDH is 156.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 77.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 82.9333 ### months." } ], "images": [ "DMFS_train_1281/0000245917.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 54.4000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 146.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 1.1300 mg/L;\n The LDH is 169.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 91.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 96.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 83.1667 ### months." } ], "images": [ "DMFS_train_1281/0000244342.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 34 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 157.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 171.0000 g/L;\nThe ALB is 54.0000 g/L;\n The CRP is 0.5000 mg/L;\n The LDH is 168.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 86.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 92.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 83.3667 ### months." } ], "images": [ "DMFS_train_1281/0000243961.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.5000 copies/mL;\nThe EBV of after treatment is 4.8800 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 3.0300 mg/L;\n The LDH is 138.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 176.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 191.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 83.4000 ### months." } ], "images": [ "DMFS_train_1281/0000244658.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 34 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 310.0000 copies/mL;\nThe EBV of after treatment is 52.5000 copies/m; \nThe HGB is 159.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 6.6400 mg/L;\n The LDH is 239.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 260 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 83.6333 ### months." } ], "images": [ "DMFS_train_1281/0000243904.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 1980.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 128.0000 g/L;\nThe ALB is 49.0000 g/L;\n The CRP is 1.5500 mg/L;\n The LDH is 192.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 95.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 111.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 83.7333 ### months." } ], "images": [ "DMFS_train_1281/0000243334.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 38.0000 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 1.4000 mg/L;\n The LDH is 140.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 69.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 83.8333 ### months." } ], "images": [ "DMFS_train_1281/0000243333.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 159.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 3.2000 mg/L;\n The LDH is 194.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 65.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 77.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 83.8333 ### months." } ], "images": [ "DMFS_train_1281/0000243739.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 47.0000 g/L;\n The CRP is 2.3000 mg/L;\n The LDH is 178.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 220 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 52.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 83.8333 ### months." } ], "images": [ "DMFS_train_1281/0000244093.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.1130 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 1.0200 mg/L;\n The LDH is 222.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 51.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 74.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 84.1667 ### months." } ], "images": [ "DMFS_train_1281/0000242977.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 262.0000 copies/mL;\nThe EBV of after treatment is 322.0000 copies/m; \nThe HGB is 133.0000 g/L;\nThe ALB is 40.0000 g/L;\n The CRP is 4.3000 mg/L;\n The LDH is 150.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 120 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 33.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 84.2333 ### months." } ], "images": [ "DMFS_train_1281/0000245339.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 550.0000 copies/mL;\nThe EBV of after treatment is 26.8000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 5.9000 mg/L;\n The LDH is 180.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 185 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 60.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 84.4333 ### months." } ], "images": [ "DMFS_train_1281/0000245454.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 769.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 15.3000 mg/L;\n The LDH is 289.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 6; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 44.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 84.5000 ### months." } ], "images": [ "DMFS_train_1281/0000242866.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 34 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 530.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 154.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 7.6000 mg/L;\n The LDH is 178.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 72.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 84.5000 ### months." } ], "images": [ "DMFS_train_1281/0000244868.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 13 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 130.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 11.3400 mg/L;\n The LDH is 194.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 37.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 84.8000 ### months." } ], "images": [ "DMFS_train_1281/0000242297.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 107.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 1.5600 mg/L;\n The LDH is 223.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 120 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 56.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 84.9000 ### months." } ], "images": [ "DMFS_train_1281/0000242880.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 11 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 5.9100 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 124.0000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 1.5700 mg/L;\n The LDH is 149.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 6; \nThe Cumulative crisplatin dose is 120 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 38.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 85.0333 ### months." } ], "images": [ "DMFS_train_1281/0000242034.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 124.0000 g/L;\nThe ALB is 52.1000 g/L;\n The CRP is 0.5300 mg/L;\n The LDH is 188.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 32.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 85.3667 ### months." } ], "images": [ "DMFS_train_1281/0000241199.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 191.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 123.0000 g/L;\nThe ALB is 47.0000 g/L;\n The CRP is 1.6000 mg/L;\n The LDH is 200.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 42.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 52.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 85.4667 ### months." } ], "images": [ "DMFS_train_1281/0000241524.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 93.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 101.0000 g/L;\nThe ALB is 39.0000 g/L;\n The CRP is 7.7000 mg/L;\n The LDH is 145.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 77.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 85.4667 ### months." } ], "images": [ "DMFS_train_1281/0000241781.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 62 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 289.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 146.0000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 1.5300 mg/L;\n The LDH is 236.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 94.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 111.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 85.8000 ### months." } ], "images": [ "DMFS_train_1281/0000241335.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 2740.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 135.9000 g/L;\nThe ALB is 42.9000 g/L;\n The CRP is 3.6600 mg/L;\n The LDH is 313.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 6; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 38.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 52.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 85.9333 ### months." } ], "images": [ "DMFS_train_1281/0000240338.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 50 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.6570 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 146.0000 g/L;\nThe ALB is 45.2000 g/L;\n The CRP is 0.4300 mg/L;\n The LDH is 153.4000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 89.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 103.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 86.1333 ### months." } ], "images": [ "DMFS_train_1281/0000240179.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 25 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 169.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 128.0000 g/L;\nThe ALB is 36.1000 g/L;\n The CRP is 13.0400 mg/L;\n The LDH is 632.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 185 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 86.4667 ### months." } ], "images": [ "DMFS_train_1281/0000239997.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.3030 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 129.6000 g/L;\nThe ALB is 42.8000 g/L;\n The CRP is 0.7500 mg/L;\n The LDH is 132.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 86.5667 ### months." } ], "images": [ "DMFS_train_1281/0000239994.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 6.1900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 119.2000 g/L;\nThe ALB is 42.0000 g/L;\n The CRP is 5.7500 mg/L;\n The LDH is 147.9000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 96.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 108.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 86.6000 ### months." } ], "images": [ "DMFS_train_1281/0000239657.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 60 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 7.2200 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 146.0000 g/L;\nThe ALB is 41.7000 g/L;\n The CRP is 3.6200 mg/L;\n The LDH is 218.9000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 120.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 129.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 86.6333 ### months." } ], "images": [ "DMFS_train_1281/0000239794.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 27 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0905 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.9000 g/L;\nThe ALB is 45.7000 g/L;\n The CRP is 6.9400 mg/L;\n The LDH is 139.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 300 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 26.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 40.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 86.7667 ### months." } ], "images": [ "DMFS_train_1281/0000239187.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 57 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 66.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 138.0000 g/L;\nThe ALB is 40.9000 g/L;\n The CRP is 2.8900 mg/L;\n The LDH is 196.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 73.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 86.8000 ### months." } ], "images": [ "DMFS_train_1281/0000240215.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.1840 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 144.5000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 2.6100 mg/L;\n The LDH is 194.8000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 2:Mild complications that require some medication or treatment to control, and may have a slight impact on daily activities.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 111.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 121.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 86.8333 ### months." } ], "images": [ "DMFS_train_1281/0000239470.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 56.9000 copies/mL;\nThe EBV of after treatment is 11.3000 copies/m; \nThe HGB is 147.0000 g/L;\nThe ALB is 44.1000 g/L;\n The CRP is 2.3700 mg/L;\n The LDH is 204.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 33.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 87.0667 ### months." } ], "images": [ "DMFS_train_1281/0000239475.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 1.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 38.4000 g/L;\n The CRP is 0.4900 mg/L;\n The LDH is 161.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 33.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 87.6667 ### months." } ], "images": [ "DMFS_train_1281/0000238666.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 1.2600 mg/L;\n The LDH is 147.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 29.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 87.7667 ### months." } ], "images": [ "DMFS_train_1281/0000237337.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 46.3000 g/L;\n The CRP is 0.5600 mg/L;\n The LDH is 214.3000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 95.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 105.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 87.7667 ### months." } ], "images": [ "DMFS_train_1281/0000237648.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 39 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.0000 g/L;\nThe ALB is 45.6000 g/L;\n The CRP is 2.8200 mg/L;\n The LDH is 146.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 87.9000 ### months." } ], "images": [ "DMFS_train_1281/0000237328.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 31.4000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 146.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 0.6300 mg/L;\n The LDH is 217.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 56.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 88.0000 ### months." } ], "images": [ "DMFS_train_1281/00C1068568.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 7.8500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 169.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 9.0000 mg/L;\n The LDH is 175.8000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 99.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 94.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 88.4333 ### months." } ], "images": [ "DMFS_train_1281/0000236160.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 1.1400 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 161.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 3.8400 mg/L;\n The LDH is 164.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 36 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 42.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 88.5333 ### months." } ], "images": [ "DMFS_train_1281/0000235830.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 39 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 36.2000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 149.4000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 1.8500 mg/L;\n The LDH is 213.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 6; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 32.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 88.7667 ### months." } ], "images": [ "DMFS_train_1281/0000235474.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.4200 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 3.0100 mg/L;\n The LDH is 191.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 155 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 88.8333 ### months." } ], "images": [ "DMFS_train_1281/0000235317.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 4.3500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 150.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 114.1400 mg/L;\n The LDH is 286.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Lobaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 89.0333 ### months." } ], "images": [ "DMFS_train_1281/0000234987.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 19 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 120.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 137.8000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 127.2100 mg/L;\n The LDH is 153.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Lobaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 89.0333 ### months." } ], "images": [ "DMFS_train_1281/0000235364.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 62 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 11.4000 copies/mL;\nThe EBV of after treatment is 1.6100 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 2.7000 mg/L;\n The LDH is 170.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 27.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 89.3000 ### months." } ], "images": [ "DMFS_train_1281/0000237082.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 31 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 140.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 1.6100 mg/L;\n The LDH is 140.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 36.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 89.3000 ### months." } ], "images": [ "DMFS_train_1281/0000234790.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 27 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 154.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 2.4900 mg/L;\n The LDH is 254.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 89.3000 ### months." } ], "images": [ "DMFS_train_1281/0000235035.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.3800 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 146.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 1.1900 mg/L;\n The LDH is 123.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 6; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is None; \nThe Chemotherapeutics is Sunitinib/ Nivolumab;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 32.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 89.9000 ### months." } ], "images": [ "DMFS_train_1281/0000233995.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 28 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.7100 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 111.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 0.1900 mg/L;\n The LDH is 145.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 31.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 89.9667 ### months." } ], "images": [ "DMFS_train_1281/0000236079.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 41 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 7.9900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 2.2800 mg/L;\n The LDH is 193.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 45.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 45.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 90.2667 ### months." } ], "images": [ "DMFS_train_1281/0000232677.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 2.1900 copies/mL;\nThe EBV of after treatment is 0.0570 copies/m; \nThe HGB is 146.5000 g/L;\nThe ALB is 47.3000 g/L;\n The CRP is 2.5400 mg/L;\n The LDH is 144.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 24.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 24.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 92.4667 ### months." } ], "images": [ "DMFS_train_1281/0000230566.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 29 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 17.2000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 173.0000 g/L;\nThe ALB is 46.5000 g/L;\n The CRP is 3.8200 mg/L;\n The LDH is 207.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 41.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 41.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 93.2000 ### months." } ], "images": [ "DMFS_train_1281/0000229732.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.4940 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 152.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 1.8100 mg/L;\n The LDH is 223.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 68.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 77.0667 ### months." } ], "images": [ "DMFS_train_1281/0000255304.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 35.2000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 126.0000 g/L;\nThe ALB is 41.4000 g/L;\n The CRP is 0.6500 mg/L;\n The LDH is 203.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 73.2667 ### months." } ], "images": [ "DMFS_train_1281/0000261612.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.6000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 5.1500 mg/L;\n The LDH is 193.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 46.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 72.2333 ### months." } ], "images": [ "DMFS_train_1281/0000263086.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 88.5000 copies/mL;\nThe EBV of after treatment is 3.1400 copies/m; \nThe HGB is 160.0000 g/L;\nThe ALB is 46.8000 g/L;\n The CRP is 1.2900 mg/L;\n The LDH is 176.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 44.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 68.0333 ### months." } ], "images": [ "DMFS_train_1281/0000270571.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 61 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 54.9000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 42.9000 g/L;\n The CRP is 1.3900 mg/L;\n The LDH is 346.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 75.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 88.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event does not occur ### and Distant Metastasis-Free Survival time is ### 54.4667 ### months." } ], "images": [ "DMFS_train_1281/00C1135566.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2290.0000 copies/mL;\nThe EBV of after treatment is 3.0800 copies/m; \nThe HGB is 129.0000 g/L;\nThe ALB is 35.5000 g/L;\n The CRP is 6.0900 mg/L;\n The LDH is 189.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 76.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 26.9000 ### months." } ], "images": [ "DMFS_train_1281/0000277655_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2290.0000 copies/mL;\nThe EBV of after treatment is 3.0800 copies/m; \nThe HGB is 129.0000 g/L;\nThe ALB is 35.5000 g/L;\n The CRP is 6.0900 mg/L;\n The LDH is 189.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 76.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 26.9000 ### months." } ], "images": [ "DMFS_train_1281/0000277655_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2290.0000 copies/mL;\nThe EBV of after treatment is 3.0800 copies/m; \nThe HGB is 129.0000 g/L;\nThe ALB is 35.5000 g/L;\n The CRP is 6.0900 mg/L;\n The LDH is 189.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 76.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 26.9000 ### months." } ], "images": [ "DMFS_train_1281/0000277655_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2290.0000 copies/mL;\nThe EBV of after treatment is 3.0800 copies/m; \nThe HGB is 129.0000 g/L;\nThe ALB is 35.5000 g/L;\n The CRP is 6.0900 mg/L;\n The LDH is 189.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 76.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 26.9000 ### months." } ], "images": [ "DMFS_train_1281/0000277655_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2290.0000 copies/mL;\nThe EBV of after treatment is 3.0800 copies/m; \nThe HGB is 129.0000 g/L;\nThe ALB is 35.5000 g/L;\n The CRP is 6.0900 mg/L;\n The LDH is 189.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 76.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 26.9000 ### months." } ], "images": [ "DMFS_train_1281/0000277655_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2290.0000 copies/mL;\nThe EBV of after treatment is 3.0800 copies/m; \nThe HGB is 129.0000 g/L;\nThe ALB is 35.5000 g/L;\n The CRP is 6.0900 mg/L;\n The LDH is 189.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 76.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 26.9000 ### months." } ], "images": [ "DMFS_train_1281/0000277655_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2290.0000 copies/mL;\nThe EBV of after treatment is 3.0800 copies/m; \nThe HGB is 129.0000 g/L;\nThe ALB is 35.5000 g/L;\n The CRP is 6.0900 mg/L;\n The LDH is 189.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 76.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 26.9000 ### months." } ], "images": [ "DMFS_train_1281/0000277655_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 12.5000 copies/mL;\nThe EBV of after treatment is 0.2240 copies/m; \nThe HGB is 128.0000 g/L;\nThe ALB is 42.2000 g/L;\n The CRP is 23.7200 mg/L;\n The LDH is 197.2100 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 93.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.9667 ### months." } ], "images": [ "DMFS_train_1281/0000288070_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 12.5000 copies/mL;\nThe EBV of after treatment is 0.2240 copies/m; \nThe HGB is 128.0000 g/L;\nThe ALB is 42.2000 g/L;\n The CRP is 23.7200 mg/L;\n The LDH is 197.2100 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 93.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.9667 ### months." } ], "images": [ "DMFS_train_1281/0000288070_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 12.5000 copies/mL;\nThe EBV of after treatment is 0.2240 copies/m; \nThe HGB is 128.0000 g/L;\nThe ALB is 42.2000 g/L;\n The CRP is 23.7200 mg/L;\n The LDH is 197.2100 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 93.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.9667 ### months." } ], "images": [ "DMFS_train_1281/0000288070_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 12.5000 copies/mL;\nThe EBV of after treatment is 0.2240 copies/m; \nThe HGB is 128.0000 g/L;\nThe ALB is 42.2000 g/L;\n The CRP is 23.7200 mg/L;\n The LDH is 197.2100 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 93.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.9667 ### months." } ], "images": [ "DMFS_train_1281/0000288070_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 12.5000 copies/mL;\nThe EBV of after treatment is 0.2240 copies/m; \nThe HGB is 128.0000 g/L;\nThe ALB is 42.2000 g/L;\n The CRP is 23.7200 mg/L;\n The LDH is 197.2100 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 93.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.9667 ### months." } ], "images": [ "DMFS_train_1281/0000288070_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 12.5000 copies/mL;\nThe EBV of after treatment is 0.2240 copies/m; \nThe HGB is 128.0000 g/L;\nThe ALB is 42.2000 g/L;\n The CRP is 23.7200 mg/L;\n The LDH is 197.2100 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 93.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.9667 ### months." } ], "images": [ "DMFS_train_1281/0000288070_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 12.5000 copies/mL;\nThe EBV of after treatment is 0.2240 copies/m; \nThe HGB is 128.0000 g/L;\nThe ALB is 42.2000 g/L;\n The CRP is 23.7200 mg/L;\n The LDH is 197.2100 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 93.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.9667 ### months." } ], "images": [ "DMFS_train_1281/0000288070_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 22.3000 copies/mL;\nThe EBV of after treatment is 1.9600 copies/m; \nThe HGB is 141.3000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 0.2700 mg/L;\n The LDH is 193.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 4.5000 ### months." } ], "images": [ "DMFS_train_1281/0000234079_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 22.3000 copies/mL;\nThe EBV of after treatment is 1.9600 copies/m; \nThe HGB is 141.3000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 0.2700 mg/L;\n The LDH is 193.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 4.5000 ### months." } ], "images": [ "DMFS_train_1281/0000234079_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 22.3000 copies/mL;\nThe EBV of after treatment is 1.9600 copies/m; \nThe HGB is 141.3000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 0.2700 mg/L;\n The LDH is 193.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 4.5000 ### months." } ], "images": [ "DMFS_train_1281/0000234079_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 22.3000 copies/mL;\nThe EBV of after treatment is 1.9600 copies/m; \nThe HGB is 141.3000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 0.2700 mg/L;\n The LDH is 193.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 4.5000 ### months." } ], "images": [ "DMFS_train_1281/0000234079_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 22.3000 copies/mL;\nThe EBV of after treatment is 1.9600 copies/m; \nThe HGB is 141.3000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 0.2700 mg/L;\n The LDH is 193.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 4.5000 ### months." } ], "images": [ "DMFS_train_1281/0000234079_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 22.3000 copies/mL;\nThe EBV of after treatment is 1.9600 copies/m; \nThe HGB is 141.3000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 0.2700 mg/L;\n The LDH is 193.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 4.5000 ### months." } ], "images": [ "DMFS_train_1281/0000234079_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 22.3000 copies/mL;\nThe EBV of after treatment is 1.9600 copies/m; \nThe HGB is 141.3000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 0.2700 mg/L;\n The LDH is 193.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 55.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 4.5000 ### months." } ], "images": [ "DMFS_train_1281/0000234079_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 54.7000 copies/mL;\nThe EBV of after treatment is 0.4380 copies/m; \nThe HGB is 161.0000 g/L;\nThe ALB is 45.9000 g/L;\n The CRP is 1.8500 mg/L;\n The LDH is 166.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 245 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.8000 ### months." } ], "images": [ "DMFS_train_1281/0000307229_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 54.7000 copies/mL;\nThe EBV of after treatment is 0.4380 copies/m; \nThe HGB is 161.0000 g/L;\nThe ALB is 45.9000 g/L;\n The CRP is 1.8500 mg/L;\n The LDH is 166.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 245 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.8000 ### months." } ], "images": [ "DMFS_train_1281/0000307229_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 54.7000 copies/mL;\nThe EBV of after treatment is 0.4380 copies/m; \nThe HGB is 161.0000 g/L;\nThe ALB is 45.9000 g/L;\n The CRP is 1.8500 mg/L;\n The LDH is 166.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 245 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.8000 ### months." } ], "images": [ "DMFS_train_1281/0000307229_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 54.7000 copies/mL;\nThe EBV of after treatment is 0.4380 copies/m; \nThe HGB is 161.0000 g/L;\nThe ALB is 45.9000 g/L;\n The CRP is 1.8500 mg/L;\n The LDH is 166.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 245 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.8000 ### months." } ], "images": [ "DMFS_train_1281/0000307229_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 54.7000 copies/mL;\nThe EBV of after treatment is 0.4380 copies/m; \nThe HGB is 161.0000 g/L;\nThe ALB is 45.9000 g/L;\n The CRP is 1.8500 mg/L;\n The LDH is 166.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 245 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.8000 ### months." } ], "images": [ "DMFS_train_1281/0000307229_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 54.7000 copies/mL;\nThe EBV of after treatment is 0.4380 copies/m; \nThe HGB is 161.0000 g/L;\nThe ALB is 45.9000 g/L;\n The CRP is 1.8500 mg/L;\n The LDH is 166.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 245 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.8000 ### months." } ], "images": [ "DMFS_train_1281/0000307229_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 54.7000 copies/mL;\nThe EBV of after treatment is 0.4380 copies/m; \nThe HGB is 161.0000 g/L;\nThe ALB is 45.9000 g/L;\n The CRP is 1.8500 mg/L;\n The LDH is 166.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 245 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.8000 ### months." } ], "images": [ "DMFS_train_1281/0000307229_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 53.2000 copies/mL;\nThe EBV of after treatment is 1.1100 copies/m; \nThe HGB is 93.0000 g/L;\nThe ALB is 35.8000 g/L;\n The CRP is 12.0400 mg/L;\n The LDH is 223.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 61.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.5000 ### months." } ], "images": [ "DMFS_train_1281/0000287271_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 53.2000 copies/mL;\nThe EBV of after treatment is 1.1100 copies/m; \nThe HGB is 93.0000 g/L;\nThe ALB is 35.8000 g/L;\n The CRP is 12.0400 mg/L;\n The LDH is 223.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 61.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.5000 ### months." } ], "images": [ "DMFS_train_1281/0000287271_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 53.2000 copies/mL;\nThe EBV of after treatment is 1.1100 copies/m; \nThe HGB is 93.0000 g/L;\nThe ALB is 35.8000 g/L;\n The CRP is 12.0400 mg/L;\n The LDH is 223.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 61.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.5000 ### months." } ], "images": [ "DMFS_train_1281/0000287271_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 53.2000 copies/mL;\nThe EBV of after treatment is 1.1100 copies/m; \nThe HGB is 93.0000 g/L;\nThe ALB is 35.8000 g/L;\n The CRP is 12.0400 mg/L;\n The LDH is 223.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 61.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.5000 ### months." } ], "images": [ "DMFS_train_1281/0000287271_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 53.2000 copies/mL;\nThe EBV of after treatment is 1.1100 copies/m; \nThe HGB is 93.0000 g/L;\nThe ALB is 35.8000 g/L;\n The CRP is 12.0400 mg/L;\n The LDH is 223.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 61.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.5000 ### months." } ], "images": [ "DMFS_train_1281/0000287271_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 53.2000 copies/mL;\nThe EBV of after treatment is 1.1100 copies/m; \nThe HGB is 93.0000 g/L;\nThe ALB is 35.8000 g/L;\n The CRP is 12.0400 mg/L;\n The LDH is 223.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 61.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.5000 ### months." } ], "images": [ "DMFS_train_1281/0000287271_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 53.2000 copies/mL;\nThe EBV of after treatment is 1.1100 copies/m; \nThe HGB is 93.0000 g/L;\nThe ALB is 35.8000 g/L;\n The CRP is 12.0400 mg/L;\n The LDH is 223.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 61.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.5000 ### months." } ], "images": [ "DMFS_train_1281/0000287271_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 3.3900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 41.9000 g/L;\n The CRP is 11.6100 mg/L;\n The LDH is 148.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 33.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 22.3333 ### months." } ], "images": [ "DMFS_train_1281/0000291959_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 3.3900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 41.9000 g/L;\n The CRP is 11.6100 mg/L;\n The LDH is 148.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 33.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 22.3333 ### months." } ], "images": [ "DMFS_train_1281/0000291959_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 3.3900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 41.9000 g/L;\n The CRP is 11.6100 mg/L;\n The LDH is 148.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 33.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 22.3333 ### months." } ], "images": [ "DMFS_train_1281/0000291959_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 3.3900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 41.9000 g/L;\n The CRP is 11.6100 mg/L;\n The LDH is 148.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 33.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 22.3333 ### months." } ], "images": [ "DMFS_train_1281/0000291959_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 3.3900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 41.9000 g/L;\n The CRP is 11.6100 mg/L;\n The LDH is 148.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 33.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 22.3333 ### months." } ], "images": [ "DMFS_train_1281/0000291959_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 3.3900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 41.9000 g/L;\n The CRP is 11.6100 mg/L;\n The LDH is 148.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 33.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 22.3333 ### months." } ], "images": [ "DMFS_train_1281/0000291959_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 3.3900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 41.9000 g/L;\n The CRP is 11.6100 mg/L;\n The LDH is 148.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 33.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 22.3333 ### months." } ], "images": [ "DMFS_train_1281/0000291959_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 193.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.5000 g/L;\nThe ALB is 47.5000 g/L;\n The CRP is 2.4100 mg/L;\n The LDH is 188.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 260 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 22.2333 ### months." } ], "images": [ "DMFS_train_1281/0000284687_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 193.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.5000 g/L;\nThe ALB is 47.5000 g/L;\n The CRP is 2.4100 mg/L;\n The LDH is 188.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 260 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 22.2333 ### months." } ], "images": [ "DMFS_train_1281/0000284687_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 193.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.5000 g/L;\nThe ALB is 47.5000 g/L;\n The CRP is 2.4100 mg/L;\n The LDH is 188.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 260 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 22.2333 ### months." } ], "images": [ "DMFS_train_1281/0000284687_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 193.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.5000 g/L;\nThe ALB is 47.5000 g/L;\n The CRP is 2.4100 mg/L;\n The LDH is 188.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 260 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 22.2333 ### months." } ], "images": [ "DMFS_train_1281/0000284687_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 193.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.5000 g/L;\nThe ALB is 47.5000 g/L;\n The CRP is 2.4100 mg/L;\n The LDH is 188.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 260 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 22.2333 ### months." } ], "images": [ "DMFS_train_1281/0000284687_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 193.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.5000 g/L;\nThe ALB is 47.5000 g/L;\n The CRP is 2.4100 mg/L;\n The LDH is 188.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 260 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 22.2333 ### months." } ], "images": [ "DMFS_train_1281/0000284687_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 193.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.5000 g/L;\nThe ALB is 47.5000 g/L;\n The CRP is 2.4100 mg/L;\n The LDH is 188.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 260 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 22.2333 ### months." } ], "images": [ "DMFS_train_1281/0000284687_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 28 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 105.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 46.3000 g/L;\n The CRP is 0.2500 mg/L;\n The LDH is 145.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.1000 ### months." } ], "images": [ "DMFS_train_1281/0000278818_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 28 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 105.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 46.3000 g/L;\n The CRP is 0.2500 mg/L;\n The LDH is 145.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.1000 ### months." } ], "images": [ "DMFS_train_1281/0000278818_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 28 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 105.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 46.3000 g/L;\n The CRP is 0.2500 mg/L;\n The LDH is 145.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.1000 ### months." } ], "images": [ "DMFS_train_1281/0000278818_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 28 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 105.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 46.3000 g/L;\n The CRP is 0.2500 mg/L;\n The LDH is 145.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.1000 ### months." } ], "images": [ "DMFS_train_1281/0000278818_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 28 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 105.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 46.3000 g/L;\n The CRP is 0.2500 mg/L;\n The LDH is 145.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.1000 ### months." } ], "images": [ "DMFS_train_1281/0000278818_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 28 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 105.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 46.3000 g/L;\n The CRP is 0.2500 mg/L;\n The LDH is 145.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.1000 ### months." } ], "images": [ "DMFS_train_1281/0000278818_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 28 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 105.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 46.3000 g/L;\n The CRP is 0.2500 mg/L;\n The LDH is 145.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.1000 ### months." } ], "images": [ "DMFS_train_1281/0000278818_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 8.3600 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.6000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 2.8500 mg/L;\n The LDH is 181.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 52.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 46.3667 ### months." } ], "images": [ "DMFS_train_1281/0000283326_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 8.3600 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.6000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 2.8500 mg/L;\n The LDH is 181.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 52.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 46.3667 ### months." } ], "images": [ "DMFS_train_1281/0000283326_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 8.3600 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.6000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 2.8500 mg/L;\n The LDH is 181.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 52.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 46.3667 ### months." } ], "images": [ "DMFS_train_1281/0000283326_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 8.3600 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.6000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 2.8500 mg/L;\n The LDH is 181.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 52.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 46.3667 ### months." } ], "images": [ "DMFS_train_1281/0000283326_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 8.3600 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.6000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 2.8500 mg/L;\n The LDH is 181.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 52.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 46.3667 ### months." } ], "images": [ "DMFS_train_1281/0000283326_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 8.3600 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.6000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 2.8500 mg/L;\n The LDH is 181.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 52.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 46.3667 ### months." } ], "images": [ "DMFS_train_1281/0000283326_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 8.3600 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.6000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 2.8500 mg/L;\n The LDH is 181.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 52.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 46.3667 ### months." } ], "images": [ "DMFS_train_1281/0000283326_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.9370 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 45.4000 g/L;\n The CRP is 0.6100 mg/L;\n The LDH is 159.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 170 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 37.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 32.4000 ### months." } ], "images": [ "DMFS_train_1281/0000295397_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.9370 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 45.4000 g/L;\n The CRP is 0.6100 mg/L;\n The LDH is 159.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 170 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 37.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 32.4000 ### months." } ], "images": [ "DMFS_train_1281/0000295397_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.9370 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 45.4000 g/L;\n The CRP is 0.6100 mg/L;\n The LDH is 159.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 170 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 37.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 32.4000 ### months." } ], "images": [ "DMFS_train_1281/0000295397_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.9370 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 45.4000 g/L;\n The CRP is 0.6100 mg/L;\n The LDH is 159.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 170 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 37.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 32.4000 ### months." } ], "images": [ "DMFS_train_1281/0000295397_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.9370 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 45.4000 g/L;\n The CRP is 0.6100 mg/L;\n The LDH is 159.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 170 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 37.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 32.4000 ### months." } ], "images": [ "DMFS_train_1281/0000295397_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.9370 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 45.4000 g/L;\n The CRP is 0.6100 mg/L;\n The LDH is 159.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 170 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 37.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 32.4000 ### months." } ], "images": [ "DMFS_train_1281/0000295397_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.9370 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 45.4000 g/L;\n The CRP is 0.6100 mg/L;\n The LDH is 159.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 170 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 37.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 32.4000 ### months." } ], "images": [ "DMFS_train_1281/0000295397_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 56.9000 copies/mL;\nThe EBV of after treatment is 4.6000 copies/m; \nThe HGB is 124.8000 g/L;\nThe ALB is 45.7000 g/L;\n The CRP is 9.0800 mg/L;\n The LDH is 191.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 46.5500 months;\nThe time interval between diagnosis and post-treatment imaging is 96.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.2000 ### months." } ], "images": [ "DMFS_train_1281/0000279251_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 56.9000 copies/mL;\nThe EBV of after treatment is 4.6000 copies/m; \nThe HGB is 124.8000 g/L;\nThe ALB is 45.7000 g/L;\n The CRP is 9.0800 mg/L;\n The LDH is 191.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 46.5500 months;\nThe time interval between diagnosis and post-treatment imaging is 96.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.2000 ### months." } ], "images": [ "DMFS_train_1281/0000279251_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 56.9000 copies/mL;\nThe EBV of after treatment is 4.6000 copies/m; \nThe HGB is 124.8000 g/L;\nThe ALB is 45.7000 g/L;\n The CRP is 9.0800 mg/L;\n The LDH is 191.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 46.5500 months;\nThe time interval between diagnosis and post-treatment imaging is 96.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.2000 ### months." } ], "images": [ "DMFS_train_1281/0000279251_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 56.9000 copies/mL;\nThe EBV of after treatment is 4.6000 copies/m; \nThe HGB is 124.8000 g/L;\nThe ALB is 45.7000 g/L;\n The CRP is 9.0800 mg/L;\n The LDH is 191.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 46.5500 months;\nThe time interval between diagnosis and post-treatment imaging is 96.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.2000 ### months." } ], "images": [ "DMFS_train_1281/0000279251_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 56.9000 copies/mL;\nThe EBV of after treatment is 4.6000 copies/m; \nThe HGB is 124.8000 g/L;\nThe ALB is 45.7000 g/L;\n The CRP is 9.0800 mg/L;\n The LDH is 191.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 46.5500 months;\nThe time interval between diagnosis and post-treatment imaging is 96.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.2000 ### months." } ], "images": [ "DMFS_train_1281/0000279251_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 56.9000 copies/mL;\nThe EBV of after treatment is 4.6000 copies/m; \nThe HGB is 124.8000 g/L;\nThe ALB is 45.7000 g/L;\n The CRP is 9.0800 mg/L;\n The LDH is 191.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 46.5500 months;\nThe time interval between diagnosis and post-treatment imaging is 96.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.2000 ### months." } ], "images": [ "DMFS_train_1281/0000279251_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 56.9000 copies/mL;\nThe EBV of after treatment is 4.6000 copies/m; \nThe HGB is 124.8000 g/L;\nThe ALB is 45.7000 g/L;\n The CRP is 9.0800 mg/L;\n The LDH is 191.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 46.5500 months;\nThe time interval between diagnosis and post-treatment imaging is 96.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.2000 ### months." } ], "images": [ "DMFS_train_1281/0000279251_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 44.2000 g/L;\n The CRP is 1.7400 mg/L;\n The LDH is 170.3000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 75.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 92.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.1333 ### months." } ], "images": [ "DMFS_train_1281/0000275271_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 44.2000 g/L;\n The CRP is 1.7400 mg/L;\n The LDH is 170.3000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 75.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 92.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.1333 ### months." } ], "images": [ "DMFS_train_1281/0000275271_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 44.2000 g/L;\n The CRP is 1.7400 mg/L;\n The LDH is 170.3000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 75.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 92.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.1333 ### months." } ], "images": [ "DMFS_train_1281/0000275271_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 44.2000 g/L;\n The CRP is 1.7400 mg/L;\n The LDH is 170.3000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 75.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 92.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.1333 ### months." } ], "images": [ "DMFS_train_1281/0000275271_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 44.2000 g/L;\n The CRP is 1.7400 mg/L;\n The LDH is 170.3000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 75.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 92.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.1333 ### months." } ], "images": [ "DMFS_train_1281/0000275271_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 44.2000 g/L;\n The CRP is 1.7400 mg/L;\n The LDH is 170.3000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 75.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 92.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.1333 ### months." } ], "images": [ "DMFS_train_1281/0000275271_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 44.2000 g/L;\n The CRP is 1.7400 mg/L;\n The LDH is 170.3000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 75.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 92.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.1333 ### months." } ], "images": [ "DMFS_train_1281/0000275271_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 62 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 12.0000 copies/mL;\nThe EBV of after treatment is 0.0119 copies/m; \nThe HGB is 145.8000 g/L;\nThe ALB is 40.8000 g/L;\n The CRP is 12.7800 mg/L;\n The LDH is 201.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 7:Severe complications, where the health of patient is significantly affected, with a potential life-threatening condition, requiring emergency medical intervention.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.1333 ### months." } ], "images": [ "DMFS_train_1281/0000267209_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 62 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 12.0000 copies/mL;\nThe EBV of after treatment is 0.0119 copies/m; \nThe HGB is 145.8000 g/L;\nThe ALB is 40.8000 g/L;\n The CRP is 12.7800 mg/L;\n The LDH is 201.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 7:Severe complications, where the health of patient is significantly affected, with a potential life-threatening condition, requiring emergency medical intervention.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.1333 ### months." } ], "images": [ "DMFS_train_1281/0000267209_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 62 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 12.0000 copies/mL;\nThe EBV of after treatment is 0.0119 copies/m; \nThe HGB is 145.8000 g/L;\nThe ALB is 40.8000 g/L;\n The CRP is 12.7800 mg/L;\n The LDH is 201.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 7:Severe complications, where the health of patient is significantly affected, with a potential life-threatening condition, requiring emergency medical intervention.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.1333 ### months." } ], "images": [ "DMFS_train_1281/0000267209_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 62 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 12.0000 copies/mL;\nThe EBV of after treatment is 0.0119 copies/m; \nThe HGB is 145.8000 g/L;\nThe ALB is 40.8000 g/L;\n The CRP is 12.7800 mg/L;\n The LDH is 201.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 7:Severe complications, where the health of patient is significantly affected, with a potential life-threatening condition, requiring emergency medical intervention.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.1333 ### months." } ], "images": [ "DMFS_train_1281/0000267209_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 62 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 12.0000 copies/mL;\nThe EBV of after treatment is 0.0119 copies/m; \nThe HGB is 145.8000 g/L;\nThe ALB is 40.8000 g/L;\n The CRP is 12.7800 mg/L;\n The LDH is 201.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 7:Severe complications, where the health of patient is significantly affected, with a potential life-threatening condition, requiring emergency medical intervention.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.1333 ### months." } ], "images": [ "DMFS_train_1281/0000267209_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 62 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 12.0000 copies/mL;\nThe EBV of after treatment is 0.0119 copies/m; \nThe HGB is 145.8000 g/L;\nThe ALB is 40.8000 g/L;\n The CRP is 12.7800 mg/L;\n The LDH is 201.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 7:Severe complications, where the health of patient is significantly affected, with a potential life-threatening condition, requiring emergency medical intervention.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.1333 ### months." } ], "images": [ "DMFS_train_1281/0000267209_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 62 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N0:No lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 12.0000 copies/mL;\nThe EBV of after treatment is 0.0119 copies/m; \nThe HGB is 145.8000 g/L;\nThe ALB is 40.8000 g/L;\n The CRP is 12.7800 mg/L;\n The LDH is 201.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 7:Severe complications, where the health of patient is significantly affected, with a potential life-threatening condition, requiring emergency medical intervention.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.1333 ### months." } ], "images": [ "DMFS_train_1281/0000267209_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 34 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 175.0000 copies/mL;\nThe EBV of after treatment is 12.0000 copies/m; \nThe HGB is 158.0000 g/L;\nThe ALB is 43.1000 g/L;\n The CRP is 1.1900 mg/L;\n The LDH is 208.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 120 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 5.2000 ### months." } ], "images": [ "DMFS_train_1281/00C1113916_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 34 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 175.0000 copies/mL;\nThe EBV of after treatment is 12.0000 copies/m; \nThe HGB is 158.0000 g/L;\nThe ALB is 43.1000 g/L;\n The CRP is 1.1900 mg/L;\n The LDH is 208.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 120 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 5.2000 ### months." } ], "images": [ "DMFS_train_1281/00C1113916_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 34 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 175.0000 copies/mL;\nThe EBV of after treatment is 12.0000 copies/m; \nThe HGB is 158.0000 g/L;\nThe ALB is 43.1000 g/L;\n The CRP is 1.1900 mg/L;\n The LDH is 208.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 120 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 5.2000 ### months." } ], "images": [ "DMFS_train_1281/00C1113916_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 34 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 175.0000 copies/mL;\nThe EBV of after treatment is 12.0000 copies/m; \nThe HGB is 158.0000 g/L;\nThe ALB is 43.1000 g/L;\n The CRP is 1.1900 mg/L;\n The LDH is 208.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 120 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 5.2000 ### months." } ], "images": [ "DMFS_train_1281/00C1113916_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 34 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 175.0000 copies/mL;\nThe EBV of after treatment is 12.0000 copies/m; \nThe HGB is 158.0000 g/L;\nThe ALB is 43.1000 g/L;\n The CRP is 1.1900 mg/L;\n The LDH is 208.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 120 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 5.2000 ### months." } ], "images": [ "DMFS_train_1281/00C1113916_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 34 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 175.0000 copies/mL;\nThe EBV of after treatment is 12.0000 copies/m; \nThe HGB is 158.0000 g/L;\nThe ALB is 43.1000 g/L;\n The CRP is 1.1900 mg/L;\n The LDH is 208.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 120 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 5.2000 ### months." } ], "images": [ "DMFS_train_1281/00C1113916_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 34 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 175.0000 copies/mL;\nThe EBV of after treatment is 12.0000 copies/m; \nThe HGB is 158.0000 g/L;\nThe ALB is 43.1000 g/L;\n The CRP is 1.1900 mg/L;\n The LDH is 208.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 120 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 66.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 5.2000 ### months." } ], "images": [ "DMFS_train_1281/00C1113916_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 16.9000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 0.8200 mg/L;\n The LDH is 122.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 43.3333 ### months." } ], "images": [ "DMFS_train_1281/0000274789_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 16.9000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 0.8200 mg/L;\n The LDH is 122.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 43.3333 ### months." } ], "images": [ "DMFS_train_1281/0000274789_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 16.9000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 0.8200 mg/L;\n The LDH is 122.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 43.3333 ### months." } ], "images": [ "DMFS_train_1281/0000274789_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 16.9000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 0.8200 mg/L;\n The LDH is 122.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 43.3333 ### months." } ], "images": [ "DMFS_train_1281/0000274789_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 16.9000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 0.8200 mg/L;\n The LDH is 122.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 43.3333 ### months." } ], "images": [ "DMFS_train_1281/0000274789_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 16.9000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 0.8200 mg/L;\n The LDH is 122.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 43.3333 ### months." } ], "images": [ "DMFS_train_1281/0000274789_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 16.9000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 0.8200 mg/L;\n The LDH is 122.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 43.3333 ### months." } ], "images": [ "DMFS_train_1281/0000274789_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 25 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 51.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 101.0000 g/L;\nThe ALB is 41.6000 g/L;\n The CRP is 10.6400 mg/L;\n The LDH is 699.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 45.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 89.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 21.1333 ### months." } ], "images": [ "DMFS_train_1281/0000279724_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 25 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 51.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 101.0000 g/L;\nThe ALB is 41.6000 g/L;\n The CRP is 10.6400 mg/L;\n The LDH is 699.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 45.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 89.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 21.1333 ### months." } ], "images": [ "DMFS_train_1281/0000279724_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 25 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 51.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 101.0000 g/L;\nThe ALB is 41.6000 g/L;\n The CRP is 10.6400 mg/L;\n The LDH is 699.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 45.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 89.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 21.1333 ### months." } ], "images": [ "DMFS_train_1281/0000279724_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 25 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 51.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 101.0000 g/L;\nThe ALB is 41.6000 g/L;\n The CRP is 10.6400 mg/L;\n The LDH is 699.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 45.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 89.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 21.1333 ### months." } ], "images": [ "DMFS_train_1281/0000279724_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 25 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 51.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 101.0000 g/L;\nThe ALB is 41.6000 g/L;\n The CRP is 10.6400 mg/L;\n The LDH is 699.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 45.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 89.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 21.1333 ### months." } ], "images": [ "DMFS_train_1281/0000279724_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 25 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 51.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 101.0000 g/L;\nThe ALB is 41.6000 g/L;\n The CRP is 10.6400 mg/L;\n The LDH is 699.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 45.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 89.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 21.1333 ### months." } ], "images": [ "DMFS_train_1281/0000279724_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 25 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 51.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 101.0000 g/L;\nThe ALB is 41.6000 g/L;\n The CRP is 10.6400 mg/L;\n The LDH is 699.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 45.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 89.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 21.1333 ### months." } ], "images": [ "DMFS_train_1281/0000279724_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 37 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.1380 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 163.0000 g/L;\nThe ALB is 44.6000 g/L;\n The CRP is 1.4100 mg/L;\n The LDH is 219.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is 5-fu;\n The time interval between induction chemotherapy and post-treatment imaging is 350.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 350.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 18.0333 ### months." } ], "images": [ "DMFS_train_1281/0000275292_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 37 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.1380 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 163.0000 g/L;\nThe ALB is 44.6000 g/L;\n The CRP is 1.4100 mg/L;\n The LDH is 219.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is 5-fu;\n The time interval between induction chemotherapy and post-treatment imaging is 350.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 350.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 18.0333 ### months." } ], "images": [ "DMFS_train_1281/0000275292_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 37 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.1380 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 163.0000 g/L;\nThe ALB is 44.6000 g/L;\n The CRP is 1.4100 mg/L;\n The LDH is 219.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is 5-fu;\n The time interval between induction chemotherapy and post-treatment imaging is 350.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 350.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 18.0333 ### months." } ], "images": [ "DMFS_train_1281/0000275292_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 37 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.1380 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 163.0000 g/L;\nThe ALB is 44.6000 g/L;\n The CRP is 1.4100 mg/L;\n The LDH is 219.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is 5-fu;\n The time interval between induction chemotherapy and post-treatment imaging is 350.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 350.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 18.0333 ### months." } ], "images": [ "DMFS_train_1281/0000275292_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 37 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.1380 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 163.0000 g/L;\nThe ALB is 44.6000 g/L;\n The CRP is 1.4100 mg/L;\n The LDH is 219.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is 5-fu;\n The time interval between induction chemotherapy and post-treatment imaging is 350.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 350.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 18.0333 ### months." } ], "images": [ "DMFS_train_1281/0000275292_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 37 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.1380 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 163.0000 g/L;\nThe ALB is 44.6000 g/L;\n The CRP is 1.4100 mg/L;\n The LDH is 219.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is 5-fu;\n The time interval between induction chemotherapy and post-treatment imaging is 350.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 350.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 18.0333 ### months." } ], "images": [ "DMFS_train_1281/0000275292_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 37 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.1380 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 163.0000 g/L;\nThe ALB is 44.6000 g/L;\n The CRP is 1.4100 mg/L;\n The LDH is 219.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is 5-fu;\n The time interval between induction chemotherapy and post-treatment imaging is 350.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 350.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 18.0333 ### months." } ], "images": [ "DMFS_train_1281/0000275292_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 30 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 5160.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 156.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 3.2300 mg/L;\n The LDH is 507.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.7000 ### months." } ], "images": [ "DMFS_train_1281/0000241900_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 30 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 5160.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 156.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 3.2300 mg/L;\n The LDH is 507.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.7000 ### months." } ], "images": [ "DMFS_train_1281/0000241900_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 30 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 5160.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 156.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 3.2300 mg/L;\n The LDH is 507.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.7000 ### months." } ], "images": [ "DMFS_train_1281/0000241900_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 30 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 5160.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 156.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 3.2300 mg/L;\n The LDH is 507.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.7000 ### months." } ], "images": [ "DMFS_train_1281/0000241900_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 30 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 5160.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 156.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 3.2300 mg/L;\n The LDH is 507.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.7000 ### months." } ], "images": [ "DMFS_train_1281/0000241900_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 30 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 5160.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 156.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 3.2300 mg/L;\n The LDH is 507.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.7000 ### months." } ], "images": [ "DMFS_train_1281/0000241900_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 30 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 5160.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 156.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 3.2300 mg/L;\n The LDH is 507.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.7000 ### months." } ], "images": [ "DMFS_train_1281/0000241900_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 131.0000 g/L;\nThe ALB is 34.0000 g/L;\n The CRP is 45.0000 mg/L;\n The LDH is 135.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 45.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 23.5333 ### months." } ], "images": [ "DMFS_train_1281/0000248891_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 131.0000 g/L;\nThe ALB is 34.0000 g/L;\n The CRP is 45.0000 mg/L;\n The LDH is 135.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 45.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 23.5333 ### months." } ], "images": [ "DMFS_train_1281/0000248891_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 131.0000 g/L;\nThe ALB is 34.0000 g/L;\n The CRP is 45.0000 mg/L;\n The LDH is 135.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 45.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 23.5333 ### months." } ], "images": [ "DMFS_train_1281/0000248891_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 131.0000 g/L;\nThe ALB is 34.0000 g/L;\n The CRP is 45.0000 mg/L;\n The LDH is 135.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 45.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 23.5333 ### months." } ], "images": [ "DMFS_train_1281/0000248891_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 131.0000 g/L;\nThe ALB is 34.0000 g/L;\n The CRP is 45.0000 mg/L;\n The LDH is 135.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 45.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 23.5333 ### months." } ], "images": [ "DMFS_train_1281/0000248891_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 131.0000 g/L;\nThe ALB is 34.0000 g/L;\n The CRP is 45.0000 mg/L;\n The LDH is 135.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 45.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 23.5333 ### months." } ], "images": [ "DMFS_train_1281/0000248891_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 59 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 131.0000 g/L;\nThe ALB is 34.0000 g/L;\n The CRP is 45.0000 mg/L;\n The LDH is 135.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 45.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 23.5333 ### months." } ], "images": [ "DMFS_train_1281/0000248891_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 54.5000 copies/mL;\nThe EBV of after treatment is 4.6000 copies/m; \nThe HGB is 137.0000 g/L;\nThe ALB is 38.1000 g/L;\n The CRP is 3.0100 mg/L;\n The LDH is 240.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 46.5500 months;\nThe time interval between diagnosis and post-treatment imaging is 132.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.7667 ### months." } ], "images": [ "DMFS_train_1281/0000258249_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 54.5000 copies/mL;\nThe EBV of after treatment is 4.6000 copies/m; \nThe HGB is 137.0000 g/L;\nThe ALB is 38.1000 g/L;\n The CRP is 3.0100 mg/L;\n The LDH is 240.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 46.5500 months;\nThe time interval between diagnosis and post-treatment imaging is 132.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.7667 ### months." } ], "images": [ "DMFS_train_1281/0000258249_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 54.5000 copies/mL;\nThe EBV of after treatment is 4.6000 copies/m; \nThe HGB is 137.0000 g/L;\nThe ALB is 38.1000 g/L;\n The CRP is 3.0100 mg/L;\n The LDH is 240.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 46.5500 months;\nThe time interval between diagnosis and post-treatment imaging is 132.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.7667 ### months." } ], "images": [ "DMFS_train_1281/0000258249_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 54.5000 copies/mL;\nThe EBV of after treatment is 4.6000 copies/m; \nThe HGB is 137.0000 g/L;\nThe ALB is 38.1000 g/L;\n The CRP is 3.0100 mg/L;\n The LDH is 240.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 46.5500 months;\nThe time interval between diagnosis and post-treatment imaging is 132.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.7667 ### months." } ], "images": [ "DMFS_train_1281/0000258249_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 54.5000 copies/mL;\nThe EBV of after treatment is 4.6000 copies/m; \nThe HGB is 137.0000 g/L;\nThe ALB is 38.1000 g/L;\n The CRP is 3.0100 mg/L;\n The LDH is 240.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 46.5500 months;\nThe time interval between diagnosis and post-treatment imaging is 132.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.7667 ### months." } ], "images": [ "DMFS_train_1281/0000258249_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 54.5000 copies/mL;\nThe EBV of after treatment is 4.6000 copies/m; \nThe HGB is 137.0000 g/L;\nThe ALB is 38.1000 g/L;\n The CRP is 3.0100 mg/L;\n The LDH is 240.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 46.5500 months;\nThe time interval between diagnosis and post-treatment imaging is 132.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.7667 ### months." } ], "images": [ "DMFS_train_1281/0000258249_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 54.5000 copies/mL;\nThe EBV of after treatment is 4.6000 copies/m; \nThe HGB is 137.0000 g/L;\nThe ALB is 38.1000 g/L;\n The CRP is 3.0100 mg/L;\n The LDH is 240.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 46.5500 months;\nThe time interval between diagnosis and post-treatment imaging is 132.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.7667 ### months." } ], "images": [ "DMFS_train_1281/0000258249_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 46.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 44.6000 g/L;\n The CRP is 0.8000 mg/L;\n The LDH is 333.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 89.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 13.5667 ### months." } ], "images": [ "DMFS_train_1281/0000268787_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 46.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 44.6000 g/L;\n The CRP is 0.8000 mg/L;\n The LDH is 333.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 89.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 13.5667 ### months." } ], "images": [ "DMFS_train_1281/0000268787_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 46.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 44.6000 g/L;\n The CRP is 0.8000 mg/L;\n The LDH is 333.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 89.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 13.5667 ### months." } ], "images": [ "DMFS_train_1281/0000268787_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 46.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 44.6000 g/L;\n The CRP is 0.8000 mg/L;\n The LDH is 333.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 89.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 13.5667 ### months." } ], "images": [ "DMFS_train_1281/0000268787_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 46.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 44.6000 g/L;\n The CRP is 0.8000 mg/L;\n The LDH is 333.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 89.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 13.5667 ### months." } ], "images": [ "DMFS_train_1281/0000268787_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 46.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 44.6000 g/L;\n The CRP is 0.8000 mg/L;\n The LDH is 333.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 89.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 13.5667 ### months." } ], "images": [ "DMFS_train_1281/0000268787_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 38 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 46.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 44.6000 g/L;\n The CRP is 0.8000 mg/L;\n The LDH is 333.8000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 89.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 13.5667 ### months." } ], "images": [ "DMFS_train_1281/0000268787_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 1:Benign or low grade malignant;\nThe Age is 52 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 33.2000 copies/mL;\nThe EBV of after treatment is 5.7800 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 0.5000 mg/L;\n The LDH is 206.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 106.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 116.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 58.9000 ### months." } ], "images": [ "DMFS_train_1281/0000245599_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 1:Benign or low grade malignant;\nThe Age is 52 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 33.2000 copies/mL;\nThe EBV of after treatment is 5.7800 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 0.5000 mg/L;\n The LDH is 206.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 106.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 116.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 58.9000 ### months." } ], "images": [ "DMFS_train_1281/0000245599_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 1:Benign or low grade malignant;\nThe Age is 52 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 33.2000 copies/mL;\nThe EBV of after treatment is 5.7800 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 0.5000 mg/L;\n The LDH is 206.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 106.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 116.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 58.9000 ### months." } ], "images": [ "DMFS_train_1281/0000245599_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 1:Benign or low grade malignant;\nThe Age is 52 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 33.2000 copies/mL;\nThe EBV of after treatment is 5.7800 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 0.5000 mg/L;\n The LDH is 206.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 106.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 116.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 58.9000 ### months." } ], "images": [ "DMFS_train_1281/0000245599_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 1:Benign or low grade malignant;\nThe Age is 52 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 33.2000 copies/mL;\nThe EBV of after treatment is 5.7800 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 0.5000 mg/L;\n The LDH is 206.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 106.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 116.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 58.9000 ### months." } ], "images": [ "DMFS_train_1281/0000245599_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 1:Benign or low grade malignant;\nThe Age is 52 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 33.2000 copies/mL;\nThe EBV of after treatment is 5.7800 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 0.5000 mg/L;\n The LDH is 206.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 106.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 116.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 58.9000 ### months." } ], "images": [ "DMFS_train_1281/0000245599_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 1:Benign or low grade malignant;\nThe Age is 52 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 33.2000 copies/mL;\nThe EBV of after treatment is 5.7800 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 0.5000 mg/L;\n The LDH is 206.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 106.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 116.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 58.9000 ### months." } ], "images": [ "DMFS_train_1281/0000245599_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 12.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.1000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 2.4600 mg/L;\n The LDH is 182.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.3333 ### months." } ], "images": [ "DMFS_train_1281/0000283926_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 12.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.1000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 2.4600 mg/L;\n The LDH is 182.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.3333 ### months." } ], "images": [ "DMFS_train_1281/0000283926_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 12.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.1000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 2.4600 mg/L;\n The LDH is 182.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.3333 ### months." } ], "images": [ "DMFS_train_1281/0000283926_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 12.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.1000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 2.4600 mg/L;\n The LDH is 182.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.3333 ### months." } ], "images": [ "DMFS_train_1281/0000283926_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 12.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.1000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 2.4600 mg/L;\n The LDH is 182.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.3333 ### months." } ], "images": [ "DMFS_train_1281/0000283926_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 12.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.1000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 2.4600 mg/L;\n The LDH is 182.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.3333 ### months." } ], "images": [ "DMFS_train_1281/0000283926_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 12.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.1000 g/L;\nThe ALB is 43.0000 g/L;\n The CRP is 2.4600 mg/L;\n The LDH is 182.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.3333 ### months." } ], "images": [ "DMFS_train_1281/0000283926_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 17.5000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 44.2000 g/L;\n The CRP is 0.4900 mg/L;\n The LDH is 143.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 29.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 47.2333 ### months." } ], "images": [ "DMFS_train_1281/0000310015_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 17.5000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 44.2000 g/L;\n The CRP is 0.4900 mg/L;\n The LDH is 143.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 29.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 47.2333 ### months." } ], "images": [ "DMFS_train_1281/0000310015_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 17.5000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 44.2000 g/L;\n The CRP is 0.4900 mg/L;\n The LDH is 143.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 29.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 47.2333 ### months." } ], "images": [ "DMFS_train_1281/0000310015_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 17.5000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 44.2000 g/L;\n The CRP is 0.4900 mg/L;\n The LDH is 143.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 29.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 47.2333 ### months." } ], "images": [ "DMFS_train_1281/0000310015_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 17.5000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 44.2000 g/L;\n The CRP is 0.4900 mg/L;\n The LDH is 143.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 29.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 47.2333 ### months." } ], "images": [ "DMFS_train_1281/0000310015_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 17.5000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 44.2000 g/L;\n The CRP is 0.4900 mg/L;\n The LDH is 143.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 29.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 47.2333 ### months." } ], "images": [ "DMFS_train_1281/0000310015_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 17.5000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 44.2000 g/L;\n The CRP is 0.4900 mg/L;\n The LDH is 143.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 29.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 47.2333 ### months." } ], "images": [ "DMFS_train_1281/0000310015_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 634.0000 copies/mL;\nThe EBV of after treatment is 10.8000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 42.0000 g/L;\n The CRP is 0.9000 mg/L;\n The LDH is 250.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 235 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 52.7000 ### months." } ], "images": [ "DMFS_train_1281/0000246555_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 634.0000 copies/mL;\nThe EBV of after treatment is 10.8000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 42.0000 g/L;\n The CRP is 0.9000 mg/L;\n The LDH is 250.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 235 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 52.7000 ### months." } ], "images": [ "DMFS_train_1281/0000246555_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 634.0000 copies/mL;\nThe EBV of after treatment is 10.8000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 42.0000 g/L;\n The CRP is 0.9000 mg/L;\n The LDH is 250.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 235 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 52.7000 ### months." } ], "images": [ "DMFS_train_1281/0000246555_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 634.0000 copies/mL;\nThe EBV of after treatment is 10.8000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 42.0000 g/L;\n The CRP is 0.9000 mg/L;\n The LDH is 250.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 235 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 52.7000 ### months." } ], "images": [ "DMFS_train_1281/0000246555_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 634.0000 copies/mL;\nThe EBV of after treatment is 10.8000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 42.0000 g/L;\n The CRP is 0.9000 mg/L;\n The LDH is 250.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 235 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 52.7000 ### months." } ], "images": [ "DMFS_train_1281/0000246555_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 634.0000 copies/mL;\nThe EBV of after treatment is 10.8000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 42.0000 g/L;\n The CRP is 0.9000 mg/L;\n The LDH is 250.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 235 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 52.7000 ### months." } ], "images": [ "DMFS_train_1281/0000246555_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 36 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 634.0000 copies/mL;\nThe EBV of after treatment is 10.8000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 42.0000 g/L;\n The CRP is 0.9000 mg/L;\n The LDH is 250.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 235 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 52.7000 ### months." } ], "images": [ "DMFS_train_1281/0000246555_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.8910 copies/mL;\nThe EBV of after treatment is 1.3300 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 43.7000 g/L;\n The CRP is 0.3500 mg/L;\n The LDH is 269.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 25.4667 ### months." } ], "images": [ "DMFS_train_1281/0000293091_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.8910 copies/mL;\nThe EBV of after treatment is 1.3300 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 43.7000 g/L;\n The CRP is 0.3500 mg/L;\n The LDH is 269.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 25.4667 ### months." } ], "images": [ "DMFS_train_1281/0000293091_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.8910 copies/mL;\nThe EBV of after treatment is 1.3300 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 43.7000 g/L;\n The CRP is 0.3500 mg/L;\n The LDH is 269.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 25.4667 ### months." } ], "images": [ "DMFS_train_1281/0000293091_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.8910 copies/mL;\nThe EBV of after treatment is 1.3300 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 43.7000 g/L;\n The CRP is 0.3500 mg/L;\n The LDH is 269.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 25.4667 ### months." } ], "images": [ "DMFS_train_1281/0000293091_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.8910 copies/mL;\nThe EBV of after treatment is 1.3300 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 43.7000 g/L;\n The CRP is 0.3500 mg/L;\n The LDH is 269.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 25.4667 ### months." } ], "images": [ "DMFS_train_1281/0000293091_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.8910 copies/mL;\nThe EBV of after treatment is 1.3300 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 43.7000 g/L;\n The CRP is 0.3500 mg/L;\n The LDH is 269.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 25.4667 ### months." } ], "images": [ "DMFS_train_1281/0000293091_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.8910 copies/mL;\nThe EBV of after treatment is 1.3300 copies/m; \nThe HGB is 139.0000 g/L;\nThe ALB is 43.7000 g/L;\n The CRP is 0.3500 mg/L;\n The LDH is 269.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 25.4667 ### months." } ], "images": [ "DMFS_train_1281/0000293091_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 7.0300 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 109.0000 g/L;\nThe ALB is 41.2000 g/L;\n The CRP is 10.6700 mg/L;\n The LDH is 163.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 127.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 144.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.1667 ### months." } ], "images": [ "DMFS_train_1281/0000265451_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 7.0300 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 109.0000 g/L;\nThe ALB is 41.2000 g/L;\n The CRP is 10.6700 mg/L;\n The LDH is 163.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 127.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 144.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.1667 ### months." } ], "images": [ "DMFS_train_1281/0000265451_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 7.0300 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 109.0000 g/L;\nThe ALB is 41.2000 g/L;\n The CRP is 10.6700 mg/L;\n The LDH is 163.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 127.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 144.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.1667 ### months." } ], "images": [ "DMFS_train_1281/0000265451_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 7.0300 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 109.0000 g/L;\nThe ALB is 41.2000 g/L;\n The CRP is 10.6700 mg/L;\n The LDH is 163.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 127.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 144.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.1667 ### months." } ], "images": [ "DMFS_train_1281/0000265451_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 7.0300 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 109.0000 g/L;\nThe ALB is 41.2000 g/L;\n The CRP is 10.6700 mg/L;\n The LDH is 163.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 127.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 144.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.1667 ### months." } ], "images": [ "DMFS_train_1281/0000265451_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 7.0300 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 109.0000 g/L;\nThe ALB is 41.2000 g/L;\n The CRP is 10.6700 mg/L;\n The LDH is 163.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 127.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 144.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.1667 ### months." } ], "images": [ "DMFS_train_1281/0000265451_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 7.0300 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 109.0000 g/L;\nThe ALB is 41.2000 g/L;\n The CRP is 10.6700 mg/L;\n The LDH is 163.1000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 127.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 144.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.1667 ### months." } ], "images": [ "DMFS_train_1281/0000265451_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 39 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 15.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 149.6000 g/L;\nThe ALB is 46.1000 g/L;\n The CRP is 1.2200 mg/L;\n The LDH is 167.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 12.3000 ### months." } ], "images": [ "DMFS_train_1281/0000283283_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 39 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 15.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 149.6000 g/L;\nThe ALB is 46.1000 g/L;\n The CRP is 1.2200 mg/L;\n The LDH is 167.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 12.3000 ### months." } ], "images": [ "DMFS_train_1281/0000283283_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 39 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 15.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 149.6000 g/L;\nThe ALB is 46.1000 g/L;\n The CRP is 1.2200 mg/L;\n The LDH is 167.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 12.3000 ### months." } ], "images": [ "DMFS_train_1281/0000283283_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 39 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 15.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 149.6000 g/L;\nThe ALB is 46.1000 g/L;\n The CRP is 1.2200 mg/L;\n The LDH is 167.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 12.3000 ### months." } ], "images": [ "DMFS_train_1281/0000283283_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 39 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 15.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 149.6000 g/L;\nThe ALB is 46.1000 g/L;\n The CRP is 1.2200 mg/L;\n The LDH is 167.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 12.3000 ### months." } ], "images": [ "DMFS_train_1281/0000283283_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 39 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 15.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 149.6000 g/L;\nThe ALB is 46.1000 g/L;\n The CRP is 1.2200 mg/L;\n The LDH is 167.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 12.3000 ### months." } ], "images": [ "DMFS_train_1281/0000283283_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 39 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 15.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 149.6000 g/L;\nThe ALB is 46.1000 g/L;\n The CRP is 1.2200 mg/L;\n The LDH is 167.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 31.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 48.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 12.3000 ### months." } ], "images": [ "DMFS_train_1281/0000283283_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 1.5900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 106.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 0.9300 mg/L;\n The LDH is 124.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 18.9667 ### months." } ], "images": [ "DMFS_train_1281/0000307952_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 1.5900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 106.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 0.9300 mg/L;\n The LDH is 124.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 18.9667 ### months." } ], "images": [ "DMFS_train_1281/0000307952_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 1.5900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 106.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 0.9300 mg/L;\n The LDH is 124.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 18.9667 ### months." } ], "images": [ "DMFS_train_1281/0000307952_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 1.5900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 106.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 0.9300 mg/L;\n The LDH is 124.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 18.9667 ### months." } ], "images": [ "DMFS_train_1281/0000307952_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 1.5900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 106.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 0.9300 mg/L;\n The LDH is 124.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 18.9667 ### months." } ], "images": [ "DMFS_train_1281/0000307952_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 1.5900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 106.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 0.9300 mg/L;\n The LDH is 124.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 18.9667 ### months." } ], "images": [ "DMFS_train_1281/0000307952_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 1.5900 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 106.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 0.9300 mg/L;\n The LDH is 124.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 18.9667 ### months." } ], "images": [ "DMFS_train_1281/0000307952_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 14.5000 copies/mL;\nThe EBV of after treatment is 7.4800 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 41.6000 g/L;\n The CRP is 0.5600 mg/L;\n The LDH is 196.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Docetaxel;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 76.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 10.5333 ### months." } ], "images": [ "DMFS_train_1281/0000289330_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 14.5000 copies/mL;\nThe EBV of after treatment is 7.4800 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 41.6000 g/L;\n The CRP is 0.5600 mg/L;\n The LDH is 196.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Docetaxel;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 76.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 10.5333 ### months." } ], "images": [ "DMFS_train_1281/0000289330_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 14.5000 copies/mL;\nThe EBV of after treatment is 7.4800 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 41.6000 g/L;\n The CRP is 0.5600 mg/L;\n The LDH is 196.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Docetaxel;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 76.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 10.5333 ### months." } ], "images": [ "DMFS_train_1281/0000289330_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 14.5000 copies/mL;\nThe EBV of after treatment is 7.4800 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 41.6000 g/L;\n The CRP is 0.5600 mg/L;\n The LDH is 196.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Docetaxel;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 76.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 10.5333 ### months." } ], "images": [ "DMFS_train_1281/0000289330_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 14.5000 copies/mL;\nThe EBV of after treatment is 7.4800 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 41.6000 g/L;\n The CRP is 0.5600 mg/L;\n The LDH is 196.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Docetaxel;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 76.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 10.5333 ### months." } ], "images": [ "DMFS_train_1281/0000289330_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 14.5000 copies/mL;\nThe EBV of after treatment is 7.4800 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 41.6000 g/L;\n The CRP is 0.5600 mg/L;\n The LDH is 196.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Docetaxel;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 76.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 10.5333 ### months." } ], "images": [ "DMFS_train_1281/0000289330_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 14.5000 copies/mL;\nThe EBV of after treatment is 7.4800 copies/m; \nThe HGB is 142.0000 g/L;\nThe ALB is 41.6000 g/L;\n The CRP is 0.5600 mg/L;\n The LDH is 196.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Docetaxel;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 76.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 10.5333 ### months." } ], "images": [ "DMFS_train_1281/0000289330_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 65 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.7810 copies/mL;\nThe EBV of after treatment is 0.3540 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 44.7000 g/L;\n The CRP is 0.2100 mg/L;\n The LDH is 190.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 28.3000 ### months." } ], "images": [ "DMFS_train_1281/0000292156_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 65 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.7810 copies/mL;\nThe EBV of after treatment is 0.3540 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 44.7000 g/L;\n The CRP is 0.2100 mg/L;\n The LDH is 190.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 28.3000 ### months." } ], "images": [ "DMFS_train_1281/0000292156_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 65 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.7810 copies/mL;\nThe EBV of after treatment is 0.3540 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 44.7000 g/L;\n The CRP is 0.2100 mg/L;\n The LDH is 190.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 28.3000 ### months." } ], "images": [ "DMFS_train_1281/0000292156_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 65 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.7810 copies/mL;\nThe EBV of after treatment is 0.3540 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 44.7000 g/L;\n The CRP is 0.2100 mg/L;\n The LDH is 190.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 28.3000 ### months." } ], "images": [ "DMFS_train_1281/0000292156_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 65 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.7810 copies/mL;\nThe EBV of after treatment is 0.3540 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 44.7000 g/L;\n The CRP is 0.2100 mg/L;\n The LDH is 190.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 28.3000 ### months." } ], "images": [ "DMFS_train_1281/0000292156_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 65 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.7810 copies/mL;\nThe EBV of after treatment is 0.3540 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 44.7000 g/L;\n The CRP is 0.2100 mg/L;\n The LDH is 190.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 28.3000 ### months." } ], "images": [ "DMFS_train_1281/0000292156_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 65 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.7810 copies/mL;\nThe EBV of after treatment is 0.3540 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 44.7000 g/L;\n The CRP is 0.2100 mg/L;\n The LDH is 190.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 28.3000 ### months." } ], "images": [ "DMFS_train_1281/0000292156_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 29 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 19.0000 copies/mL;\nThe EBV of after treatment is 62.1000 copies/m; \nThe HGB is 156.0000 g/L;\nThe ALB is 49.6000 g/L;\n The CRP is 1.4500 mg/L;\n The LDH is 224.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 41.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 57.3333 ### months." } ], "images": [ "DMFS_train_1281/0000240391_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 29 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 19.0000 copies/mL;\nThe EBV of after treatment is 62.1000 copies/m; \nThe HGB is 156.0000 g/L;\nThe ALB is 49.6000 g/L;\n The CRP is 1.4500 mg/L;\n The LDH is 224.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 41.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 57.3333 ### months." } ], "images": [ "DMFS_train_1281/0000240391_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 29 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 19.0000 copies/mL;\nThe EBV of after treatment is 62.1000 copies/m; \nThe HGB is 156.0000 g/L;\nThe ALB is 49.6000 g/L;\n The CRP is 1.4500 mg/L;\n The LDH is 224.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 41.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 57.3333 ### months." } ], "images": [ "DMFS_train_1281/0000240391_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 29 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 19.0000 copies/mL;\nThe EBV of after treatment is 62.1000 copies/m; \nThe HGB is 156.0000 g/L;\nThe ALB is 49.6000 g/L;\n The CRP is 1.4500 mg/L;\n The LDH is 224.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 41.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 57.3333 ### months." } ], "images": [ "DMFS_train_1281/0000240391_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 29 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 19.0000 copies/mL;\nThe EBV of after treatment is 62.1000 copies/m; \nThe HGB is 156.0000 g/L;\nThe ALB is 49.6000 g/L;\n The CRP is 1.4500 mg/L;\n The LDH is 224.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 41.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 57.3333 ### months." } ], "images": [ "DMFS_train_1281/0000240391_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 29 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 19.0000 copies/mL;\nThe EBV of after treatment is 62.1000 copies/m; \nThe HGB is 156.0000 g/L;\nThe ALB is 49.6000 g/L;\n The CRP is 1.4500 mg/L;\n The LDH is 224.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 41.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 57.3333 ### months." } ], "images": [ "DMFS_train_1281/0000240391_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 29 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 19.0000 copies/mL;\nThe EBV of after treatment is 62.1000 copies/m; \nThe HGB is 156.0000 g/L;\nThe ALB is 49.6000 g/L;\n The CRP is 1.4500 mg/L;\n The LDH is 224.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 41.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 57.3333 ### months." } ], "images": [ "DMFS_train_1281/0000240391_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 102.1000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 0.1800 mg/L;\n The LDH is 176.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 36.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 13.8333 ### months." } ], "images": [ "DMFS_train_1281/0000275246_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 102.1000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 0.1800 mg/L;\n The LDH is 176.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 36.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 13.8333 ### months." } ], "images": [ "DMFS_train_1281/0000275246_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 102.1000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 0.1800 mg/L;\n The LDH is 176.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 36.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 13.8333 ### months." } ], "images": [ "DMFS_train_1281/0000275246_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 102.1000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 0.1800 mg/L;\n The LDH is 176.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 36.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 13.8333 ### months." } ], "images": [ "DMFS_train_1281/0000275246_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 102.1000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 0.1800 mg/L;\n The LDH is 176.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 36.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 13.8333 ### months." } ], "images": [ "DMFS_train_1281/0000275246_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 102.1000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 0.1800 mg/L;\n The LDH is 176.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 36.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 13.8333 ### months." } ], "images": [ "DMFS_train_1281/0000275246_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 102.1000 g/L;\nThe ALB is 45.3000 g/L;\n The CRP is 0.1800 mg/L;\n The LDH is 176.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 36.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 13.8333 ### months." } ], "images": [ "DMFS_train_1281/0000275246_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 53 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 39.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 122.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 3.0000 mg/L;\n The LDH is 151.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 49.9333 ### months." } ], "images": [ "DMFS_train_1281/0000246031_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 53 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 39.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 122.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 3.0000 mg/L;\n The LDH is 151.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 49.9333 ### months." } ], "images": [ "DMFS_train_1281/0000246031_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 53 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 39.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 122.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 3.0000 mg/L;\n The LDH is 151.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 49.9333 ### months." } ], "images": [ "DMFS_train_1281/0000246031_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 53 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 39.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 122.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 3.0000 mg/L;\n The LDH is 151.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 49.9333 ### months." } ], "images": [ "DMFS_train_1281/0000246031_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 53 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 39.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 122.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 3.0000 mg/L;\n The LDH is 151.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 49.9333 ### months." } ], "images": [ "DMFS_train_1281/0000246031_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 53 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 39.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 122.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 3.0000 mg/L;\n The LDH is 151.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 49.9333 ### months." } ], "images": [ "DMFS_train_1281/0000246031_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 53 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 39.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 122.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 3.0000 mg/L;\n The LDH is 151.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 46.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 49.9333 ### months." } ], "images": [ "DMFS_train_1281/0000246031_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 53 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 97.4000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.6000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 5.1500 mg/L;\n The LDH is 253.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.9667 ### months." } ], "images": [ "DMFS_train_1281/0000234661_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 53 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 97.4000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.6000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 5.1500 mg/L;\n The LDH is 253.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.9667 ### months." } ], "images": [ "DMFS_train_1281/0000234661_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 53 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 97.4000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.6000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 5.1500 mg/L;\n The LDH is 253.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.9667 ### months." } ], "images": [ "DMFS_train_1281/0000234661_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 53 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 97.4000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.6000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 5.1500 mg/L;\n The LDH is 253.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.9667 ### months." } ], "images": [ "DMFS_train_1281/0000234661_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 53 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 97.4000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.6000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 5.1500 mg/L;\n The LDH is 253.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.9667 ### months." } ], "images": [ "DMFS_train_1281/0000234661_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 53 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 97.4000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.6000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 5.1500 mg/L;\n The LDH is 253.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.9667 ### months." } ], "images": [ "DMFS_train_1281/0000234661_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 53 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 97.4000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.6000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 5.1500 mg/L;\n The LDH is 253.1000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.9667 ### months." } ], "images": [ "DMFS_train_1281/0000234661_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.8770 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 159.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 3.6300 mg/L;\n The LDH is 199.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 2:Mild complications that require some medication or treatment to control, and may have a slight impact on daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 31.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 27.5333 ### months." } ], "images": [ "DMFS_train_1281/0000312261_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.8770 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 159.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 3.6300 mg/L;\n The LDH is 199.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 2:Mild complications that require some medication or treatment to control, and may have a slight impact on daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 31.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 27.5333 ### months." } ], "images": [ "DMFS_train_1281/0000312261_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.8770 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 159.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 3.6300 mg/L;\n The LDH is 199.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 2:Mild complications that require some medication or treatment to control, and may have a slight impact on daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 31.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 27.5333 ### months." } ], "images": [ "DMFS_train_1281/0000312261_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.8770 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 159.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 3.6300 mg/L;\n The LDH is 199.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 2:Mild complications that require some medication or treatment to control, and may have a slight impact on daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 31.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 27.5333 ### months." } ], "images": [ "DMFS_train_1281/0000312261_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.8770 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 159.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 3.6300 mg/L;\n The LDH is 199.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 2:Mild complications that require some medication or treatment to control, and may have a slight impact on daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 31.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 27.5333 ### months." } ], "images": [ "DMFS_train_1281/0000312261_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.8770 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 159.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 3.6300 mg/L;\n The LDH is 199.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 2:Mild complications that require some medication or treatment to control, and may have a slight impact on daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 31.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 27.5333 ### months." } ], "images": [ "DMFS_train_1281/0000312261_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.8770 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 159.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 3.6300 mg/L;\n The LDH is 199.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 2:Mild complications that require some medication or treatment to control, and may have a slight impact on daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 31.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 27.5333 ### months." } ], "images": [ "DMFS_train_1281/0000312261_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 44.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 42.3000 g/L;\n The CRP is 19.0600 mg/L;\n The LDH is 200.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 20.9333 ### months." } ], "images": [ "DMFS_train_1281/0000307320_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 44.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 42.3000 g/L;\n The CRP is 19.0600 mg/L;\n The LDH is 200.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 20.9333 ### months." } ], "images": [ "DMFS_train_1281/0000307320_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 44.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 42.3000 g/L;\n The CRP is 19.0600 mg/L;\n The LDH is 200.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 20.9333 ### months." } ], "images": [ "DMFS_train_1281/0000307320_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 44.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 42.3000 g/L;\n The CRP is 19.0600 mg/L;\n The LDH is 200.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 20.9333 ### months." } ], "images": [ "DMFS_train_1281/0000307320_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 44.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 42.3000 g/L;\n The CRP is 19.0600 mg/L;\n The LDH is 200.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 20.9333 ### months." } ], "images": [ "DMFS_train_1281/0000307320_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 44.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 42.3000 g/L;\n The CRP is 19.0600 mg/L;\n The LDH is 200.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 20.9333 ### months." } ], "images": [ "DMFS_train_1281/0000307320_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 44.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 42.3000 g/L;\n The CRP is 19.0600 mg/L;\n The LDH is 200.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 3; \nThe Cumulative crisplatin dose is 240 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 54.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 20.9333 ### months." } ], "images": [ "DMFS_train_1281/0000307320_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 152.0000 g/L;\nThe ALB is 52.2000 g/L;\n The CRP is 0.5100 mg/L;\n The LDH is 169.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 5:More severe complications that require the patient to be hospitalized or undergo more frequent medical interventions.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 37.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.0333 ### months." } ], "images": [ "DMFS_train_1281/0000293387_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 152.0000 g/L;\nThe ALB is 52.2000 g/L;\n The CRP is 0.5100 mg/L;\n The LDH is 169.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 5:More severe complications that require the patient to be hospitalized or undergo more frequent medical interventions.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 37.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.0333 ### months." } ], "images": [ "DMFS_train_1281/0000293387_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 152.0000 g/L;\nThe ALB is 52.2000 g/L;\n The CRP is 0.5100 mg/L;\n The LDH is 169.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 5:More severe complications that require the patient to be hospitalized or undergo more frequent medical interventions.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 37.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.0333 ### months." } ], "images": [ "DMFS_train_1281/0000293387_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 152.0000 g/L;\nThe ALB is 52.2000 g/L;\n The CRP is 0.5100 mg/L;\n The LDH is 169.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 5:More severe complications that require the patient to be hospitalized or undergo more frequent medical interventions.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 37.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.0333 ### months." } ], "images": [ "DMFS_train_1281/0000293387_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 152.0000 g/L;\nThe ALB is 52.2000 g/L;\n The CRP is 0.5100 mg/L;\n The LDH is 169.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 5:More severe complications that require the patient to be hospitalized or undergo more frequent medical interventions.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 37.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.0333 ### months." } ], "images": [ "DMFS_train_1281/0000293387_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 152.0000 g/L;\nThe ALB is 52.2000 g/L;\n The CRP is 0.5100 mg/L;\n The LDH is 169.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 5:More severe complications that require the patient to be hospitalized or undergo more frequent medical interventions.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 37.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.0333 ### months." } ], "images": [ "DMFS_train_1281/0000293387_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 52 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 152.0000 g/L;\nThe ALB is 52.2000 g/L;\n The CRP is 0.5100 mg/L;\n The LDH is 169.1000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 5:More severe complications that require the patient to be hospitalized or undergo more frequent medical interventions.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 37.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.0333 ### months." } ], "images": [ "DMFS_train_1281/0000293387_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 415.0000 copies/mL;\nThe EBV of after treatment is 25.6000 copies/m; \nThe HGB is 172.0000 g/L;\nThe ALB is 39.5000 g/L;\n The CRP is 2.8900 mg/L;\n The LDH is 243.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 16.5333 ### months." } ], "images": [ "DMFS_train_1281/0000272021_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 415.0000 copies/mL;\nThe EBV of after treatment is 25.6000 copies/m; \nThe HGB is 172.0000 g/L;\nThe ALB is 39.5000 g/L;\n The CRP is 2.8900 mg/L;\n The LDH is 243.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 16.5333 ### months." } ], "images": [ "DMFS_train_1281/0000272021_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 415.0000 copies/mL;\nThe EBV of after treatment is 25.6000 copies/m; \nThe HGB is 172.0000 g/L;\nThe ALB is 39.5000 g/L;\n The CRP is 2.8900 mg/L;\n The LDH is 243.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 16.5333 ### months." } ], "images": [ "DMFS_train_1281/0000272021_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 415.0000 copies/mL;\nThe EBV of after treatment is 25.6000 copies/m; \nThe HGB is 172.0000 g/L;\nThe ALB is 39.5000 g/L;\n The CRP is 2.8900 mg/L;\n The LDH is 243.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 16.5333 ### months." } ], "images": [ "DMFS_train_1281/0000272021_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 415.0000 copies/mL;\nThe EBV of after treatment is 25.6000 copies/m; \nThe HGB is 172.0000 g/L;\nThe ALB is 39.5000 g/L;\n The CRP is 2.8900 mg/L;\n The LDH is 243.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 16.5333 ### months." } ], "images": [ "DMFS_train_1281/0000272021_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 415.0000 copies/mL;\nThe EBV of after treatment is 25.6000 copies/m; \nThe HGB is 172.0000 g/L;\nThe ALB is 39.5000 g/L;\n The CRP is 2.8900 mg/L;\n The LDH is 243.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 16.5333 ### months." } ], "images": [ "DMFS_train_1281/0000272021_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 415.0000 copies/mL;\nThe EBV of after treatment is 25.6000 copies/m; \nThe HGB is 172.0000 g/L;\nThe ALB is 39.5000 g/L;\n The CRP is 2.8900 mg/L;\n The LDH is 243.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 16.5333 ### months." } ], "images": [ "DMFS_train_1281/0000272021_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.4100 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 163.0000 g/L;\nThe ALB is 42.8000 g/L;\n The CRP is 0.5300 mg/L;\n The LDH is 162.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 140 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 2:Mild complications that require some medication or treatment to control, and may have a slight impact on daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.2667 ### months." } ], "images": [ "DMFS_train_1281/0000238087_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.4100 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 163.0000 g/L;\nThe ALB is 42.8000 g/L;\n The CRP is 0.5300 mg/L;\n The LDH is 162.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 140 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 2:Mild complications that require some medication or treatment to control, and may have a slight impact on daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.2667 ### months." } ], "images": [ "DMFS_train_1281/0000238087_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.4100 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 163.0000 g/L;\nThe ALB is 42.8000 g/L;\n The CRP is 0.5300 mg/L;\n The LDH is 162.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 140 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 2:Mild complications that require some medication or treatment to control, and may have a slight impact on daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.2667 ### months." } ], "images": [ "DMFS_train_1281/0000238087_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.4100 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 163.0000 g/L;\nThe ALB is 42.8000 g/L;\n The CRP is 0.5300 mg/L;\n The LDH is 162.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 140 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 2:Mild complications that require some medication or treatment to control, and may have a slight impact on daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.2667 ### months." } ], "images": [ "DMFS_train_1281/0000238087_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.4100 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 163.0000 g/L;\nThe ALB is 42.8000 g/L;\n The CRP is 0.5300 mg/L;\n The LDH is 162.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 140 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 2:Mild complications that require some medication or treatment to control, and may have a slight impact on daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.2667 ### months." } ], "images": [ "DMFS_train_1281/0000238087_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.4100 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 163.0000 g/L;\nThe ALB is 42.8000 g/L;\n The CRP is 0.5300 mg/L;\n The LDH is 162.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 140 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 2:Mild complications that require some medication or treatment to control, and may have a slight impact on daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.2667 ### months." } ], "images": [ "DMFS_train_1281/0000238087_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 54 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.4100 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 163.0000 g/L;\nThe ALB is 42.8000 g/L;\n The CRP is 0.5300 mg/L;\n The LDH is 162.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 140 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 2:Mild complications that require some medication or treatment to control, and may have a slight impact on daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.2667 ### months." } ], "images": [ "DMFS_train_1281/0000238087_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 20 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 39.7000 copies/mL;\nThe EBV of after treatment is 0.5950 copies/m; \nThe HGB is 149.0000 g/L;\nThe ALB is 46.2000 g/L;\n The CRP is 3.9600 mg/L;\n The LDH is 273.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 100 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 46.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 26.3333 ### months." } ], "images": [ "DMFS_train_1281/0000282281_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 20 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 39.7000 copies/mL;\nThe EBV of after treatment is 0.5950 copies/m; \nThe HGB is 149.0000 g/L;\nThe ALB is 46.2000 g/L;\n The CRP is 3.9600 mg/L;\n The LDH is 273.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 100 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 46.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 26.3333 ### months." } ], "images": [ "DMFS_train_1281/0000282281_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 20 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 39.7000 copies/mL;\nThe EBV of after treatment is 0.5950 copies/m; \nThe HGB is 149.0000 g/L;\nThe ALB is 46.2000 g/L;\n The CRP is 3.9600 mg/L;\n The LDH is 273.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 100 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 46.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 26.3333 ### months." } ], "images": [ "DMFS_train_1281/0000282281_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 20 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 39.7000 copies/mL;\nThe EBV of after treatment is 0.5950 copies/m; \nThe HGB is 149.0000 g/L;\nThe ALB is 46.2000 g/L;\n The CRP is 3.9600 mg/L;\n The LDH is 273.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 100 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 46.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 26.3333 ### months." } ], "images": [ "DMFS_train_1281/0000282281_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 20 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 39.7000 copies/mL;\nThe EBV of after treatment is 0.5950 copies/m; \nThe HGB is 149.0000 g/L;\nThe ALB is 46.2000 g/L;\n The CRP is 3.9600 mg/L;\n The LDH is 273.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 100 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 46.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 26.3333 ### months." } ], "images": [ "DMFS_train_1281/0000282281_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 20 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 39.7000 copies/mL;\nThe EBV of after treatment is 0.5950 copies/m; \nThe HGB is 149.0000 g/L;\nThe ALB is 46.2000 g/L;\n The CRP is 3.9600 mg/L;\n The LDH is 273.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 100 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 46.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 26.3333 ### months." } ], "images": [ "DMFS_train_1281/0000282281_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 20 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 39.7000 copies/mL;\nThe EBV of after treatment is 0.5950 copies/m; \nThe HGB is 149.0000 g/L;\nThe ALB is 46.2000 g/L;\n The CRP is 3.9600 mg/L;\n The LDH is 273.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 100 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 46.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 55.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 26.3333 ### months." } ], "images": [ "DMFS_train_1281/0000282281_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 695.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 169.0000 g/L;\nThe ALB is 47.0000 g/L;\n The CRP is 1.4500 mg/L;\n The LDH is 219.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 65.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 85.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 41.5000 ### months." } ], "images": [ "DMFS_train_1281/00C1075158_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 695.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 169.0000 g/L;\nThe ALB is 47.0000 g/L;\n The CRP is 1.4500 mg/L;\n The LDH is 219.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 65.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 85.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 41.5000 ### months." } ], "images": [ "DMFS_train_1281/00C1075158_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 695.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 169.0000 g/L;\nThe ALB is 47.0000 g/L;\n The CRP is 1.4500 mg/L;\n The LDH is 219.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 65.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 85.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 41.5000 ### months." } ], "images": [ "DMFS_train_1281/00C1075158_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 695.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 169.0000 g/L;\nThe ALB is 47.0000 g/L;\n The CRP is 1.4500 mg/L;\n The LDH is 219.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 65.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 85.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 41.5000 ### months." } ], "images": [ "DMFS_train_1281/00C1075158_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 695.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 169.0000 g/L;\nThe ALB is 47.0000 g/L;\n The CRP is 1.4500 mg/L;\n The LDH is 219.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 65.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 85.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 41.5000 ### months." } ], "images": [ "DMFS_train_1281/00C1075158_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 695.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 169.0000 g/L;\nThe ALB is 47.0000 g/L;\n The CRP is 1.4500 mg/L;\n The LDH is 219.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 65.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 85.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 41.5000 ### months." } ], "images": [ "DMFS_train_1281/00C1075158_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 695.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 169.0000 g/L;\nThe ALB is 47.0000 g/L;\n The CRP is 1.4500 mg/L;\n The LDH is 219.0000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 65.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 85.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 41.5000 ### months." } ], "images": [ "DMFS_train_1281/00C1075158_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 29.2000 copies/mL;\nThe EBV of after treatment is 47.9000 copies/m; \nThe HGB is 113.0000 g/L;\nThe ALB is 40.0000 g/L;\n The CRP is 1.8000 mg/L;\n The LDH is 151.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 4:Moderate complications that affect daily life, require medical intervention, and may lead to a decline in some aspects of self-care ability.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 38.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 71.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.8667 ### months." } ], "images": [ "DMFS_train_1281/0000249999_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 29.2000 copies/mL;\nThe EBV of after treatment is 47.9000 copies/m; \nThe HGB is 113.0000 g/L;\nThe ALB is 40.0000 g/L;\n The CRP is 1.8000 mg/L;\n The LDH is 151.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 4:Moderate complications that affect daily life, require medical intervention, and may lead to a decline in some aspects of self-care ability.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 38.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 71.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.8667 ### months." } ], "images": [ "DMFS_train_1281/0000249999_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 29.2000 copies/mL;\nThe EBV of after treatment is 47.9000 copies/m; \nThe HGB is 113.0000 g/L;\nThe ALB is 40.0000 g/L;\n The CRP is 1.8000 mg/L;\n The LDH is 151.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 4:Moderate complications that affect daily life, require medical intervention, and may lead to a decline in some aspects of self-care ability.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 38.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 71.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.8667 ### months." } ], "images": [ "DMFS_train_1281/0000249999_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 29.2000 copies/mL;\nThe EBV of after treatment is 47.9000 copies/m; \nThe HGB is 113.0000 g/L;\nThe ALB is 40.0000 g/L;\n The CRP is 1.8000 mg/L;\n The LDH is 151.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 4:Moderate complications that affect daily life, require medical intervention, and may lead to a decline in some aspects of self-care ability.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 38.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 71.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.8667 ### months." } ], "images": [ "DMFS_train_1281/0000249999_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 29.2000 copies/mL;\nThe EBV of after treatment is 47.9000 copies/m; \nThe HGB is 113.0000 g/L;\nThe ALB is 40.0000 g/L;\n The CRP is 1.8000 mg/L;\n The LDH is 151.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 4:Moderate complications that affect daily life, require medical intervention, and may lead to a decline in some aspects of self-care ability.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 38.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 71.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.8667 ### months." } ], "images": [ "DMFS_train_1281/0000249999_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 29.2000 copies/mL;\nThe EBV of after treatment is 47.9000 copies/m; \nThe HGB is 113.0000 g/L;\nThe ALB is 40.0000 g/L;\n The CRP is 1.8000 mg/L;\n The LDH is 151.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 4:Moderate complications that affect daily life, require medical intervention, and may lead to a decline in some aspects of self-care ability.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 38.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 71.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.8667 ### months." } ], "images": [ "DMFS_train_1281/0000249999_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 29.2000 copies/mL;\nThe EBV of after treatment is 47.9000 copies/m; \nThe HGB is 113.0000 g/L;\nThe ALB is 40.0000 g/L;\n The CRP is 1.8000 mg/L;\n The LDH is 151.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 4:Moderate complications that affect daily life, require medical intervention, and may lead to a decline in some aspects of self-care ability.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 38.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 71.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.8667 ### months." } ], "images": [ "DMFS_train_1281/0000249999_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 23.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 158.0000 g/L;\nThe ALB is 48.0000 g/L;\n The CRP is 2.5300 mg/L;\n The LDH is 194.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 6:More severe complications, where the health of patient is significantly affected and they may be unable to perform normal daily activities. Hospitalization or more frequent medical interventions are required.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.6333 ### months." } ], "images": [ "DMFS_train_1281/0000233512_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 23.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 158.0000 g/L;\nThe ALB is 48.0000 g/L;\n The CRP is 2.5300 mg/L;\n The LDH is 194.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 6:More severe complications, where the health of patient is significantly affected and they may be unable to perform normal daily activities. Hospitalization or more frequent medical interventions are required.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.6333 ### months." } ], "images": [ "DMFS_train_1281/0000233512_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 23.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 158.0000 g/L;\nThe ALB is 48.0000 g/L;\n The CRP is 2.5300 mg/L;\n The LDH is 194.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 6:More severe complications, where the health of patient is significantly affected and they may be unable to perform normal daily activities. Hospitalization or more frequent medical interventions are required.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.6333 ### months." } ], "images": [ "DMFS_train_1281/0000233512_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 23.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 158.0000 g/L;\nThe ALB is 48.0000 g/L;\n The CRP is 2.5300 mg/L;\n The LDH is 194.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 6:More severe complications, where the health of patient is significantly affected and they may be unable to perform normal daily activities. Hospitalization or more frequent medical interventions are required.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.6333 ### months." } ], "images": [ "DMFS_train_1281/0000233512_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 23.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 158.0000 g/L;\nThe ALB is 48.0000 g/L;\n The CRP is 2.5300 mg/L;\n The LDH is 194.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 6:More severe complications, where the health of patient is significantly affected and they may be unable to perform normal daily activities. Hospitalization or more frequent medical interventions are required.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.6333 ### months." } ], "images": [ "DMFS_train_1281/0000233512_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 23.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 158.0000 g/L;\nThe ALB is 48.0000 g/L;\n The CRP is 2.5300 mg/L;\n The LDH is 194.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 6:More severe complications, where the health of patient is significantly affected and they may be unable to perform normal daily activities. Hospitalization or more frequent medical interventions are required.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.6333 ### months." } ], "images": [ "DMFS_train_1281/0000233512_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 23.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 158.0000 g/L;\nThe ALB is 48.0000 g/L;\n The CRP is 2.5300 mg/L;\n The LDH is 194.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 6:More severe complications, where the health of patient is significantly affected and they may be unable to perform normal daily activities. Hospitalization or more frequent medical interventions are required.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.6333 ### months." } ], "images": [ "DMFS_train_1281/0000233512_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 11.5000 copies/mL;\nThe EBV of after treatment is 2.1900 copies/m; \nThe HGB is 96.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 0.2700 mg/L;\n The LDH is 213.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 16.3333 ### months." } ], "images": [ "DMFS_train_1281/0000264822_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 11.5000 copies/mL;\nThe EBV of after treatment is 2.1900 copies/m; \nThe HGB is 96.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 0.2700 mg/L;\n The LDH is 213.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 16.3333 ### months." } ], "images": [ "DMFS_train_1281/0000264822_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 11.5000 copies/mL;\nThe EBV of after treatment is 2.1900 copies/m; \nThe HGB is 96.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 0.2700 mg/L;\n The LDH is 213.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 16.3333 ### months." } ], "images": [ "DMFS_train_1281/0000264822_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 11.5000 copies/mL;\nThe EBV of after treatment is 2.1900 copies/m; \nThe HGB is 96.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 0.2700 mg/L;\n The LDH is 213.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 16.3333 ### months." } ], "images": [ "DMFS_train_1281/0000264822_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 11.5000 copies/mL;\nThe EBV of after treatment is 2.1900 copies/m; \nThe HGB is 96.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 0.2700 mg/L;\n The LDH is 213.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 16.3333 ### months." } ], "images": [ "DMFS_train_1281/0000264822_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 11.5000 copies/mL;\nThe EBV of after treatment is 2.1900 copies/m; \nThe HGB is 96.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 0.2700 mg/L;\n The LDH is 213.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 16.3333 ### months." } ], "images": [ "DMFS_train_1281/0000264822_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 45 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 11.5000 copies/mL;\nThe EBV of after treatment is 2.1900 copies/m; \nThe HGB is 96.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 0.2700 mg/L;\n The LDH is 213.2000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 16.3333 ### months." } ], "images": [ "DMFS_train_1281/0000264822_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.2220 copies/mL;\nThe EBV of after treatment is 1.0200 copies/m; \nThe HGB is 141.1000 g/L;\nThe ALB is 41.3000 g/L;\n The CRP is 1.9900 mg/L;\n The LDH is 158.8000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 39.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 53.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 17.4333 ### months." } ], "images": [ "DMFS_train_1281/0000302389_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.2220 copies/mL;\nThe EBV of after treatment is 1.0200 copies/m; \nThe HGB is 141.1000 g/L;\nThe ALB is 41.3000 g/L;\n The CRP is 1.9900 mg/L;\n The LDH is 158.8000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 39.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 53.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 17.4333 ### months." } ], "images": [ "DMFS_train_1281/0000302389_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.2220 copies/mL;\nThe EBV of after treatment is 1.0200 copies/m; \nThe HGB is 141.1000 g/L;\nThe ALB is 41.3000 g/L;\n The CRP is 1.9900 mg/L;\n The LDH is 158.8000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 39.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 53.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 17.4333 ### months." } ], "images": [ "DMFS_train_1281/0000302389_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.2220 copies/mL;\nThe EBV of after treatment is 1.0200 copies/m; \nThe HGB is 141.1000 g/L;\nThe ALB is 41.3000 g/L;\n The CRP is 1.9900 mg/L;\n The LDH is 158.8000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 39.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 53.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 17.4333 ### months." } ], "images": [ "DMFS_train_1281/0000302389_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.2220 copies/mL;\nThe EBV of after treatment is 1.0200 copies/m; \nThe HGB is 141.1000 g/L;\nThe ALB is 41.3000 g/L;\n The CRP is 1.9900 mg/L;\n The LDH is 158.8000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 39.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 53.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 17.4333 ### months." } ], "images": [ "DMFS_train_1281/0000302389_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.2220 copies/mL;\nThe EBV of after treatment is 1.0200 copies/m; \nThe HGB is 141.1000 g/L;\nThe ALB is 41.3000 g/L;\n The CRP is 1.9900 mg/L;\n The LDH is 158.8000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 39.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 53.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 17.4333 ### months." } ], "images": [ "DMFS_train_1281/0000302389_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 46 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.2220 copies/mL;\nThe EBV of after treatment is 1.0200 copies/m; \nThe HGB is 141.1000 g/L;\nThe ALB is 41.3000 g/L;\n The CRP is 1.9900 mg/L;\n The LDH is 158.8000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 39.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 53.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 17.4333 ### months." } ], "images": [ "DMFS_train_1281/0000302389_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 62.0000 copies/mL;\nThe EBV of after treatment is 1.9700 copies/m; \nThe HGB is 168.0000 g/L;\nThe ALB is 45.1000 g/L;\n The CRP is 0.5300 mg/L;\n The LDH is 171.6000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 70.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 90.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 18.5333 ### months." } ], "images": [ "DMFS_train_1281/0000343586_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 62.0000 copies/mL;\nThe EBV of after treatment is 1.9700 copies/m; \nThe HGB is 168.0000 g/L;\nThe ALB is 45.1000 g/L;\n The CRP is 0.5300 mg/L;\n The LDH is 171.6000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 70.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 90.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 18.5333 ### months." } ], "images": [ "DMFS_train_1281/0000343586_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 62.0000 copies/mL;\nThe EBV of after treatment is 1.9700 copies/m; \nThe HGB is 168.0000 g/L;\nThe ALB is 45.1000 g/L;\n The CRP is 0.5300 mg/L;\n The LDH is 171.6000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 70.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 90.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 18.5333 ### months." } ], "images": [ "DMFS_train_1281/0000343586_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 62.0000 copies/mL;\nThe EBV of after treatment is 1.9700 copies/m; \nThe HGB is 168.0000 g/L;\nThe ALB is 45.1000 g/L;\n The CRP is 0.5300 mg/L;\n The LDH is 171.6000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 70.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 90.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 18.5333 ### months." } ], "images": [ "DMFS_train_1281/0000343586_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 62.0000 copies/mL;\nThe EBV of after treatment is 1.9700 copies/m; \nThe HGB is 168.0000 g/L;\nThe ALB is 45.1000 g/L;\n The CRP is 0.5300 mg/L;\n The LDH is 171.6000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 70.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 90.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 18.5333 ### months." } ], "images": [ "DMFS_train_1281/0000343586_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 62.0000 copies/mL;\nThe EBV of after treatment is 1.9700 copies/m; \nThe HGB is 168.0000 g/L;\nThe ALB is 45.1000 g/L;\n The CRP is 0.5300 mg/L;\n The LDH is 171.6000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 70.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 90.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 18.5333 ### months." } ], "images": [ "DMFS_train_1281/0000343586_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 62.0000 copies/mL;\nThe EBV of after treatment is 1.9700 copies/m; \nThe HGB is 168.0000 g/L;\nThe ALB is 45.1000 g/L;\n The CRP is 0.5300 mg/L;\n The LDH is 171.6000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 70.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 90.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 18.5333 ### months." } ], "images": [ "DMFS_train_1281/0000343586_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.5400 copies/mL;\nThe EBV of after treatment is 0.1520 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 0.4200 mg/L;\n The LDH is 150.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 8:Extremely severe complications that may be life-threatening, with impaired function of multiple organ systems, requiring intensive care and emergency treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 31.2000 ### months." } ], "images": [ "DMFS_train_1281/0000288189_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.5400 copies/mL;\nThe EBV of after treatment is 0.1520 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 0.4200 mg/L;\n The LDH is 150.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 8:Extremely severe complications that may be life-threatening, with impaired function of multiple organ systems, requiring intensive care and emergency treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 31.2000 ### months." } ], "images": [ "DMFS_train_1281/0000288189_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.5400 copies/mL;\nThe EBV of after treatment is 0.1520 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 0.4200 mg/L;\n The LDH is 150.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 8:Extremely severe complications that may be life-threatening, with impaired function of multiple organ systems, requiring intensive care and emergency treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 31.2000 ### months." } ], "images": [ "DMFS_train_1281/0000288189_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.5400 copies/mL;\nThe EBV of after treatment is 0.1520 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 0.4200 mg/L;\n The LDH is 150.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 8:Extremely severe complications that may be life-threatening, with impaired function of multiple organ systems, requiring intensive care and emergency treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 31.2000 ### months." } ], "images": [ "DMFS_train_1281/0000288189_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.5400 copies/mL;\nThe EBV of after treatment is 0.1520 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 0.4200 mg/L;\n The LDH is 150.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 8:Extremely severe complications that may be life-threatening, with impaired function of multiple organ systems, requiring intensive care and emergency treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 31.2000 ### months." } ], "images": [ "DMFS_train_1281/0000288189_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.5400 copies/mL;\nThe EBV of after treatment is 0.1520 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 0.4200 mg/L;\n The LDH is 150.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 8:Extremely severe complications that may be life-threatening, with impaired function of multiple organ systems, requiring intensive care and emergency treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 31.2000 ### months." } ], "images": [ "DMFS_train_1281/0000288189_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.5400 copies/mL;\nThe EBV of after treatment is 0.1520 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 0.4200 mg/L;\n The LDH is 150.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 8:Extremely severe complications that may be life-threatening, with impaired function of multiple organ systems, requiring intensive care and emergency treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 31.2000 ### months." } ], "images": [ "DMFS_train_1281/0000288189_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 24 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 24.8000 copies/mL;\nThe EBV of after treatment is 0.0862 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 48.9000 g/L;\n The CRP is 0.6600 mg/L;\n The LDH is 191.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 63.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 16.4000 ### months." } ], "images": [ "DMFS_train_1281/0000287466_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 24 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 24.8000 copies/mL;\nThe EBV of after treatment is 0.0862 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 48.9000 g/L;\n The CRP is 0.6600 mg/L;\n The LDH is 191.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 63.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 16.4000 ### months." } ], "images": [ "DMFS_train_1281/0000287466_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 24 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 24.8000 copies/mL;\nThe EBV of after treatment is 0.0862 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 48.9000 g/L;\n The CRP is 0.6600 mg/L;\n The LDH is 191.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 63.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 16.4000 ### months." } ], "images": [ "DMFS_train_1281/0000287466_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 24 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 24.8000 copies/mL;\nThe EBV of after treatment is 0.0862 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 48.9000 g/L;\n The CRP is 0.6600 mg/L;\n The LDH is 191.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 63.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 16.4000 ### months." } ], "images": [ "DMFS_train_1281/0000287466_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 24 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 24.8000 copies/mL;\nThe EBV of after treatment is 0.0862 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 48.9000 g/L;\n The CRP is 0.6600 mg/L;\n The LDH is 191.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 63.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 16.4000 ### months." } ], "images": [ "DMFS_train_1281/0000287466_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 24 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 24.8000 copies/mL;\nThe EBV of after treatment is 0.0862 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 48.9000 g/L;\n The CRP is 0.6600 mg/L;\n The LDH is 191.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 63.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 16.4000 ### months." } ], "images": [ "DMFS_train_1281/0000287466_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 24 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 24.8000 copies/mL;\nThe EBV of after treatment is 0.0862 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 48.9000 g/L;\n The CRP is 0.6600 mg/L;\n The LDH is 191.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 63.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 16.4000 ### months." } ], "images": [ "DMFS_train_1281/0000287466_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 50 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 20.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 137.0000 g/L;\nThe ALB is 44.9000 g/L;\n The CRP is 2.0600 mg/L;\n The LDH is 160.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 14.0333 ### months." } ], "images": [ "DMFS_train_1281/0000269151_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 50 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 20.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 137.0000 g/L;\nThe ALB is 44.9000 g/L;\n The CRP is 2.0600 mg/L;\n The LDH is 160.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 14.0333 ### months." } ], "images": [ "DMFS_train_1281/0000269151_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 50 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 20.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 137.0000 g/L;\nThe ALB is 44.9000 g/L;\n The CRP is 2.0600 mg/L;\n The LDH is 160.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 14.0333 ### months." } ], "images": [ "DMFS_train_1281/0000269151_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 50 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 20.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 137.0000 g/L;\nThe ALB is 44.9000 g/L;\n The CRP is 2.0600 mg/L;\n The LDH is 160.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 14.0333 ### months." } ], "images": [ "DMFS_train_1281/0000269151_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 50 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 20.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 137.0000 g/L;\nThe ALB is 44.9000 g/L;\n The CRP is 2.0600 mg/L;\n The LDH is 160.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 14.0333 ### months." } ], "images": [ "DMFS_train_1281/0000269151_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 50 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 20.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 137.0000 g/L;\nThe ALB is 44.9000 g/L;\n The CRP is 2.0600 mg/L;\n The LDH is 160.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 14.0333 ### months." } ], "images": [ "DMFS_train_1281/0000269151_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 2:Low grade malignant whth proliferation and invasion ability;\nThe Age is 50 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 20.6000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 137.0000 g/L;\nThe ALB is 44.9000 g/L;\n The CRP is 2.0600 mg/L;\n The LDH is 160.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 14.0333 ### months." } ], "images": [ "DMFS_train_1281/0000269151_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 216.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 147.0000 g/L;\nThe ALB is 43.5000 g/L;\n The CRP is 6.4900 mg/L;\n The LDH is 359.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.4333 ### months." } ], "images": [ "DMFS_train_1281/0000238505_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 216.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 147.0000 g/L;\nThe ALB is 43.5000 g/L;\n The CRP is 6.4900 mg/L;\n The LDH is 359.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.4333 ### months." } ], "images": [ "DMFS_train_1281/0000238505_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 216.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 147.0000 g/L;\nThe ALB is 43.5000 g/L;\n The CRP is 6.4900 mg/L;\n The LDH is 359.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.4333 ### months." } ], "images": [ "DMFS_train_1281/0000238505_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 216.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 147.0000 g/L;\nThe ALB is 43.5000 g/L;\n The CRP is 6.4900 mg/L;\n The LDH is 359.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.4333 ### months." } ], "images": [ "DMFS_train_1281/0000238505_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 216.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 147.0000 g/L;\nThe ALB is 43.5000 g/L;\n The CRP is 6.4900 mg/L;\n The LDH is 359.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.4333 ### months." } ], "images": [ "DMFS_train_1281/0000238505_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 216.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 147.0000 g/L;\nThe ALB is 43.5000 g/L;\n The CRP is 6.4900 mg/L;\n The LDH is 359.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.4333 ### months." } ], "images": [ "DMFS_train_1281/0000238505_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 42 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 216.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 147.0000 g/L;\nThe ALB is 43.5000 g/L;\n The CRP is 6.4900 mg/L;\n The LDH is 359.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 49.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.4333 ### months." } ], "images": [ "DMFS_train_1281/0000238505_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.7500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 43.1000 g/L;\n The CRP is 0.5600 mg/L;\n The LDH is 369.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 7.5667 ### months." } ], "images": [ "DMFS_train_1281/0000263289_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.7500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 43.1000 g/L;\n The CRP is 0.5600 mg/L;\n The LDH is 369.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 7.5667 ### months." } ], "images": [ "DMFS_train_1281/0000263289_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.7500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 43.1000 g/L;\n The CRP is 0.5600 mg/L;\n The LDH is 369.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 7.5667 ### months." } ], "images": [ "DMFS_train_1281/0000263289_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.7500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 43.1000 g/L;\n The CRP is 0.5600 mg/L;\n The LDH is 369.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 7.5667 ### months." } ], "images": [ "DMFS_train_1281/0000263289_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.7500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 43.1000 g/L;\n The CRP is 0.5600 mg/L;\n The LDH is 369.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 7.5667 ### months." } ], "images": [ "DMFS_train_1281/0000263289_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.7500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 43.1000 g/L;\n The CRP is 0.5600 mg/L;\n The LDH is 369.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 7.5667 ### months." } ], "images": [ "DMFS_train_1281/0000263289_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.7500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 43.1000 g/L;\n The CRP is 0.5600 mg/L;\n The LDH is 369.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 56.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 7.5667 ### months." } ], "images": [ "DMFS_train_1281/0000263289_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 74.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 113.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 0.4600 mg/L;\n The LDH is 212.4000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 112.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 132.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.3333 ### months." } ], "images": [ "DMFS_train_1281/0000238035_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 74.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 113.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 0.4600 mg/L;\n The LDH is 212.4000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 112.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 132.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.3333 ### months." } ], "images": [ "DMFS_train_1281/0000238035_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 74.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 113.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 0.4600 mg/L;\n The LDH is 212.4000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 112.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 132.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.3333 ### months." } ], "images": [ "DMFS_train_1281/0000238035_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 74.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 113.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 0.4600 mg/L;\n The LDH is 212.4000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 112.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 132.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.3333 ### months." } ], "images": [ "DMFS_train_1281/0000238035_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 74.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 113.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 0.4600 mg/L;\n The LDH is 212.4000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 112.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 132.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.3333 ### months." } ], "images": [ "DMFS_train_1281/0000238035_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 74.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 113.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 0.4600 mg/L;\n The LDH is 212.4000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 112.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 132.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.3333 ### months." } ], "images": [ "DMFS_train_1281/0000238035_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 74.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 113.0000 g/L;\nThe ALB is 45.0000 g/L;\n The CRP is 0.4600 mg/L;\n The LDH is 212.4000 U/L; \nThe Number of course is 4;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 112.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 132.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 11.3333 ### months." } ], "images": [ "DMFS_train_1281/0000238035_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 70.2000 copies/mL;\nThe EBV of after treatment is 161.0000 copies/m; \nThe HGB is 155.0000 g/L;\nThe ALB is 46.7000 g/L;\n The CRP is 3.4800 mg/L;\n The LDH is 229.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 60 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Lobaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 19.5667 ### months." } ], "images": [ "DMFS_train_1281/0000257528_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 70.2000 copies/mL;\nThe EBV of after treatment is 161.0000 copies/m; \nThe HGB is 155.0000 g/L;\nThe ALB is 46.7000 g/L;\n The CRP is 3.4800 mg/L;\n The LDH is 229.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 60 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Lobaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 19.5667 ### months." } ], "images": [ "DMFS_train_1281/0000257528_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 70.2000 copies/mL;\nThe EBV of after treatment is 161.0000 copies/m; \nThe HGB is 155.0000 g/L;\nThe ALB is 46.7000 g/L;\n The CRP is 3.4800 mg/L;\n The LDH is 229.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 60 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Lobaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 19.5667 ### months." } ], "images": [ "DMFS_train_1281/0000257528_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 70.2000 copies/mL;\nThe EBV of after treatment is 161.0000 copies/m; \nThe HGB is 155.0000 g/L;\nThe ALB is 46.7000 g/L;\n The CRP is 3.4800 mg/L;\n The LDH is 229.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 60 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Lobaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 19.5667 ### months." } ], "images": [ "DMFS_train_1281/0000257528_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 70.2000 copies/mL;\nThe EBV of after treatment is 161.0000 copies/m; \nThe HGB is 155.0000 g/L;\nThe ALB is 46.7000 g/L;\n The CRP is 3.4800 mg/L;\n The LDH is 229.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 60 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Lobaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 19.5667 ### months." } ], "images": [ "DMFS_train_1281/0000257528_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 70.2000 copies/mL;\nThe EBV of after treatment is 161.0000 copies/m; \nThe HGB is 155.0000 g/L;\nThe ALB is 46.7000 g/L;\n The CRP is 3.4800 mg/L;\n The LDH is 229.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 60 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Lobaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 19.5667 ### months." } ], "images": [ "DMFS_train_1281/0000257528_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 70.2000 copies/mL;\nThe EBV of after treatment is 161.0000 copies/m; \nThe HGB is 155.0000 g/L;\nThe ALB is 46.7000 g/L;\n The CRP is 3.4800 mg/L;\n The LDH is 229.6000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 60 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Lobaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 35.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 42.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 19.5667 ### months." } ], "images": [ "DMFS_train_1281/0000257528_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 22 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2220.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 39.4000 g/L;\n The CRP is 9.6900 mg/L;\n The LDH is 357.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.1667 ### months." } ], "images": [ "DMFS_train_1281/0000259582_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 22 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2220.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 39.4000 g/L;\n The CRP is 9.6900 mg/L;\n The LDH is 357.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.1667 ### months." } ], "images": [ "DMFS_train_1281/0000259582_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 22 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2220.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 39.4000 g/L;\n The CRP is 9.6900 mg/L;\n The LDH is 357.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.1667 ### months." } ], "images": [ "DMFS_train_1281/0000259582_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 22 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2220.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 39.4000 g/L;\n The CRP is 9.6900 mg/L;\n The LDH is 357.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.1667 ### months." } ], "images": [ "DMFS_train_1281/0000259582_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 22 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2220.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 39.4000 g/L;\n The CRP is 9.6900 mg/L;\n The LDH is 357.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.1667 ### months." } ], "images": [ "DMFS_train_1281/0000259582_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 22 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2220.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 39.4000 g/L;\n The CRP is 9.6900 mg/L;\n The LDH is 357.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.1667 ### months." } ], "images": [ "DMFS_train_1281/0000259582_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 22 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 2220.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 135.0000 g/L;\nThe ALB is 39.4000 g/L;\n The CRP is 9.6900 mg/L;\n The LDH is 357.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.1667 ### months." } ], "images": [ "DMFS_train_1281/0000259582_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 93.9000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 42.9000 g/L;\n The CRP is 1.7600 mg/L;\n The LDH is 244.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 42.3333 ### months." } ], "images": [ "DMFS_train_1281/0000279540_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 93.9000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 42.9000 g/L;\n The CRP is 1.7600 mg/L;\n The LDH is 244.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 42.3333 ### months." } ], "images": [ "DMFS_train_1281/0000279540_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 93.9000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 42.9000 g/L;\n The CRP is 1.7600 mg/L;\n The LDH is 244.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 42.3333 ### months." } ], "images": [ "DMFS_train_1281/0000279540_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 93.9000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 42.9000 g/L;\n The CRP is 1.7600 mg/L;\n The LDH is 244.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 42.3333 ### months." } ], "images": [ "DMFS_train_1281/0000279540_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 93.9000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 42.9000 g/L;\n The CRP is 1.7600 mg/L;\n The LDH is 244.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 42.3333 ### months." } ], "images": [ "DMFS_train_1281/0000279540_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 93.9000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 42.9000 g/L;\n The CRP is 1.7600 mg/L;\n The LDH is 244.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 42.3333 ### months." } ], "images": [ "DMFS_train_1281/0000279540_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 93.9000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 148.0000 g/L;\nThe ALB is 42.9000 g/L;\n The CRP is 1.7600 mg/L;\n The LDH is 244.5000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 180 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 42.3333 ### months." } ], "images": [ "DMFS_train_1281/0000279540_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 14.7000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.4000 g/L;\nThe ALB is 47.1000 g/L;\n The CRP is 0.3800 mg/L;\n The LDH is 223.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 10.5333 ### months." } ], "images": [ "DMFS_train_1281/0000294160_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 14.7000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.4000 g/L;\nThe ALB is 47.1000 g/L;\n The CRP is 0.3800 mg/L;\n The LDH is 223.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 10.5333 ### months." } ], "images": [ "DMFS_train_1281/0000294160_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 14.7000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.4000 g/L;\nThe ALB is 47.1000 g/L;\n The CRP is 0.3800 mg/L;\n The LDH is 223.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 10.5333 ### months." } ], "images": [ "DMFS_train_1281/0000294160_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 14.7000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.4000 g/L;\nThe ALB is 47.1000 g/L;\n The CRP is 0.3800 mg/L;\n The LDH is 223.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 10.5333 ### months." } ], "images": [ "DMFS_train_1281/0000294160_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 14.7000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.4000 g/L;\nThe ALB is 47.1000 g/L;\n The CRP is 0.3800 mg/L;\n The LDH is 223.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 10.5333 ### months." } ], "images": [ "DMFS_train_1281/0000294160_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 14.7000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.4000 g/L;\nThe ALB is 47.1000 g/L;\n The CRP is 0.3800 mg/L;\n The LDH is 223.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 10.5333 ### months." } ], "images": [ "DMFS_train_1281/0000294160_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 33 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 14.7000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.4000 g/L;\nThe ALB is 47.1000 g/L;\n The CRP is 0.3800 mg/L;\n The LDH is 223.3000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 57.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 10.5333 ### months." } ], "images": [ "DMFS_train_1281/0000294160_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 22.9000 copies/mL;\nThe EBV of after treatment is 61.4000 copies/m; \nThe HGB is 140.0000 g/L;\nThe ALB is 43.2000 g/L;\n The CRP is 0.4400 mg/L;\n The LDH is 225.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 80.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 27.1667 ### months." } ], "images": [ "DMFS_train_1281/0000276422_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 22.9000 copies/mL;\nThe EBV of after treatment is 61.4000 copies/m; \nThe HGB is 140.0000 g/L;\nThe ALB is 43.2000 g/L;\n The CRP is 0.4400 mg/L;\n The LDH is 225.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 80.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 27.1667 ### months." } ], "images": [ "DMFS_train_1281/0000276422_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 22.9000 copies/mL;\nThe EBV of after treatment is 61.4000 copies/m; \nThe HGB is 140.0000 g/L;\nThe ALB is 43.2000 g/L;\n The CRP is 0.4400 mg/L;\n The LDH is 225.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 80.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 27.1667 ### months." } ], "images": [ "DMFS_train_1281/0000276422_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 22.9000 copies/mL;\nThe EBV of after treatment is 61.4000 copies/m; \nThe HGB is 140.0000 g/L;\nThe ALB is 43.2000 g/L;\n The CRP is 0.4400 mg/L;\n The LDH is 225.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 80.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 27.1667 ### months." } ], "images": [ "DMFS_train_1281/0000276422_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 22.9000 copies/mL;\nThe EBV of after treatment is 61.4000 copies/m; \nThe HGB is 140.0000 g/L;\nThe ALB is 43.2000 g/L;\n The CRP is 0.4400 mg/L;\n The LDH is 225.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 80.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 27.1667 ### months." } ], "images": [ "DMFS_train_1281/0000276422_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 22.9000 copies/mL;\nThe EBV of after treatment is 61.4000 copies/m; \nThe HGB is 140.0000 g/L;\nThe ALB is 43.2000 g/L;\n The CRP is 0.4400 mg/L;\n The LDH is 225.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 80.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 27.1667 ### months." } ], "images": [ "DMFS_train_1281/0000276422_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 56 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 22.9000 copies/mL;\nThe EBV of after treatment is 61.4000 copies/m; \nThe HGB is 140.0000 g/L;\nThe ALB is 43.2000 g/L;\n The CRP is 0.4400 mg/L;\n The LDH is 225.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 165 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 52.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 80.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 27.1667 ### months." } ], "images": [ "DMFS_train_1281/0000276422_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 71.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 0.9700 mg/L;\n The LDH is 177.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 27.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 13.7333 ### months." } ], "images": [ "DMFS_train_1281/0000234802_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 71.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 0.9700 mg/L;\n The LDH is 177.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 27.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 13.7333 ### months." } ], "images": [ "DMFS_train_1281/0000234802_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 71.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 0.9700 mg/L;\n The LDH is 177.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 27.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 13.7333 ### months." } ], "images": [ "DMFS_train_1281/0000234802_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 71.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 0.9700 mg/L;\n The LDH is 177.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 27.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 13.7333 ### months." } ], "images": [ "DMFS_train_1281/0000234802_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 71.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 0.9700 mg/L;\n The LDH is 177.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 27.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 13.7333 ### months." } ], "images": [ "DMFS_train_1281/0000234802_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 71.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 0.9700 mg/L;\n The LDH is 177.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 27.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 13.7333 ### months." } ], "images": [ "DMFS_train_1281/0000234802_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 71.1000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 44.8000 g/L;\n The CRP is 0.9700 mg/L;\n The LDH is 177.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 27.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 27.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 13.7333 ### months." } ], "images": [ "DMFS_train_1281/0000234802_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 16 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.1500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 110.3000 g/L;\nThe ALB is 39.7000 g/L;\n The CRP is 1.0000 mg/L;\n The LDH is 203.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 34.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 60.2667 ### months." } ], "images": [ "DMFS_train_1281/0000269109_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 16 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.1500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 110.3000 g/L;\nThe ALB is 39.7000 g/L;\n The CRP is 1.0000 mg/L;\n The LDH is 203.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 34.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 60.2667 ### months." } ], "images": [ "DMFS_train_1281/0000269109_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 16 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.1500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 110.3000 g/L;\nThe ALB is 39.7000 g/L;\n The CRP is 1.0000 mg/L;\n The LDH is 203.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 34.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 60.2667 ### months." } ], "images": [ "DMFS_train_1281/0000269109_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 16 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.1500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 110.3000 g/L;\nThe ALB is 39.7000 g/L;\n The CRP is 1.0000 mg/L;\n The LDH is 203.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 34.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 60.2667 ### months." } ], "images": [ "DMFS_train_1281/0000269109_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 16 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.1500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 110.3000 g/L;\nThe ALB is 39.7000 g/L;\n The CRP is 1.0000 mg/L;\n The LDH is 203.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 34.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 60.2667 ### months." } ], "images": [ "DMFS_train_1281/0000269109_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 16 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.1500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 110.3000 g/L;\nThe ALB is 39.7000 g/L;\n The CRP is 1.0000 mg/L;\n The LDH is 203.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 34.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 60.2667 ### months." } ], "images": [ "DMFS_train_1281/0000269109_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 16 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.1500 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 110.3000 g/L;\nThe ALB is 39.7000 g/L;\n The CRP is 1.0000 mg/L;\n The LDH is 203.9000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 28.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 34.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 60.2667 ### months." } ], "images": [ "DMFS_train_1281/0000269109_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 81.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 128.3000 g/L;\nThe ALB is 45.6000 g/L;\n The CRP is 1.9600 mg/L;\n The LDH is 166.0000 U/L; \nThe Number of course is 6;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 214.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 229.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.1000 ### months." } ], "images": [ "DMFS_train_1281/0000271157_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 81.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 128.3000 g/L;\nThe ALB is 45.6000 g/L;\n The CRP is 1.9600 mg/L;\n The LDH is 166.0000 U/L; \nThe Number of course is 6;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 214.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 229.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.1000 ### months." } ], "images": [ "DMFS_train_1281/0000271157_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 81.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 128.3000 g/L;\nThe ALB is 45.6000 g/L;\n The CRP is 1.9600 mg/L;\n The LDH is 166.0000 U/L; \nThe Number of course is 6;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 214.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 229.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.1000 ### months." } ], "images": [ "DMFS_train_1281/0000271157_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 81.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 128.3000 g/L;\nThe ALB is 45.6000 g/L;\n The CRP is 1.9600 mg/L;\n The LDH is 166.0000 U/L; \nThe Number of course is 6;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 214.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 229.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.1000 ### months." } ], "images": [ "DMFS_train_1281/0000271157_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 81.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 128.3000 g/L;\nThe ALB is 45.6000 g/L;\n The CRP is 1.9600 mg/L;\n The LDH is 166.0000 U/L; \nThe Number of course is 6;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 214.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 229.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.1000 ### months." } ], "images": [ "DMFS_train_1281/0000271157_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 81.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 128.3000 g/L;\nThe ALB is 45.6000 g/L;\n The CRP is 1.9600 mg/L;\n The LDH is 166.0000 U/L; \nThe Number of course is 6;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 214.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 229.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.1000 ### months." } ], "images": [ "DMFS_train_1281/0000271157_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 47 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 81.3000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 128.3000 g/L;\nThe ALB is 45.6000 g/L;\n The CRP is 1.9600 mg/L;\n The LDH is 166.0000 U/L; \nThe Number of course is 6;\n The Concurrent chemotherapy is None;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 0; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 214.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 229.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 9.1000 ### months." } ], "images": [ "DMFS_train_1281/0000271157_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 21 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 25.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 104.0000 g/L;\nThe ALB is 38.1000 g/L;\n The CRP is 54.3700 mg/L;\n The LDH is 197.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 519.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 28.0000 ### months." } ], "images": [ "DMFS_train_1281/0000322644_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 21 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 25.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 104.0000 g/L;\nThe ALB is 38.1000 g/L;\n The CRP is 54.3700 mg/L;\n The LDH is 197.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 519.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 28.0000 ### months." } ], "images": [ "DMFS_train_1281/0000322644_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 21 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 25.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 104.0000 g/L;\nThe ALB is 38.1000 g/L;\n The CRP is 54.3700 mg/L;\n The LDH is 197.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 519.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 28.0000 ### months." } ], "images": [ "DMFS_train_1281/0000322644_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 21 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 25.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 104.0000 g/L;\nThe ALB is 38.1000 g/L;\n The CRP is 54.3700 mg/L;\n The LDH is 197.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 519.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 28.0000 ### months." } ], "images": [ "DMFS_train_1281/0000322644_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 21 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 25.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 104.0000 g/L;\nThe ALB is 38.1000 g/L;\n The CRP is 54.3700 mg/L;\n The LDH is 197.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 519.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 28.0000 ### months." } ], "images": [ "DMFS_train_1281/0000322644_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 21 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 25.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 104.0000 g/L;\nThe ALB is 38.1000 g/L;\n The CRP is 54.3700 mg/L;\n The LDH is 197.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 519.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 28.0000 ### months." } ], "images": [ "DMFS_train_1281/0000322644_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 21 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 25.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 104.0000 g/L;\nThe ALB is 38.1000 g/L;\n The CRP is 54.3700 mg/L;\n The LDH is 197.2000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 48.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 519.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 28.0000 ### months." } ], "images": [ "DMFS_train_1281/0000322644_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 68 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 11.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.4000 g/L;\nThe ALB is 41.8000 g/L;\n The CRP is 4.7900 mg/L;\n The LDH is 183.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 185 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 36.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 74.7333 ### months." } ], "images": [ "DMFS_train_1281/0000230159_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 68 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 11.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.4000 g/L;\nThe ALB is 41.8000 g/L;\n The CRP is 4.7900 mg/L;\n The LDH is 183.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 185 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 36.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 74.7333 ### months." } ], "images": [ "DMFS_train_1281/0000230159_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 68 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 11.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.4000 g/L;\nThe ALB is 41.8000 g/L;\n The CRP is 4.7900 mg/L;\n The LDH is 183.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 185 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 36.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 74.7333 ### months." } ], "images": [ "DMFS_train_1281/0000230159_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 68 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 11.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.4000 g/L;\nThe ALB is 41.8000 g/L;\n The CRP is 4.7900 mg/L;\n The LDH is 183.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 185 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 36.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 74.7333 ### months." } ], "images": [ "DMFS_train_1281/0000230159_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 68 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 11.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.4000 g/L;\nThe ALB is 41.8000 g/L;\n The CRP is 4.7900 mg/L;\n The LDH is 183.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 185 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 36.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 74.7333 ### months." } ], "images": [ "DMFS_train_1281/0000230159_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 68 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 11.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.4000 g/L;\nThe ALB is 41.8000 g/L;\n The CRP is 4.7900 mg/L;\n The LDH is 183.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 185 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 36.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 74.7333 ### months." } ], "images": [ "DMFS_train_1281/0000230159_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 68 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 11.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 141.4000 g/L;\nThe ALB is 41.8000 g/L;\n The CRP is 4.7900 mg/L;\n The LDH is 183.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 185 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is None; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 36.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 36.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 74.7333 ### months." } ], "images": [ "DMFS_train_1281/0000230159_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 336.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 17.0000 mg/L;\n The LDH is 256.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.1667 ### months." } ], "images": [ "DMFS_train_1281/0000246867_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 336.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 17.0000 mg/L;\n The LDH is 256.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.1667 ### months." } ], "images": [ "DMFS_train_1281/0000246867_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 336.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 17.0000 mg/L;\n The LDH is 256.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.1667 ### months." } ], "images": [ "DMFS_train_1281/0000246867_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 336.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 17.0000 mg/L;\n The LDH is 256.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.1667 ### months." } ], "images": [ "DMFS_train_1281/0000246867_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 336.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 17.0000 mg/L;\n The LDH is 256.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.1667 ### months." } ], "images": [ "DMFS_train_1281/0000246867_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 336.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 17.0000 mg/L;\n The LDH is 256.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.1667 ### months." } ], "images": [ "DMFS_train_1281/0000246867_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 336.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 134.0000 g/L;\nThe ALB is 44.0000 g/L;\n The CRP is 17.0000 mg/L;\n The LDH is 256.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 5; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 59.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.1667 ### months." } ], "images": [ "DMFS_train_1281/0000246867_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1160.0000 copies/mL;\nThe EBV of after treatment is 0.1240 copies/m; \nThe HGB is 116.9000 g/L;\nThe ALB is 32.7000 g/L;\n The CRP is 6.0600 mg/L;\n The LDH is 627.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 60.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 90.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.3667 ### months." } ], "images": [ "DMFS_train_1281/0000284028_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1160.0000 copies/mL;\nThe EBV of after treatment is 0.1240 copies/m; \nThe HGB is 116.9000 g/L;\nThe ALB is 32.7000 g/L;\n The CRP is 6.0600 mg/L;\n The LDH is 627.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 60.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 90.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.3667 ### months." } ], "images": [ "DMFS_train_1281/0000284028_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1160.0000 copies/mL;\nThe EBV of after treatment is 0.1240 copies/m; \nThe HGB is 116.9000 g/L;\nThe ALB is 32.7000 g/L;\n The CRP is 6.0600 mg/L;\n The LDH is 627.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 60.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 90.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.3667 ### months." } ], "images": [ "DMFS_train_1281/0000284028_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1160.0000 copies/mL;\nThe EBV of after treatment is 0.1240 copies/m; \nThe HGB is 116.9000 g/L;\nThe ALB is 32.7000 g/L;\n The CRP is 6.0600 mg/L;\n The LDH is 627.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 60.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 90.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.3667 ### months." } ], "images": [ "DMFS_train_1281/0000284028_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1160.0000 copies/mL;\nThe EBV of after treatment is 0.1240 copies/m; \nThe HGB is 116.9000 g/L;\nThe ALB is 32.7000 g/L;\n The CRP is 6.0600 mg/L;\n The LDH is 627.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 60.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 90.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.3667 ### months." } ], "images": [ "DMFS_train_1281/0000284028_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1160.0000 copies/mL;\nThe EBV of after treatment is 0.1240 copies/m; \nThe HGB is 116.9000 g/L;\nThe ALB is 32.7000 g/L;\n The CRP is 6.0600 mg/L;\n The LDH is 627.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 60.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 90.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.3667 ### months." } ], "images": [ "DMFS_train_1281/0000284028_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1160.0000 copies/mL;\nThe EBV of after treatment is 0.1240 copies/m; \nThe HGB is 116.9000 g/L;\nThe ALB is 32.7000 g/L;\n The CRP is 6.0600 mg/L;\n The LDH is 627.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 1; \nThe Cumulative crisplatin dose is 80 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 60.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 90.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 8.3667 ### months." } ], "images": [ "DMFS_train_1281/0000284028_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 45.8000 copies/mL;\nThe EBV of after treatment is 3.3000 copies/m; \nThe HGB is 142.7000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 3.0600 mg/L;\n The LDH is 254.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Sunitinib/ Nivolumab;\n The time interval between induction chemotherapy and post-treatment imaging is 40.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 60.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 7.3667 ### months." } ], "images": [ "DMFS_train_1281/0000292626_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 45.8000 copies/mL;\nThe EBV of after treatment is 3.3000 copies/m; \nThe HGB is 142.7000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 3.0600 mg/L;\n The LDH is 254.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Sunitinib/ Nivolumab;\n The time interval between induction chemotherapy and post-treatment imaging is 40.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 60.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 7.3667 ### months." } ], "images": [ "DMFS_train_1281/0000292626_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 45.8000 copies/mL;\nThe EBV of after treatment is 3.3000 copies/m; \nThe HGB is 142.7000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 3.0600 mg/L;\n The LDH is 254.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Sunitinib/ Nivolumab;\n The time interval between induction chemotherapy and post-treatment imaging is 40.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 60.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 7.3667 ### months." } ], "images": [ "DMFS_train_1281/0000292626_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 45.8000 copies/mL;\nThe EBV of after treatment is 3.3000 copies/m; \nThe HGB is 142.7000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 3.0600 mg/L;\n The LDH is 254.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Sunitinib/ Nivolumab;\n The time interval between induction chemotherapy and post-treatment imaging is 40.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 60.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 7.3667 ### months." } ], "images": [ "DMFS_train_1281/0000292626_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 45.8000 copies/mL;\nThe EBV of after treatment is 3.3000 copies/m; \nThe HGB is 142.7000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 3.0600 mg/L;\n The LDH is 254.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Sunitinib/ Nivolumab;\n The time interval between induction chemotherapy and post-treatment imaging is 40.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 60.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 7.3667 ### months." } ], "images": [ "DMFS_train_1281/0000292626_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 45.8000 copies/mL;\nThe EBV of after treatment is 3.3000 copies/m; \nThe HGB is 142.7000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 3.0600 mg/L;\n The LDH is 254.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Sunitinib/ Nivolumab;\n The time interval between induction chemotherapy and post-treatment imaging is 40.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 60.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 7.3667 ### months." } ], "images": [ "DMFS_train_1281/0000292626_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 58 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T2:The tumor diameter is greater than 3 cm but less than or equal to 7 cm, or it invades the lung lobe without involving adjacent structures.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 45.8000 copies/mL;\nThe EBV of after treatment is 3.3000 copies/m; \nThe HGB is 142.7000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 3.0600 mg/L;\n The LDH is 254.8000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is None; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 0 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Sunitinib/ Nivolumab;\n The time interval between induction chemotherapy and post-treatment imaging is 40.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 60.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 7.3667 ### months." } ], "images": [ "DMFS_train_1281/0000292626_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 2.3500 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 3.0900 mg/L;\n The LDH is 166.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 155 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 51.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 51.5000 ### months." } ], "images": [ "DMFS_train_1281/0000239925_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 2.3500 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 3.0900 mg/L;\n The LDH is 166.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 155 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 51.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 51.5000 ### months." } ], "images": [ "DMFS_train_1281/0000239925_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 2.3500 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 3.0900 mg/L;\n The LDH is 166.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 155 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 51.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 51.5000 ### months." } ], "images": [ "DMFS_train_1281/0000239925_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 2.3500 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 3.0900 mg/L;\n The LDH is 166.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 155 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 51.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 51.5000 ### months." } ], "images": [ "DMFS_train_1281/0000239925_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 2.3500 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 3.0900 mg/L;\n The LDH is 166.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 155 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 51.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 51.5000 ### months." } ], "images": [ "DMFS_train_1281/0000239925_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 2.3500 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 3.0900 mg/L;\n The LDH is 166.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 155 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 51.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 51.5000 ### months." } ], "images": [ "DMFS_train_1281/0000239925_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Non-smoking;The Drinke is Drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 2.3500 copies/m; \nThe HGB is 145.0000 g/L;\nThe ALB is 43.8000 g/L;\n The CRP is 3.0900 mg/L;\n The LDH is 166.4000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 155 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 1:Mild complications that may not require treatment or medical intervention. These complications usually do not affect daily activities.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 34.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 51.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 51.5000 ### months." } ], "images": [ "DMFS_train_1281/0000239925_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 170.0000 copies/mL;\nThe EBV of after treatment is 5.2500 copies/m; \nThe HGB is 160.0000 g/L;\nThe ALB is 46.8000 g/L;\n The CRP is 0.8900 mg/L;\n The LDH is 181.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 36.5000 ### months." } ], "images": [ "DMFS_train_1281/0000271216_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 170.0000 copies/mL;\nThe EBV of after treatment is 5.2500 copies/m; \nThe HGB is 160.0000 g/L;\nThe ALB is 46.8000 g/L;\n The CRP is 0.8900 mg/L;\n The LDH is 181.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 36.5000 ### months." } ], "images": [ "DMFS_train_1281/0000271216_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 170.0000 copies/mL;\nThe EBV of after treatment is 5.2500 copies/m; \nThe HGB is 160.0000 g/L;\nThe ALB is 46.8000 g/L;\n The CRP is 0.8900 mg/L;\n The LDH is 181.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 36.5000 ### months." } ], "images": [ "DMFS_train_1281/0000271216_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 170.0000 copies/mL;\nThe EBV of after treatment is 5.2500 copies/m; \nThe HGB is 160.0000 g/L;\nThe ALB is 46.8000 g/L;\n The CRP is 0.8900 mg/L;\n The LDH is 181.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 36.5000 ### months." } ], "images": [ "DMFS_train_1281/0000271216_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 170.0000 copies/mL;\nThe EBV of after treatment is 5.2500 copies/m; \nThe HGB is 160.0000 g/L;\nThe ALB is 46.8000 g/L;\n The CRP is 0.8900 mg/L;\n The LDH is 181.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 36.5000 ### months." } ], "images": [ "DMFS_train_1281/0000271216_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 170.0000 copies/mL;\nThe EBV of after treatment is 5.2500 copies/m; \nThe HGB is 160.0000 g/L;\nThe ALB is 46.8000 g/L;\n The CRP is 0.8900 mg/L;\n The LDH is 181.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 36.5000 ### months." } ], "images": [ "DMFS_train_1281/0000271216_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 37 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 170.0000 copies/mL;\nThe EBV of after treatment is 5.2500 copies/m; \nThe HGB is 160.0000 g/L;\nThe ALB is 46.8000 g/L;\n The CRP is 0.8900 mg/L;\n The LDH is 181.4000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 70.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 36.5000 ### months." } ], "images": [ "DMFS_train_1281/0000271216_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 62.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.0000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 12.2000 mg/L;\n The LDH is 195.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 33.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 21.4667 ### months." } ], "images": [ "DMFS_train_1281/0000249641_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 62.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.0000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 12.2000 mg/L;\n The LDH is 195.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 33.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 21.4667 ### months." } ], "images": [ "DMFS_train_1281/0000249641_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 62.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.0000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 12.2000 mg/L;\n The LDH is 195.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 33.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 21.4667 ### months." } ], "images": [ "DMFS_train_1281/0000249641_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 62.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.0000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 12.2000 mg/L;\n The LDH is 195.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 33.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 21.4667 ### months." } ], "images": [ "DMFS_train_1281/0000249641_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 62.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.0000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 12.2000 mg/L;\n The LDH is 195.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 33.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 21.4667 ### months." } ], "images": [ "DMFS_train_1281/0000249641_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 62.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.0000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 12.2000 mg/L;\n The LDH is 195.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 33.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 21.4667 ### months." } ], "images": [ "DMFS_train_1281/0000249641_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is female;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 43 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 62.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 132.0000 g/L;\nThe ALB is 41.0000 g/L;\n The CRP is 12.2000 mg/L;\n The LDH is 195.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 4; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 33.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 43.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 21.4667 ### months." } ], "images": [ "DMFS_train_1281/0000249641_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 15.2000 copies/mL;\nThe EBV of after treatment is 0.6020 copies/m; \nThe HGB is 155.5000 g/L;\nThe ALB is 39.7000 g/L;\n The CRP is 3.1000 mg/L;\n The LDH is 207.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 51.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 3.5667 ### months." } ], "images": [ "DMFS_train_1281/0000292857_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 15.2000 copies/mL;\nThe EBV of after treatment is 0.6020 copies/m; \nThe HGB is 155.5000 g/L;\nThe ALB is 39.7000 g/L;\n The CRP is 3.1000 mg/L;\n The LDH is 207.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 51.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 3.5667 ### months." } ], "images": [ "DMFS_train_1281/0000292857_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 15.2000 copies/mL;\nThe EBV of after treatment is 0.6020 copies/m; \nThe HGB is 155.5000 g/L;\nThe ALB is 39.7000 g/L;\n The CRP is 3.1000 mg/L;\n The LDH is 207.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 51.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 3.5667 ### months." } ], "images": [ "DMFS_train_1281/0000292857_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 15.2000 copies/mL;\nThe EBV of after treatment is 0.6020 copies/m; \nThe HGB is 155.5000 g/L;\nThe ALB is 39.7000 g/L;\n The CRP is 3.1000 mg/L;\n The LDH is 207.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 51.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 3.5667 ### months." } ], "images": [ "DMFS_train_1281/0000292857_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 15.2000 copies/mL;\nThe EBV of after treatment is 0.6020 copies/m; \nThe HGB is 155.5000 g/L;\nThe ALB is 39.7000 g/L;\n The CRP is 3.1000 mg/L;\n The LDH is 207.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 51.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 3.5667 ### months." } ], "images": [ "DMFS_train_1281/0000292857_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 15.2000 copies/mL;\nThe EBV of after treatment is 0.6020 copies/m; \nThe HGB is 155.5000 g/L;\nThe ALB is 39.7000 g/L;\n The CRP is 3.1000 mg/L;\n The LDH is 207.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 51.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 3.5667 ### months." } ], "images": [ "DMFS_train_1281/0000292857_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 51 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 15.2000 copies/mL;\nThe EBV of after treatment is 0.6020 copies/m; \nThe HGB is 155.5000 g/L;\nThe ALB is 39.7000 g/L;\n The CRP is 3.1000 mg/L;\n The LDH is 207.7000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 32.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 51.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 3.5667 ### months." } ], "images": [ "DMFS_train_1281/0000292857_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1740.0000 copies/mL;\nThe EBV of after treatment is 19.8000 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 43.2000 g/L;\n The CRP is 4.7200 mg/L;\n The LDH is 304.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 65.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.4333 ### months." } ], "images": [ "DMFS_train_1281/0000232635_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1740.0000 copies/mL;\nThe EBV of after treatment is 19.8000 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 43.2000 g/L;\n The CRP is 4.7200 mg/L;\n The LDH is 304.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 65.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.4333 ### months." } ], "images": [ "DMFS_train_1281/0000232635_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1740.0000 copies/mL;\nThe EBV of after treatment is 19.8000 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 43.2000 g/L;\n The CRP is 4.7200 mg/L;\n The LDH is 304.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 65.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.4333 ### months." } ], "images": [ "DMFS_train_1281/0000232635_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1740.0000 copies/mL;\nThe EBV of after treatment is 19.8000 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 43.2000 g/L;\n The CRP is 4.7200 mg/L;\n The LDH is 304.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 65.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.4333 ### months." } ], "images": [ "DMFS_train_1281/0000232635_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1740.0000 copies/mL;\nThe EBV of after treatment is 19.8000 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 43.2000 g/L;\n The CRP is 4.7200 mg/L;\n The LDH is 304.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 65.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.4333 ### months." } ], "images": [ "DMFS_train_1281/0000232635_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1740.0000 copies/mL;\nThe EBV of after treatment is 19.8000 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 43.2000 g/L;\n The CRP is 4.7200 mg/L;\n The LDH is 304.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 65.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.4333 ### months." } ], "images": [ "DMFS_train_1281/0000232635_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 48 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N3:Lymph node metastasis or fusion of lymph nodes into masses, possibly reaching the contralateral lymph nodes or distant lymph node metastasis.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1740.0000 copies/mL;\nThe EBV of after treatment is 19.8000 copies/m; \nThe HGB is 157.0000 g/L;\nThe ALB is 43.2000 g/L;\n The CRP is 4.7200 mg/L;\n The LDH is 304.5000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 50.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 65.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 24.4333 ### months." } ], "images": [ "DMFS_train_1281/0000232635_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 55 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.5700 copies/mL;\nThe EBV of after treatment is 0.2970 copies/m; \nThe HGB is 146.0000 g/L;\nThe ALB is 40.4000 g/L;\n The CRP is 2.6200 mg/L;\n The LDH is 197.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 82.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 33.2667 ### months." } ], "images": [ "DMFS_train_1281/0000297982_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 55 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.5700 copies/mL;\nThe EBV of after treatment is 0.2970 copies/m; \nThe HGB is 146.0000 g/L;\nThe ALB is 40.4000 g/L;\n The CRP is 2.6200 mg/L;\n The LDH is 197.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 82.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 33.2667 ### months." } ], "images": [ "DMFS_train_1281/0000297982_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 55 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.5700 copies/mL;\nThe EBV of after treatment is 0.2970 copies/m; \nThe HGB is 146.0000 g/L;\nThe ALB is 40.4000 g/L;\n The CRP is 2.6200 mg/L;\n The LDH is 197.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 82.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 33.2667 ### months." } ], "images": [ "DMFS_train_1281/0000297982_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 55 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.5700 copies/mL;\nThe EBV of after treatment is 0.2970 copies/m; \nThe HGB is 146.0000 g/L;\nThe ALB is 40.4000 g/L;\n The CRP is 2.6200 mg/L;\n The LDH is 197.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 82.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 33.2667 ### months." } ], "images": [ "DMFS_train_1281/0000297982_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 55 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.5700 copies/mL;\nThe EBV of after treatment is 0.2970 copies/m; \nThe HGB is 146.0000 g/L;\nThe ALB is 40.4000 g/L;\n The CRP is 2.6200 mg/L;\n The LDH is 197.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 82.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 33.2667 ### months." } ], "images": [ "DMFS_train_1281/0000297982_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 55 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.5700 copies/mL;\nThe EBV of after treatment is 0.2970 copies/m; \nThe HGB is 146.0000 g/L;\nThe ALB is 40.4000 g/L;\n The CRP is 2.6200 mg/L;\n The LDH is 197.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 82.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 33.2667 ### months." } ], "images": [ "DMFS_train_1281/0000297982_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 55 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T1:The tumor diameter is less than or equal to 3 cm, and is confined to the lung tissue.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 4.5700 copies/mL;\nThe EBV of after treatment is 0.2970 copies/m; \nThe HGB is 146.0000 g/L;\nThe ALB is 40.4000 g/L;\n The CRP is 2.6200 mg/L;\n The LDH is 197.6000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 200 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 82.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 33.2667 ### months." } ], "images": [ "DMFS_train_1281/0000297982_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 31 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.2700 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 0.2000 mg/L;\n The LDH is 170.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 175 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 5:More severe complications that require the patient to be hospitalized or undergo more frequent medical interventions.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 29.8000 ### months." } ], "images": [ "DMFS_train_1281/0000249885_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 31 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.2700 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 0.2000 mg/L;\n The LDH is 170.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 175 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 5:More severe complications that require the patient to be hospitalized or undergo more frequent medical interventions.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 29.8000 ### months." } ], "images": [ "DMFS_train_1281/0000249885_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 31 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.2700 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 0.2000 mg/L;\n The LDH is 170.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 175 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 5:More severe complications that require the patient to be hospitalized or undergo more frequent medical interventions.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 29.8000 ### months." } ], "images": [ "DMFS_train_1281/0000249885_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 31 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.2700 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 0.2000 mg/L;\n The LDH is 170.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 175 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 5:More severe complications that require the patient to be hospitalized or undergo more frequent medical interventions.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 29.8000 ### months." } ], "images": [ "DMFS_train_1281/0000249885_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 31 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.2700 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 0.2000 mg/L;\n The LDH is 170.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 175 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 5:More severe complications that require the patient to be hospitalized or undergo more frequent medical interventions.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 29.8000 ### months." } ], "images": [ "DMFS_train_1281/0000249885_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 31 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.2700 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 0.2000 mg/L;\n The LDH is 170.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 175 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 5:More severe complications that require the patient to be hospitalized or undergo more frequent medical interventions.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 29.8000 ### months." } ], "images": [ "DMFS_train_1281/0000249885_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 31 years;\nThe Smoke is Non-smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N1:A small number of lymph node metastases, possibly located around the tumor.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1.2700 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 151.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 0.2000 mg/L;\n The LDH is 170.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 175 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 5:More severe complications that require the patient to be hospitalized or undergo more frequent medical interventions.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 64.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 29.8000 ### months." } ], "images": [ "DMFS_train_1281/0000249885_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 37.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 31.3000 mg/L;\n The LDH is 218.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 145 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.2000 ### months." } ], "images": [ "DMFS_train_1281/0000251188_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 37.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 31.3000 mg/L;\n The LDH is 218.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 145 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.2000 ### months." } ], "images": [ "DMFS_train_1281/0000251188_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 37.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 31.3000 mg/L;\n The LDH is 218.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 145 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.2000 ### months." } ], "images": [ "DMFS_train_1281/0000251188_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 37.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 31.3000 mg/L;\n The LDH is 218.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 145 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.2000 ### months." } ], "images": [ "DMFS_train_1281/0000251188_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 37.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 31.3000 mg/L;\n The LDH is 218.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 145 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.2000 ### months." } ], "images": [ "DMFS_train_1281/0000251188_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 37.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 31.3000 mg/L;\n The LDH is 218.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 145 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.2000 ### months." } ], "images": [ "DMFS_train_1281/0000251188_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 35 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 37.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 153.0000 g/L;\nThe ALB is 46.0000 g/L;\n The CRP is 31.3000 mg/L;\n The LDH is 218.0000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 145 mg/m² ; \nThe Supplementary course is Yes; \nThe Targeted therapy is None; \nThe Complication is 3:Moderate complications, where the patient can manage daily activities but may be affected in certain tasks or require regular treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 29.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 50.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.2000 ### months." } ], "images": [ "DMFS_train_1281/0000251188_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 55 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 10.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 120.8000 g/L;\nThe ALB is 35.0000 g/L;\n The CRP is 3.2300 mg/L;\n The LDH is 173.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 309.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.7667 ### months." } ], "images": [ "DMFS_train_1281/0000298175_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 55 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 10.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 120.8000 g/L;\nThe ALB is 35.0000 g/L;\n The CRP is 3.2300 mg/L;\n The LDH is 173.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 309.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.7667 ### months." } ], "images": [ "DMFS_train_1281/0000298175_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 55 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 10.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 120.8000 g/L;\nThe ALB is 35.0000 g/L;\n The CRP is 3.2300 mg/L;\n The LDH is 173.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 309.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.7667 ### months." } ], "images": [ "DMFS_train_1281/0000298175_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 55 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 10.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 120.8000 g/L;\nThe ALB is 35.0000 g/L;\n The CRP is 3.2300 mg/L;\n The LDH is 173.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 309.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.7667 ### months." } ], "images": [ "DMFS_train_1281/0000298175_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 55 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 10.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 120.8000 g/L;\nThe ALB is 35.0000 g/L;\n The CRP is 3.2300 mg/L;\n The LDH is 173.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 309.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.7667 ### months." } ], "images": [ "DMFS_train_1281/0000298175_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 55 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 10.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 120.8000 g/L;\nThe ALB is 35.0000 g/L;\n The CRP is 3.2300 mg/L;\n The LDH is 173.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 309.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.7667 ### months." } ], "images": [ "DMFS_train_1281/0000298175_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 55 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 10.8000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 120.8000 g/L;\nThe ALB is 35.0000 g/L;\n The CRP is 3.2300 mg/L;\n The LDH is 173.9000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is Yes; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is None;\n The time interval between induction chemotherapy and post-treatment imaging is 54.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 309.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 15.7667 ### months." } ], "images": [ "DMFS_train_1281/0000298175_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1360.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 39.8000 g/L;\n The CRP is 6.1800 mg/L;\n The LDH is 254.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.3333 ### months." } ], "images": [ "DMFS_train_1281/0000293099_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1360.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 39.8000 g/L;\n The CRP is 6.1800 mg/L;\n The LDH is 254.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.3333 ### months." } ], "images": [ "DMFS_train_1281/0000293099_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1360.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 39.8000 g/L;\n The CRP is 6.1800 mg/L;\n The LDH is 254.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.3333 ### months." } ], "images": [ "DMFS_train_1281/0000293099_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1360.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 39.8000 g/L;\n The CRP is 6.1800 mg/L;\n The LDH is 254.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.3333 ### months." } ], "images": [ "DMFS_train_1281/0000293099_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1360.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 39.8000 g/L;\n The CRP is 6.1800 mg/L;\n The LDH is 254.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.3333 ### months." } ], "images": [ "DMFS_train_1281/0000293099_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1360.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 39.8000 g/L;\n The CRP is 6.1800 mg/L;\n The LDH is 254.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.3333 ### months." } ], "images": [ "DMFS_train_1281/0000293099_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 44 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 1360.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 143.0000 g/L;\nThe ALB is 39.8000 g/L;\n The CRP is 6.1800 mg/L;\n The LDH is 254.3000 U/L; \nThe Number of course is 2;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 160 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 30.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 35.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 6.3333 ### months." } ], "images": [ "DMFS_train_1281/0000293099_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 63.3000 copies/mL;\nThe EBV of after treatment is 4.7800 copies/m; \nThe HGB is 148.9000 g/L;\nThe ALB is 45.4000 g/L;\n The CRP is 7.6800 mg/L;\n The LDH is 227.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 10.9000 ### months." } ], "images": [ "DMFS_train_1281/0000267484_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 63.3000 copies/mL;\nThe EBV of after treatment is 4.7800 copies/m; \nThe HGB is 148.9000 g/L;\nThe ALB is 45.4000 g/L;\n The CRP is 7.6800 mg/L;\n The LDH is 227.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 10.9000 ### months." } ], "images": [ "DMFS_train_1281/0000267484_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 63.3000 copies/mL;\nThe EBV of after treatment is 4.7800 copies/m; \nThe HGB is 148.9000 g/L;\nThe ALB is 45.4000 g/L;\n The CRP is 7.6800 mg/L;\n The LDH is 227.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 10.9000 ### months." } ], "images": [ "DMFS_train_1281/0000267484_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 63.3000 copies/mL;\nThe EBV of after treatment is 4.7800 copies/m; \nThe HGB is 148.9000 g/L;\nThe ALB is 45.4000 g/L;\n The CRP is 7.6800 mg/L;\n The LDH is 227.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 10.9000 ### months." } ], "images": [ "DMFS_train_1281/0000267484_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 63.3000 copies/mL;\nThe EBV of after treatment is 4.7800 copies/m; \nThe HGB is 148.9000 g/L;\nThe ALB is 45.4000 g/L;\n The CRP is 7.6800 mg/L;\n The LDH is 227.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 10.9000 ### months." } ], "images": [ "DMFS_train_1281/0000267484_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 63.3000 copies/mL;\nThe EBV of after treatment is 4.7800 copies/m; \nThe HGB is 148.9000 g/L;\nThe ALB is 45.4000 g/L;\n The CRP is 7.6800 mg/L;\n The LDH is 227.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 10.9000 ### months." } ], "images": [ "DMFS_train_1281/0000267484_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 49 years;\nThe Smoke is Smoking;The Drinke is Drinking;The family history of cancer is Yes;\n The T_stage is T3:The tumor invades adjacent structures such as the pleura, pericardium, aorta, esophagus, or the tumor diameter is greater than 7 cm.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage3:The primary tumor invades adjacent structures, or there is larger lymph node metastasis (>6 cm but ≤9 cm). The tumor may extend to regional lymph nodes but has not yet metastasized to distant organs.; \nThe EBV of before treatment is 63.3000 copies/mL;\nThe EBV of after treatment is 4.7800 copies/m; \nThe HGB is 148.9000 g/L;\nThe ALB is 45.4000 g/L;\n The CRP is 7.6800 mg/L;\n The LDH is 227.7000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 150 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 0:Without any complications or symptoms.; \nThe Chemotherapeutics is Nedaplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 49.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 10.9000 ### months." } ], "images": [ "DMFS_train_1281/0000267484_8.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 144.0000 g/L;\nThe ALB is 43.5000 g/L;\n The CRP is 21.2300 mg/L;\n The LDH is 158.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 8:Extremely severe complications that may be life-threatening, with impaired function of multiple organ systems, requiring intensive care and emergency treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 28.1000 ### months." } ], "images": [ "DMFS_train_1281/0000258637_2.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 144.0000 g/L;\nThe ALB is 43.5000 g/L;\n The CRP is 21.2300 mg/L;\n The LDH is 158.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 8:Extremely severe complications that may be life-threatening, with impaired function of multiple organ systems, requiring intensive care and emergency treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 28.1000 ### months." } ], "images": [ "DMFS_train_1281/0000258637_3.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 144.0000 g/L;\nThe ALB is 43.5000 g/L;\n The CRP is 21.2300 mg/L;\n The LDH is 158.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 8:Extremely severe complications that may be life-threatening, with impaired function of multiple organ systems, requiring intensive care and emergency treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 28.1000 ### months." } ], "images": [ "DMFS_train_1281/0000258637_4.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 144.0000 g/L;\nThe ALB is 43.5000 g/L;\n The CRP is 21.2300 mg/L;\n The LDH is 158.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 8:Extremely severe complications that may be life-threatening, with impaired function of multiple organ systems, requiring intensive care and emergency treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 28.1000 ### months." } ], "images": [ "DMFS_train_1281/0000258637_5.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 144.0000 g/L;\nThe ALB is 43.5000 g/L;\n The CRP is 21.2300 mg/L;\n The LDH is 158.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 8:Extremely severe complications that may be life-threatening, with impaired function of multiple organ systems, requiring intensive care and emergency treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 28.1000 ### months." } ], "images": [ "DMFS_train_1281/0000258637_6.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 144.0000 g/L;\nThe ALB is 43.5000 g/L;\n The CRP is 21.2300 mg/L;\n The LDH is 158.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 8:Extremely severe complications that may be life-threatening, with impaired function of multiple organ systems, requiring intensive care and emergency treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 28.1000 ### months." } ], "images": [ "DMFS_train_1281/0000258637_7.png" ] }, { "conversations": [ { "from": "human", "value": "The Sex is male;\nThe WHO_type is 3:Higher malignant degree;\nThe Age is 40 years;\nThe Smoke is Smoking;The Drinke is Non-drinking;The family history of cancer is None;\n The T_stage is T4:The tumor invades structures such as the mediastinum, major blood vessels, and chest wall.; \nThe N_stage is N2:An increase in the number of lymph node metastases, possibly involving the central lymph nodes.; \nThe All_stage is Stage4:The primary tumor has spread extensively or there are widespread lymph node metastases, or distant metastasis has occurred. In this stage, the tumor may have invaded the skull base, brain, major blood vessels, or other vital structures, or it may have already spread to distant organs.; \nThe EBV of before treatment is 0.0000 copies/mL;\nThe EBV of after treatment is 0.0000 copies/m; \nThe HGB is 144.0000 g/L;\nThe ALB is 43.5000 g/L;\n The CRP is 21.2300 mg/L;\n The LDH is 158.0000 U/L; \nThe Number of course is 3;\n The Concurrent chemotherapy is Yes;\n The In addition to simple targeting at the same time is Yes; \nThe Number of course_A is 2; \nThe Cumulative crisplatin dose is 195 mg/m² ; \nThe Supplementary course is None; \nThe Targeted therapy is None; \nThe Complication is 8:Extremely severe complications that may be life-threatening, with impaired function of multiple organ systems, requiring intensive care and emergency treatment.; \nThe Chemotherapeutics is Cisplatin;\n The time interval between induction chemotherapy and post-treatment imaging is 53.0000 months;\nThe time interval between diagnosis and post-treatment imaging is 78.0000 months;\nWhat is the patient's Distant Metastasis-Free Survival statu and corresponding Distant Metastasis-Free Survival time within a 94-month follow-up period?\n" }, { "from": "gpt", "value": "The Distant Metastasis-Free Survival statu is ### the event occurs ### and Distant Metastasis-Free Survival time is ### 28.1000 ### months." } ], "images": [ "DMFS_train_1281/0000258637_8.png" ] } ]